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Abstract: 
 
The complement system is a bastion of the innate immune system which mediates opsonic, 
inflammatory and lytic responses to pathogenic activating stimuli, culminating in the 
formation of the membrane attack complex (MAC) (Sarma and Ward 2011). MAC deposition 
on non-nucleated or bacterial cell membranes results in chemiosmotic flux; subsequently 
inducing cell swelling and rupture (Morgan 2000). However, sublytic MAC formation may 
occur on nucleated self-cells, inducing the release of inflammatory cytokines, including  IL-
1β (Tegla et al 2011; Ricklin, Reis and Lambris 2016).  IL-1β  proteolytic maturation and 
secretion requires activation of inflammasomes, with the NLRP3 inflammasome being 
demonstrated as the central mediator of MAC induced IL-1β secretion in a range of cell 
types  (Triantafilou et al 2013; Laudisi et al 2013;  Suresh et al 2016). However, the cellular 
mechanisms linking MAC deposition and NLRP3 activation are poorly defined, with a range 
of activation mechanisms proposed. 
In the work described in this thesis I investigated the mechanisms linking sublytic MAC to 
NLRP3 activation in monocytic and synovial cell lines to delineate conserved cell signalling 
pathways involved in NLRP3 activation, as well as investigating the broader interactions of 
NLRP3 with the complement system.   
Firstly, classical and reactive lysis systems of complement activation were established and 
validated to generate sublytic membrane attack on cells for study of the interaction with 
NLRP3. Within these experiments, interesting observations surrounding the role of CD59 in 
the regulation of C3b, as well as the role of C5 depletion or inhibition on C3b deposition 
were made. LPS primed THP-1 monocytes were used as a model for NLRP3 activation by 
sublytic MAC. In concordance with the published literature and studies by our group, both 
primary and secondary Ca2+flux and ROS production had roles in MAC mediated IL-1β 
secretion (Triantafilou et al 2013). However,  extracellular KCl was demonstrated to be a 
non-specific inhibitor of IL-1β  release as the addition of NaCl to the stimulation media 
demonstrated inhibition of NLRP3 activation in the same manner as KCl in this system. To 
further explore pharmacological manipulation of sublytic MAC mediated activation, 
inhibitors of a range of known MAC activated kinases were used to identify signalling 
pathways linking sublytic MAC and NLRP3 activation. Only an AKT inhibitor, Perifosine, 
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induced statistically significant changes in MAC mediated IL-1β release; however, this was 
shown to be through the activation of cell death and stress pathways such as JNK rather 
than attributable to its effects on AKT signalling. Subsequent simultaneous inhibition of JNK 
and ERK signalling significantly inhibited both IL-1β secretion and Caspase-1 activation in 
response to sublytic MAC. MAC-induced activation of NLRP3 and the induction of IL-1β 
release was also subsequently demonstrated using purified components in the reactive lysis 
system; cells exposed to sublytic MAC via reactive lysis were subjected to RNA-Seq analysis, 
providing preliminary evidence of transcriptomic changes with implications for 
inflammatory cell signalling in response to MAC.  
Finally, NLRP3 expression was knocked out using the CRISPR/CAS9 system in SW 982 
synoviocytes, to  investigate interactions between NLRP3 expression and MAC mediated 
responses. NLRP3 -/- cells were protected from MAC mediated cell death, a consequence of 
increased CD59 expression on the cell surface.  
Collectively, this thesis improves understanding of the mechanisms linking complement and 
NLR inflammasomes, highlighting novel cell signalling pathways linking the two systems and 
providing evidence that NLRP3 modulates MAC sensitivity by regulating CD59 localisation 
within the cell.   
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Chapter 1 – Introduction: 
 
The innate immune system is a fundamental cornerstone of the body’s ability to rapidly react 
and respond to the multitudes of potentially harmful stimuli, whether self-derived or from 
exogenous pathogens, encountered in everyday life (Holers and Banda 2018). One of the 
crucial effectors for the innate immune system is the complement system. The complement 
system comprises of a proteolytic cascade generating a range of effector molecules as a front-
line response to pathogens and altered self-cells, which is kept in check by an array of cell 
surface and fluid phase regulators (Sarma and Ward 2011).  
 
Activation of the complement system induces the production of opsonic fragments, 
anaphylatoxins and membranolytic agents; therefore, it is unsurprising that the complement 
system can exert a highly potent pro-inflammatory, pro-necrotic and opsonic effect (Rus et al 
2006). Subsequently, the aberrant activation and dysregulation of complement can result in 
a range of pathological conditions. These range from well-characterised diseases where 
complement dysregulation is the key factor such as paroxysmal nocturnal haemoglobinuria 
(PNH) and atypical haemolytic uremic syndrome (aHUS), to other conditions where insidious 
roles for the pro-inflammatory effects of complement are becoming increasingly elucidated, 
including cardiovascular disease and atherosclerosis, Alzheimer’s disease and 
neurodegenerative conditions and rheumatoid arthritis (RA) (Caroll and Sim 2011).  
 
Complement activation in RA is well documented, with studies highlighting complement 
activation as a central driver of RA inflammation in both in vitro and in vivo models (Low and 
Moore 2005). The cause of complement activation in the RA joint is unclear; however, a range 
of possible complement activators are generated in disease progression. Potential activators 
include rheumatoid factor (RF), anti-citrullinated protein antibody (ACPA) and other immune 
complexes, CRP deposition or cartilage components such as fibromodulin, which have all been 
demonstrated to activate classical or alternative pathways (Ballanti et al 2011).   
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Nevertheless, the cell signalling mechanisms enabling complement activation to drive the 
inflammatory state in the resident joint synoviocytes  and infiltrating monocytes are unclear, 
with the intracellular cascades activated by C5a and sublytic membrane attack complex (MAC) 
being largely undefined in these cell types. Furthermore, the interaction between the 
complement cascade and the intracellular “danger sensing” machinery of the NLRP3 
inflammasome may be pathological in RA, with the inflammasome activation product IL-1β 
already being targeted, albeit with limited efficacy, in the disease (Mertens and Singh 2009; 
Triantafilou et al 2013). Therefore, in this thesis I set out to elucidate the mechanisms linking 
complement and the activation of the NLRP3 inflammasome in synoviocytes and monocytic 
cell line models, to identify cell signalling pathways for the mediation of complement 
mediated NLRP3 activation and potentially highlight new therapeutic targets for RA in the 
future.  
 
1.1 – Background to the complement system 
 
The discovery of the heat labile bactericidal properties of serum by early immunologists such 
as Bordet and initiated our understanding of this innate immune pathway (Buchner 1895; 
Bordet 1898). The function of innate immunity within the overall immunological landscape is 
to, alongside the adaptive immune response, protect the host from pathogenic infection. 
From Bordet’s simple observation, our understanding of complement has developed to 
encompass a system of overlapping, synergistic and antagonistic pathways mediating the 
effects of complement in both health and disease (Ogundele 2001).  
 
The complement system consists of over 30 components and regulators which make up 
around 15% of the protein content of blood plasma. Complement proteins circulate as 
zymogens until induced to activate through conformational change or proteolytic cleavage, 
or in the case of C3, through spontaneous hydrolysis (Dunkelberger 2009). The historical 
interpretation of this pathway as merely "complementing" the more defined humoral 
response upon the recognition of pathogens is becoming increasingly challenged. The recent 
elucidation of the wide-reaching roles of complement signalling in lipid metabolism, 
coagulation and synaptic development highlight complement and result in it becoming 
increasingly viewed as a central homeostatic mechanism (Amara 2008; Stephen 2012; 
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Guavreau et al 2013). The complement components are predominantly synthesised 
hepatically and released into the circulation; however, localised extrahepatic synthesis can 
occur in many organs and tissues, including the epithelia of the GI tract, skin fibroblasts, the 
eye and most significantly in monocytes and mononuclear cells to act as a rapid response to 
injury (Noris and Remuzzi 2013). The recent discovery of intracellular activities of complement 
opens a range of roles for complement in cellular homeostasis, which will undoubtedly be 
explored and diversify in the coming years (Arbore, Kemper and Kolev 2017).  
 
 Despite the seeming complexity underlying the cascade with the large number of proteins 
and regulators involved, the primary role of the system is to recognise and eliminate 
pathogens or altered self-cells. This is managed in several ways, including the induction of 
inflammation and recruitment of immune cells through the anaphylatoxins and MAC, MAC 
mediated cell lysis or opsonisation through C3b products (Chen, Daha and Kallenberg 2010). 
The importance and potency of the responses induced by the complement system are further 
demonstrated by the range of pathophysiological conditions with which ectopic complement 
activity is associated, including Alzheimer's disease, cancer, type II diabetes and rheumatoid 
arthritis (Holers et al 2014; Reis et al 2017; King and Blom 2017). These common, chronic 
conditions are becoming causes of increasing financial and medical strain in the aging western 
population, consequently, the understanding and potential management of the roles of 
complement signalling in these conditions is hugely significant in the development of 
therapeutics and potentially mitigating their impact upon society (Holers 2014). 
 
1.2 – Complement activation pathways 
 
The complement system consists of three established activation pathways, classical, lectin 
and alternative pathways. All three activation pathways converge on a common terminal 
pathway. Although the active products are the same, the activating ligands, activation 
complexes and regulation are unique to each pathway, allowing fine detail and regulation of 
key steps within the cascade to modulate activity (reviewed in Sarma and Ward 2011). A 
schematic overview of the complete complement system can be seen in Figure 1.1 a, and a 
schematic of complement activation pathways in Figure 1.1 b.  
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Figure 1.1. Schematic of complement cascade. Activation pathways triggered in response to agonists converge at the C3 
convertase, which subsequently binds C3b to alter the convertase affinity to C5. C5 convertase activity allows C5 cleavage in 
to C5a and C5b, with the latter forming the nidus of the forming MAC complex. Subsequent C6, C7, C8 and C9 binding results 
in MAC formation on the cell surface.  
Alternative  
pathway C5 
convertase 
Classical  
pathway C5 
convertase 
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1.2.1 The classical pathway – C1q binding and activation 
 
Classical activation acts as an interface between innate and adaptive immunity by interaction 
of C1q with immunoglobulins (multiple IgG molecules or a single IgM) to initiate activation 
(Duncan and Winter 1988). C1q binding to immunoglobulin Fc regions is dependent on either 
IgM deformation from planar to a staple-like shape on ligand binding or proximity of multiple 
ligand-bound IgG molecules (reviewed in Sarma and Ward 2011). IgG-mediated C1q activation 
has been shown to be optimal with six IgG molecules in close proximity and in a specific array 
formation on the target surface, suggesting IgM is a more efficient classical pathway activator 
(Diebolder et al 2014). However, C1q is also capable of interacting with and becoming 
activated by an array of other molecules including LPS, apoptotic cells and CRP, causing 
complement-based responses to a range of PAMPS and DAMPS (Gal et al 2009).  
 
The C1 complex consists of a single C1q associated with a C1r2/C1s2 tetramer, with a combined 
molecular mass of 790 kDa. C1q itself is a 460 kDa collagenous protein formed from 18 
homologous polypeptide chains (6 A, 6 B and 6 C chains), which form the C1q "stalk" region 
and the 6 arms culminating in globular head regions resembling a bouquet structure (Figure 
1.2) (Arlaud 2002). The structure is highly dependent on interchain disulphide bond formation 
from conserved Cysteine residues to generate the A-B and C-C chain subunits of the molecule, 
whilst further conserved Cysteine residues are believed to contribute to intrachain bridge 
forming (Kishore and Reid 2000). Activation of the C1q complex is dependent on the presence 
of Ca2+ to allow interaction of K61 from the B chain or K58 of the C chain of the collagen like 
stem region of C1q with a shallow groove on the C1r2 /C1s2 complex to allow oligomerisation 
(Girija et al 2013).  
 
The interaction of the globular C1q heads with activators induces a conformational change 
within C1q which transposes into activation of C1r via association of the collagen-binding 
domain with the protease. This occurs via an intermediate structure in a similar mechanism 
to Trypsin-mediated cleavage before the auto-proteolysis of C1r, yielding the functional 
protease form (Gaboriaud 2014). Upon activation, a single C1r subunit within the highly 
flexible tetramer can cause subsequent proteolysis of both C1s zymogens within the complex, 
to yield a fully active C1 complex (Major et al 2010).  
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The C1s proteases in turn induce the cleavage of C4 and C2 to generate the focal point of the 
various complement pathways, the C3 convertase (C4bC2a in the classical pathway). This is 
possible due to the high flexibility of the C1 complex around the C1r/s proteolytic domains, 
allowing them to swing out of the complex upon activation and instigate the initial cleavage 
of C4 (Wallis et al 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. The intricate heterotrimeric structure of C1q with the collagen-like stalk region forming into the six globular heads 
required for IgG and pathogen recognition (Image edited from Gaboriaud et al 2012). Upon binding, the C1q complex 
undergoes conformational change to a permissive state for C1r and C1s activation. 
 
 
 
Classical pathway 
activation 
1. IgG binds to activating 
surface (e.g. Bacterial cell) 
2. C1q complex binds 
IgG FC region 
3. C1q complex binding induces 
conformational change – inducing C1r and 
C1s activation 
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1.2.2 C1q signalling and non-complement roles 
 
Alongside the traditional role of C1q as the mediator of C1 complex target recognition and 
activation, a range of non-complement mediated roles are becoming elucidated. These 
include important functions in angiogenesis in neonates of relevance to preeclampsia, and 
roles in cell adherence and apoptosis in prostate cancer; these activities have been attributed 
to its cytokine-like structure and apparent evolution from a TNF-α precursor (Ghebriwet et al 
2012).  Importantly, in the context of this project, C1q has distinct roles in the induction and 
regulation of inflammation. C1q deposition in Drusen deposits, the pathological hallmark of 
AMD, was demonstrated to have a pro-inflammatory effect through activation of NLRP3 and 
the induction of IL-1ß and IL-18 secretion; however, the mechanism of which remains unclear 
but seems to involve phagolysosomal destabilisation through endocytosis of the C1 complex 
(Doyle et al 2012). However, other groups have demonstrated a role for C1q in the inhibition 
of NLRP3 activation in macrophages, primed macrophages exhibiting a decrease in pro-IL-1β 
and Caspase-1 cleavage in response to extracellular ATP when exposed to C1q-opsonised 
apoptotic lymphocytes, alongside a decrease in IFN and IL-27 responses suggesting a global 
anti-inflammatory effect (Benoit et al 2012). 
 
1.2.3 C4 activation and classical pathway convertase formation 
 
Upon C4 cleavage the smaller C4a fragment is released, allowing it to act as an anaphylatoxin 
alongside C3a and C5a. Although C4a is the weakest of the complement anaphylatoxins, 
indeed it has been suggested to have no biological activity, it has also been postulated that 
there is cross talk and interaction between these inflammatory mediators. This was 
demonstrated by testing the effects of C4a on C5a induced neointima formation in mice with 
arterial injury - mice receiving C4a alongside C5a showed significantly inhibited neointima 
formation as well as inhibition of the expression of various proinflammatory molecules such 
as TNFα and IL-6 (Zhao 2014). The recent demonstration that C4a binds the receptors PAR1 
and PAR4 suggests a biological significance of the molecule, with a capacity to induce ERK 
signalling and Ca2+ mobilisation as well as affecting endothelial permeability (Lambris, Ricklin 
and Wang 2017).  
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The larger fragment, C4b becomes anchored to the target cell surface through its reactive 
thioester group, which becomes exposed upon cleavage, allowing it to remain fixed adjacent 
the C1 complex.  C2 binds fixed C4b and is presented for C1s cleavage, releasing a fragment 
C2b while the enzymatic fragment C2a remain bound to form the classical C3 convertase, 
C4bC2a (Mathern and Heeger 2015).  
 
1.2.4 The Lectin Pathway 
 
The second activation pathway of the complement cascade is the Lectin Pathway (LP) which 
is comparable, although not completely analogous, to the classical pathway. Mannan binding 
lectin (MBL) is a member of the Collectin family of proteins (alongside SP-A and SP-D) encoded 
on a gene cluster on the long arm of chromosome 10 in humans and is the prototypical 
activator of the Lectin pathway (Ip et al 2000). The structure of the MBL monomer comprises 
a cysteine rich N terminal domain, multiple collagen repeats and a C terminal "neck" domain 
which orientates the six globular recognition heads in to the correct geometry. However, In 
vivo, MBL associates into different oligomeric states, including dimers, trimers and hexamers 
(Turner 1998). 
 
 A second, less well characterised group of activators of the lectin pathway are the multimeric 
lectin Ficolin family, consisting of three members (H, L and M Ficolin) which are highly 
homologous to MBL, demonstrated in Figure 1.3. Ficolins recognise acetylated moieties on 
the cell surface including N-acetyl-Glucosamine and N-acetyl-Galactosamine - allowing 
recognition of a range of pathogens including Escherichia coli, Staphylococcus aureus and 
Salmonella typhimurium (Matsushita 2013). Furthermore, the recognition of human 
cytokeratin, exposed after endothelial oxidative stress, demonstrates a potential mechanism 
of recognition of "altered self" cells and a route for activation of complement in response to 
oxidative stress and ischaemia (Osthoff et al 2018). 
 
 
 
 
 
 
 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 – Comparative schematic structures of MBL (Top) and Ficolins (Bottom), which highlights their structural similarity 
to C1q shown previously (Image edited  from Matsushita and Fujita 2002) 
 
MBL is synthesised in hepatocytes before secretion into plasma, where it can induce 
complement activation via interactions with a range of pathogens. These can include both 
gram negative and gram-positive bacteria, viruses, parasites and yeasts - alongside the 
fundamentally important property of distinguishing healthy self from apoptotic/necrotic and 
non-self-cells (Takahashi 2005). Upon infection, serum levels of MBL increase 2-3-fold, 
indicating that it is an important acute phase response protein (Dommet, Klein and Turner 
2006). The process of target recognition by MBL is dependent on the geometry and spatial 
orientation of carbohydrate binding domains on the target cell surface, and the differences 
in composition and orientation between these and the arrangement of glycoproteins on a 
human cell allow specificity of MBL targeting (Takahashi 2005).  
 
Upon activation via binding to correctly orientated carbohydrate residues on the cell surface, 
MBL oligomerisation is fundamental to activity, with the carbohydrate recognition domains 
(CRDs) forming high avidity, polyvalent interactions with the ligands and providing a platform 
for the interactions required for MASP activation (Laursen 2012). Three forms of MASP's are 
present in the MBL immunocomplexes, MASP1 - 3 alongside a further truncated form of 
MASP2 known as sMAP. Of the associated MASPs, MASP-2 has been highlighted as the central 
Homologous 
collagen like 
domains 
Similar 
overall 
structure 
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(and possibly only necessary) form for activation (Takahashi 2008). The roles of MASP-1 / 3 
seem to be more subsidiary and supportive or regulating to the activity of MASP-2.  
 
1.2.5 The alternative pathway 
 
The final activation pathway of the complement system, known as the alternative pathway 
(AP), is fundamentally different from the homologous classical / Lectin pathways. The 
labelling of the AP as a distinct pathway is something of a misnomer because it is in fact the 
central complement amplification loop. The AP operates via a distinctly separate mechanism 
to create a differently constituted, but functionally identical C3 convertase. It should be noted 
that whilst most molecules within the Classical/ Lectin pathways have homologues or 
domains of similar function, the alternative pathway has three unique components in the 
forms of Factor B (FB) Factor D (FD) and Properdin (FP).  
 
In contrast to the other pathways which require specific antibody: protein/carbohydrate: 
protein interactions to induce pathway activation, the AP undergoes a low rate of continuous 
activation equalling roughly 1% of total C3 / hour, termed "tickover" (Thurman 2006). The 
"tickover" theory of C3 activation in the alternative pathway originated in the 1970's; slow, 
spontaneous hydrolysis of C3 in the fluid phase by nucleophilic attack of water to yield C3H2O 
(Lachmann and Nichol 1973; Pangburn et al 1981; Daha 2013). This attack creates a more 
open structure in the C3d region which in turn facilitates the interaction of C3H20 with factor 
B (FB) (Winters 2005). FB bound to C3H20 is cleaved by the serum protease factor D (FD) to 
yield the fluid-phase convertase C3H20Bb.  
  
FB is a 93 kDa glycoprotein which binds C3b in the presence of Mg2+ and is then cleaved by FD 
(Lambris and Muller-Eberhard 1984). FB binding to C3b induces an open conformation, 
exposing the scissile loop in FB that FD cleaves, releasing the Ba fragment from the complex 
(Forneris et al 2010). Bb bound to immobilised C3b comprises the amplification loop C3 
convertase (C3bBb).  
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FD is a small (25 kDa) single domain chymotrypsin-like protease that circulates in a self-
inhibited form via its loop domain that disrupts the catalytic triad of the protease. This causes 
an increased distance between catalytic residues by forming a salt bridge with Asp 177 of the 
S1 substrate binding pocket, the displacement of which upon enzyme activation is crucial for 
catalytic activity (Forneris et al 2010). Plasma concentrations of FD are the lowest of any 
complement component, indicating its importance in the regulation and activation of the AP, 
maintained by a high rate of turnover within the blood (Katschke et al 2012).  
  
The C3 convertase (C3bBb) is stabilised by properdin, a 53 kDa, highly positively charged 
molecule synthesised in a range of cell types (unlike most complement factors which are 
predominantly hepatocyte synthesised) which in vivo oligomerises into dimers, trimers and 
tetramers by head to tail association of the monomer units (Agarwal 2010). Properdin was 
the first, and for a long time only, established positive regulator of complement activation, 
prior to the recent discovery of FHR1 acting as a competitor for FH binding to the C3 
convertase and therefore reducing delay acceleration factor activity (Reuter et al 2010). 
Properdin functions by forming a curving vertex around the C3 convertase via interactions 
with both C3b and Bb that displaces the C3b thioester domain (TED), thus occluding the 
binding sites of convertase inhibitors, resulting in an increase in C3bBb half-life up to 10-fold 
(Alcorlo et al 2013). Further roles for properdin in the induction of cell signalling and later 
stages of complement regulation have been postulated but are still controversial.  
 
Therefore, C3 convertase initiates the amplification loop of the alternative pathway; 
irrespective of the initial activation pathway, the amplification loop is responsible for around 
80-90% of complement effectiveness (Lambris and Ricklin 2016). 
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1.3 - Regulation of complement activation 
 
1.3.1 Regulation of Classical pathway activation 
 
The initial stages of complement activation are regulated by C1 inhibitor (C1-Inh), a potent 
down-regulator of complement activation and inflammatory processes in the blood (Beinrohr 
2007). The 105 kDa protein is present in plasma at around 0.24 g/L, indicative of an important 
and widespread role (Caliezi et al 2000).  C1-Inh, a member of the Serpin family of inhibitors 
of cysteine and serine proteases, functions via a non-competitive mechanism by acting as a 
pseudo substrate for the enzyme, locking the active site in an intermediate, non-functional 
state (Patston et al 1991). This binding causes changes within the Serpin structure that 
irreversibly inactivate the enzyme and expose clearance and degradation epitopes that 
facilitate complex removal (Cugno 2009). 
 
The effects of C1-Inh deficiencies, which manifest in the condition Hereditary angioedema  
(HAE), highlight the importance of early stage regulation of complement. HAE is caused by an 
autosomal dominant mutation within the C1-Inh gene, which results in serious symptoms, 
predominantly in recurrent swelling of the skin (angioedema), occasionally involving mucosa 
of the upper airways or bowels, which can be life threatening (Gower et al 2011). The 
administration of recombinant or purified C1-Inh for the treatment of HAE is a mainstay of 
prophylactic treatment alongside attenuated androgens. The role of C1-Inh in HAE is 
independent of its complement regulatory function; loss of regulation of coagulation by C1-
Inh, specifically activation of FXII and the subsequent release of Bradykinin, drives the 
condition (Gower et al 2011).  
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1.3.2 Regulation of the C3 convertases 
 
The C3 convertases C4bC2a and C3bBb are labile and decay with time; nevertheless, there 
are several proteins in plasma and on cell surfaces that function to further regulate the 
convertases.  The key regulator is Factor I (FI), a heterodimeric, heavily glycosylated serine 
protease present in plasma in an inactive zymogen form at relatively high concentrations (~35 
µg/ml) (Alba-Dominguez et al 2012). FI, in the presence of appropriate cofactors, cleaves C3b 
or C4b to inactive forms (iC3b, iC4b and smaller fragments) that are incapable of forming 
convertase. Inactivation of C3b prevents a spiralling of the positive feedback loop within the 
alternative pathway and hence C3 depletion through uncontrolled activation. The 
degradation products of FI mediated C3b/C4b cleavage have specific roles in the modulation 
of phagocytosis and induction of the acquired immune response (Roversi et al 2011). A 
schematic of the sequential proteolytic cleavage of C3 into subsequent fragments is shown in 
Figure 1.4. 
 
 
Figure 1.4. The roles of FI / FH as cofactors in the proteolytic degradation of C3b to inactive C3 products as well as mediating 
delay accelerating activity of the alternative pathway C3 convertase, increasing Bb dissociation rates and thus inhibiting the 
amplification of the AP. 
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For AP regulation FI is highly dependent on factor H (FH) as co-factor; FH also regulates by 
accelerating the decay of AP convertases. FH plasma concentrations are relatively high, up to 
300 µg/ml, highlighting its importance; FH deficiency in man and mouse leads to spontaneous, 
complete C3 consumption (Schreiber et al 1978; Fakhouri et al 2010). Beyond FH total 
deficiency, a diverse range of single nucleotide polymorphisms (SNPs) in FH can incur different 
levels of activity. The most well characterised FH polymorphism is Y402H, a strong genetic risk 
factor for AMD. Despite the large genetic load of Y402H risk for AMD, the mechanism was 
unclear. The polymorphism does not alter FH affinity for C3bBb or affect AP convertase 
regulation; however, Y402H mutation may alter interactions with CRP, sulphated 
glycosaminoglycans and other cell surface proteins, reducing FH association with the 
membrane (Hageman et al 2005). This was subsequently demonstrated to be important for 
FH binding to Bruch’s membrane via Heparin sulphate, with a different region of FH being 
implicated in binding to the differently sulphated GAG’s in the kidney, suggesting the 
mechanism by which Y402H confers AMD risk (Clark et al 2013). 
The observation that the complement polymorphisms has been further explored beyond 
Y402H, with the array of SNPs in an individual cumulatively strongly affecting complement 
activity. This concept of an individual’s array of complement SNPs conferring a higher or lower 
level of complement activity generated the complotype hypothesis. The  complotype concept 
suggests the range of common polymorphisms in any individual affect the overall activity of 
the system and may predispose the individual to complement mediated disease or increased 
susceptibility of infection, depending on the balance of the SNPs. The combinations of 
common SNPs in complement AP components generate up to a 6-fold difference in 
haemolytic activity, demonstrating that individual small changes in activity may cumulatively 
have profound effects (Harris et al 2012).  
FH therefore acts as something of a “reverse recognition” marker by binding to and protecting 
cells expressing self-epitopes (polyanionic molecules such as sialic acid and 
glycosaminoglycans) but not foreign cells lacking the required recognition markers (Ferreira 
et al 2010).  Furthermore, FH recognises markers of apoptosis such as DNA and the 
cytoplasmic phospholipid annexin II. The binding of FH in this instance regulates complement 
activation and C3b deposition resulting in opsonisation by phagocytes whilst preventing 
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excessive inflammatory responses or the release of intracellular autoantigens in the 
surrounding environment (Trouw et al 2007). The involvement of FH in self-recognition is 
highlighted by the presence of autoantibodies against FH in a range of rheumatic diseases 
including RA, SLE and aHUS – although the mechanism by which FH is aberrantly recognised 
in these conditions is unclear (Zadura et al 2012). 
 
1.3.3 Membrane bound C3 convertase regulation 
 
On cell surfaces, C3 convertases are controlled by two proteins working in tandem, CD55 and 
CD46.  CD55 (decay accelerating factor/DAF) is formed of four short consensus repeats (SCRs) 
followed by a short, heavily glycosylated stalk region and a GPI anchor (Weller and Wang 
1994). Binding of CD55 to the C3bBb or C4b2a convertase leads to accelerated decay by 
displacing the enzymatic component (Harris et al 2007). CD46 (membrane cofactor protein; 
MCP) is a ubiquitous membrane bound glycoprotein regulator present on all nucleated cells, 
with multiple roles in the co-ordination of innate and adaptive immune responses (Yamamoto 
et al 2013). CD46 also has an important role in modulation of inflammation, importantly in 
the context of this work, through priming of NLRP3 and induction of changes in cell 
metabolism (Arbore and Kemper 2016).  In complement regulation, CD46 acts as a cofactor 
for FI cleavage of C3b and C4b, thus irreversibly inactivating the C3 convertase. 
The C3 convertase generated either by the classical/lectin (C4b2a) or the alternative (C3bBb) 
pathways acts as a focal point of the complement pathway, uniting the three activation 
mechanisms and inducing a common downstream response. It should be noted however that 
the alternative pathway has the unique ability to self-amplify in a positive feedback loop, C3 
convertase generating more C3b which may be deposited on the target cell surface via its 
thioester bond, leading to further FB binding and convertase generation. This amplification is 
crucial for all activation pathways, with C3b generated from a CP convertase capable of 
forming an AP convertase to allow signal propagation, with amplification dependent on the 
balance between activation and inhibition (Lachmann 2009).  
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1.3.4 C3b, opsonisation and cell signalling 
 
C3b and its degradation products iC3b, C3c and C3dg also have crucial roles as opsonins to 
facilitate phagocytosis of bacteria or dysfunctional host cells, with all C3 derived ligands and 
receptors shown in Figure 1.5. Although phagocytes are capable of PAMP and DAMP 
recognition directly, the diversity and effectiveness of the phagocytic response can be 
modulated by the presence of opsonins. C3 products, as well as other complement proteins 
such as C1q, have been shown to activate macrophages in vitro (Ezekowitz et al 1985; Bobak 
et al 1988). Interestingly, the interactions of C3b with membrane acceptors is selective for 
non-self surfaces, dictated by factors such as the position of primary hydroxyl groups on 
sugars and specific residues on proteins as points of interaction (Sahu 2001). This selectivity 
focusses C3b deposition onto bacterial, altered or immune complex coated surfaces, 
therefore limiting downstream “collateral damage” to healthy cells. The recognition of C3b 
and its degradation products is mediated by members of three gene super families; the 
regulators of complement activation (RCA) family short consensus repeat (SCR) module-
containing CR1 and CR2, the β2-integrin family members CR3 and CR4 and the 
immunoglobulin-like receptor family member CRIg (Campange et al 2007).  
 
SCR-containing receptors CR1 and CR2 recognise both C3b and C4b through distinct sites each 
comprising three SCR repeats. The expression level of CR1 (also known as CD35) was found 
to be crucial for erythrocyte mediated immune complex clearance to the liver and spleen 
where hepatic / splenic macrophages strip the complexes from erythrocytes and elicit an 
immune response through antigen presentation (Krych-Goldberg and Atkinson 2001) 
(Liszewski et al 2015). Monocyte/macrophage binding of C3 fragments involves initial 
interaction with CR1 followed by crosstalk with CR3 to induce the phagocytic process. The 
exact interactions of the receptors and the intracellular morphological remodelling machinery 
required for pathogen uptake remains unclear (Rittig et al 1998). 
 
CR3 is also the predominant regulator of phagocytic uptake of cholesterol crystals (CCs) in the 
atherosclerosis model, where CR3 expression on granulocytes and monocytes was increased 
by C5a and correlated strongly with inflammasome activation and cytokine production, 
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demonstrating the importance of the phagocytic response in the mediation of inflammation 
(Samstad et al 2014). 
 
 
 
Figure 1.5 – The array of complement activation products and receptors mediating opsonisation and phagocytosis (Figure  
based on image in Dunkelberger and Song 2010) 
 
1.3.5 C3a and C5a function 
 
From the central C3 convertase the first potent anaphylatoxin is generated, C3a. The 
anaphylatoxins C3a and C5a are strikingly similar molecules with similar polypeptide chain 
lengths, high sequence homology, similar charge and a core structure based on four helix 
bundles, and therefore, will be addressed together (Nettesheim et al 1988). The subtle 
differences between the anaphylatoxin structures are highlighted in Figure 1.6. C3a and C5a 
induce potent effects, including inducing tachycardia, neutrophil mobilization, monocyte 
cytokine secretion, altered microvasculature permeability and vasodilation, smooth muscle 
contraction and mast cell degranulation (Verschoor et al 2016). These effects are mediated 
by their interactions with their respective receptors (C3aR, C5aR1 and C5aR2). The C3aR is 
highly specific for C3a with a Kd of 1 nm and has limited affinity for C3a-desArg or C5a; 
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selectivity is highly dependent on the large second extracellular loop and sulphation of Tyr174 
(Gao et al 2003). C3aR activation triggers downstream intracellular signalling via activation of 
heterotrimeric G-proteins in a cell dependent manner, with different G-proteins involved in 
different cell types (Schraufstetter et al 2003). These in turn trigger various potent signalling 
cascades including MAPK, PLC and AKT, leading to cytokine activation and release 
(Venkatesha et al 2005).  
 
C3a/C5a activities are controlled by carboxypeptidases in plasma that inactivate by cleavage 
of terminal arginine residues (Klos et al 2009). The generated C3a-desArg is incapable of 
interacting with C3aR in any form, although C5a-desArg retains around 10% of its functionality 
(Campbell et al 2002). Although C3a-desArg cannot bind C3aR1, it has been demonstrated to 
bind C5aR2 and mediate a range of effects within lipid metabolism and intracellular pathways 
(Kolev and Kemper 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6– Structures of C3a, C4a and C5a highlighting the conserved helical structure between the anaphylatoxins, with the 
major variation occurring in the α-1 helix as highlighted (Image edited from Bajic et al 2012) 
 
 
 
 
Conserved regions 
Variable regions 
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1.3.6  The generation of C5a 
 
 The generation of a C5 convertase from any of the activation pathways C3 convertases is 
dependent on the covalent binding of an additional C3b with the non-catalytic subunit of the 
convertase to create C5 convertases, C4b2a3b or C3bBbC3b. The additional C3b alters the 
substrate specificity of the convertase from C3 to C5, allowing C5 cleavage and initiation of 
the terminal complement pathway (Pangburn and Rawal 2002). The importance of C5 is 
highlighted by the exceptionally low numbers of C5 deficient individuals within the 
population, with a pronounced increase in susceptibility to meningococcal infection being a 
prominent symptom (Arnaout et al 2013).  
 
1.3.7 C5a signalling through C5aR1 
 
The effects of C5a binding C5aR1 are far more clearly elucidated than the relatively enigmatic 
C5aR2. C5aR1 is a classical G protein coupled receptor (GPCR) which mediates its cell 
signalling effects through Gαi and G16 subunits (Monk et al 2007). C5aR1 was originally 
reported to only be expressed on leukocyte cell lineages such as neutrophils and monocytes; 
however, it has now been shown to be expressed on a range of non-immune cells, including 
fibroblast-like synoviocytes (Yuan et al 2003).  Activation of the GPCR induces signalling 
predominantly through Gβ / Gγ subunit translocation in the membrane allowing activation of 
a range of downstream signalling cascades including cAMP, ERK, PLC and RAS/RAF (Ward 
2004). Interestingly, the exact pathways induced vary between cell types, for example, the 
cAMP response, prominent in neutrophils and hepatocytes, is markedly reduced in dendritic 
cells and monocytes (Ward 2004; Peng et al 2009; Li et al 2012; Das et al 2014). These 
differences in cAMP activity between cells can also be demonstrated in other aspects of cell 
signalling. C5a is classically a highly pro-inflammatory mediator, causing upregulation of IL-8, 
IL-1 and IL-6 in HUVECs and neutrophils (Shuster et al 1997; Monsinjon et al 2003); however, 
in LPS primed monocytes C5aR signalling modulated TLR4 signalling via Gαi/ Raf/MEK/ERK, 
downregulating the IL-6 and TNFα pro-inflammatory response and inducing IL-10 release, a 
potent anti-inflammatory cytokine (Seow et al 2013). Some of the conserved, central C5aR1 
mediated signalling pathways are highlighted in Figure 1.7.  
 
 
20 
 
 
 
Figure 1.7. Cell signalling transduction in neutrophils induced by C5aR1 GPCR activation, including the synthesis of 
inflammatory mediators such as Leukotrienes and Thromboxane (Image derived from Ward 2004).  
 
C5a also induces pro-inflammatory effects in non-immune cells, including interactions and 
synergisms with the Toll like receptor (TLR) family of pattern recognition receptors (PRRs) and 
the cell danger sensing and inflammatory machinery of the inflammasome. This centrality to 
a plethora of inflammatory signalling pathways is then mirrored in C5a involvement in a wide 
range of pathological conditions, for example, atherosclerosis, chronic obstructive pulmonary 
disease, asthma and allergy, ischaemia / reperfusion injury and RA; hence, targeting of C5aR 
or modulation of C5a signalling are areas of intense interest in therapeutic development (Lee 
et al 2008).  
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1.4 – The complement terminal pathway 
 
1.4.1 MAC intermediates and formation 
 
The role of the larger C5 fragment, C5b, is to form the nidus for the terminal complement 
components to assemble into the lytic membrane attack complex (MAC) pore leading to 
target cell rupture and death (Nauta et al 2002). C5b binds C6 to form C5b6, a stable 
intermediate complex which can associate with target plasma membranes through 
hydrophobic interactions (Cooper et al 1970; Hu et al 1981). C7 can then bind the complex, 
increasing its lipophilic properties and strengthening association with the membrane 
(Tschopp, Podack and Muller Eberhard 1982). The interactions of C5b-7 with the membrane 
only involve the outer lamella of the bilayer; therefore, C5b-7 has no lytic capability.  
The binding of C8 to membrane-associated C5b-7 C5b causes a deeper insertion of the 
complex into the bilayer. C5b-8 complexes act as small, unstable pores that may induce ion 
flux in some targets (Ramm et al 1982; Niculescu and Rus 2001).  
The final requirement for effective transmembrane pore formation is binding and 
polymerisation of multiple C9 molecules; individual C9 molecules sequentially bind, unfold 
and insert into the membrane, assembling a β–barrel pore resembling the T cell pore former 
perforin (Hadders et al 2012; Arber et al 2013; Bubeck 2014). The mechanism of C9 
multimerisation was recently demonstrated, with the TMH1 region acting as an inhibitor of 
C9 self-assembly in the absence of C5b-8 and upon C5b-8 binding. The TMH1 region is the 
first region of C9 to traverse the cell membrane, with the subsequent  conformational change 
upon membrane interaction allowing the unidirectional binding of further C9 molecules 
(Spicer et al 2018). Once the MAC is assembled, the large multimeric complex is over 1 MDa 
in mass and over 10 nm in pore diameter (Tschopp 1984). A schematic of sequential MAC 
formation is shown in Figure 1.8 
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Figure 1.8. Schematic of sequential complement terminal pathway intermediates and subsequent MAC formation on a 
nucleated cell surface. 
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1.4.2 MAC structure and lytic effects 
 
The exact structure of MAC pores was long debated; however, recent advances in imaging 
techniques have generated new MAC structure which provide clarity and insight into function. 
Utilising cryo-EM of MAC extracted from liposomes has clearly demonstrated an asymmetric 
pore with a “split washer” appearance, posing interesting new questions relating to MAC 
structure / function (Menny et al 2018).  
The MAC transmembrane channel is a non-specific ion channel allowing K+ efflux, Ca2+ influx, 
osmotic swelling and ultimately cell lysis. Classically, cell death in response to MAC was 
hypothesised to be mediated through osmotic lysis due to perturbation of the chemiosmotic 
homeostasis maintained by the intact cell membrane; however, a recent paper hypothesised 
that bacterial cell death was in fact induced by the build-up of methylglyoxal from glucose 
metabolism which cannot be detoxified because of the altered biochemical composition of 
the cytosol (Bloch et al 2011).  
 
In contrast, self-cells have a range of mechanisms that protect from MAC induced cell death 
and consequently do not usually undergo cell lysis in a similar manner to gram negative 
bacteria due to the regulation of MAC deposition.  However, when MAC is deposited to a level 
which induces cell death in nucleated cells, different mechanisms of killing may occur, 
including apoptotic and necrotic pathways (Kim et al 1987; Bohana-Kashtan et al 2004). 
Necrotic cell death induced by MAC is Ca2+ dependent, with loss of AMP, ADP and ATP and 
loss of inner mitochondrial membrane potential contributing factors (Papadimitrou et al 
1991). Other potential mechanisms behind MAC mediated nucleated cell death will be 
discussed later in the context of NLR activation.  
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1.5 – Regulation of the complement terminal pathway 
 
As mentioned previously, MAC deposition on metabolically active, nucleated cells is 
predominantly sublytic due to a range of protective mechanisms (Rutkowski et al 2010). These 
mechanisms can be broadly subdivided in to regulation of the preceding complement cascade 
to reduce MAC formation, regulation of MAC deposition by specific fluid and membrane 
bound inhibitors, MAC removal through endocytosis or exocytosis, and finally mitigation of 
the lytic effects of the MAC through normalisation of the induced chemiosmotic gradient 
(Lakkaraju et al 2014). Therefore, the regulation of complement terminal pathway activation 
is crucial for the protection of self-cells. 
 
1.5.1 – Regulation of MAC formation by CD59 
 
The predominant membrane regulator of the MAC is CD59, a small (around 20 kDa; 77 amino 
acids), GPI anchored, globular glycoprotein (Kimberley, Sivasankar and Morgan 2007). The 
glycosylation of the molecule is extensive, with a single N-linked glycosylation site at the Asn 
18 which accounts for between 4 and 6 kDa of the molecular mass (Wheeler et al 2002). The 
functional importance of this extensive and heterogenous carbohydrate moiety is unclear, 
with some studies suggesting an important functional role (Suzuki et al 1996), whilst others 
report no such role (Yu et al 1997). The structure of CD59, including the highlighted extensive 
glycosylation is shown in Figure 1.9.  
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Figure 1.9 – A  schematic of CD59 structure which highlights the GPI anchor (Dark green), the extensive N-linked glycosylation 
(Blue) and the active site residues highlighted in yellow (Image edited  from Hill et al 2006). 
 
CD59 inhibits MAC formation by tightly binding to the membrane-bound C5b-8 complex, 
preventing the subsequent C9 polymerisation and unfolding to form the mature MAC (Meri 
et al 1990). Despite CD59 binding to the C5b-8 complex, a single C9 molecule may still bind 
but is prevented from unfolding thus preventing further C9 recruitment and MAC pore 
formation. Binding of CD59 to C5b-8 involves a hydrophobic pocket, highlighted by both 
mutational and peptide docking assays (Huang et al 2006). 
The biological significance of CD59 is clear when cases of CD59 deficiency are considered, 
most notably in the case of PNH. PNH occurs due to a clonal expansion of hematopoietic stem 
cells with a mutation in the PIGA gene, resulting in the deficiency of the encoded GPI anchor 
synthesising protein (phosphatidylinositol N-acetylglucosaminyltransferase subunit A), which 
in turn prevents the effective expression of GPI anchored proteins such as CD55 and CD59. 
The resulting deficiency of these complement regulators, most notably CD59 as a missense 
mutation in humans in CD59 alone result in chronic haemolysis and neuropathy, allows 
dysregulated complement activation on the erythrocyte surface and complement mediated 
haemolysis (Nevo et al 2013; Brodsky 2014; Mevorach 2015). CD59 expression, whilst 
GPI anchor 
N-linked 
glycosylation  
C9 binding site 
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ubiquitous, is also subject to modulation. Cell surface levels of CD59 have been demonstrated 
to be elevated on activated neutrophils in response to formyl like peptide or calcium 
ionophore A23187, likely due to translocation from cytosolic stores (Okada et al 1994). A 
putative intracellular role for CD59 was demonstrated in the translocation and secretion of 
insulin from pancreatic β cells, with the loss of CD59 preventing VAMP/syntaxin 2 complexes 
forming at the cell membrane and limiting exocytic events (Krus et al 2014).  
 A soluble form of CD59 (sCD59) is also found in plasma, released from cells by GPI anchor 
cleavage. sCD59 was shown to be an effective inhibitor of MAC formation In Vitro (Sugita et 
al 1994), but a poor inhibitor In Vivo (Lambris et al 2012). Despite this sCD59 has been shown 
to reduce disease in a mouse model of AMD. Mice injected with recombinant sCD59 exhibited 
reduced choroidal neovascularisation, a hallmark of wet AMD (Bora et al 2007). 
Alongside its regulatory function, CD59 may also be intrinsically linked to complement 
induced cell signalling by its GPI anchor. It was demonstrated that when CD59 was bound to 
or crosslinked through Vaginolysin,  CD59 could act as a signalling platform for tyrosine 
kinases such as SYK, resulting in necroptotic cell signalling (La Rocca et al 2015).  CD59 
crosslinking and signalling may also be reproducible by other CD59 ligands such as MAC, with 
CD59 binding both C5b8 and C9 in the nascent MAC it is feasible that two CD59 molecules 
may bind to the same MAC complex. A schematic of a postulated CD59 signalling mechanism 
is shown in Figure 1.10. Furthermore, MAC deposition induced CD59 clustering in CHO-K1 
cells by stabilising homotypic CD59 ectodomain interactions, making cell signalling via CD59 
an area of interest in terms of MAC induced cell responses (Suzuki et al 2012). Therefore, 
when trying to dissect apart the mechanisms of sublytic MAC induced cell signalling, the role 
of CD59 must be considered, especially as previous studies have utilised anti-CD59 antibodies 
as complement activating and fixing agents – therefore using a system with no anti-CD59 
antibody use or CD59 deletion would demonstrate any GPI anchor mediated signalling effects.  
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Figure 1.10 - CD59 clustering proposed by Suzuki et al in response to MAC deposition, via stabilisation of homotypic CD59 
ectodomain interactions within the lipid raft membrane microenvironment (Image of CD59 sourced from Hill et al 2006, 
proposed signalling from Suzuki et al 2012) 
 
 
 
 
 
 
1.5.2 - Fluid phase regulation of MAC 
 
Fluid phase regulation of MAC formation is medicated by Clusterin and Vitronectin, which 
both regulate the process at the C5b-7 stage. Binding of Clusterin / Vitronectin to C5b-7 
prevents the insertion of the complex in to the membrane but allows the further binding of 
C8 and C9 to form a soluble MAC complex (sC5b-9). The binding of Clusterin / Vitronectin 
prevents the soluble MAC from interacting with the cell membrane, subsequently inhibiting 
lytic capacity (Choi et al 1990). The process of inhibition is dependent on recognition of 
hydrophobic domains in C7 and the β subunits of C8 and C9, the latter dependent on folding 
of the molecule, with poly-C9 competing with the Clusterin binding site (Tschopp et al 1993; 
Chuahan and Moore 2006).  
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1.5.3 - Membrane repair and MAC removal 
 
The final mechanism of defence of nucleated cells against MAC is through the removal of MAC 
from the membrane by endocytosis or membrane shedding followed by repair of the 
membrane (Campbell and Morgan 1985; Morgan, Dankert and Esser 1987).  
The shedding of MAC through exocytosis or ectocytosis has been shown in a range of cell 
types, including neutrophils and various cell lines (Morgan et al 1987; Pilzer and Fishelson 
2005). Exocytosis and ectocytosis of MAC occur via different mechanisms; ectosomes form 
through pinching off regions of the membrane, whereas exosomes require internalisation and 
sorting into multivesicular bodies (MVBs) before release from the cell; these differential 
processing pathways are illustrated in Figure 1.11 (Yellon and Davidson 2014).  
 
Figure 1.11- Schematic of MAC ectosome, endosome and exosome formation and sorting within multivesicular bodies (CRyo-
EM image of the MAC sourced from Menny et al 2018, figure based on Image of MAC internalisation from Pilzer et al 2005) 
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The initial Ca2+ flux induced by the MAC is crucial for signalling MAC expulsion, with chelation 
of intracellular Ca2+ inhibiting the removal of the lesions and increasing cell death (Carney et 
al 1985; Morgan and Campbell 1985). The mechanism by which Ca2+ mediates the removal of 
MAC lesions from the membrane involves kinase activation, with inhibition of ERK being 
shown to decrease the rate of MAC exocytosis (Pilzer et al 2005). Further clues to the 
mechanism of MAC lesion removal can be discerned from experiments utilising the bacterial 
pore forming toxin streptolysin. Streptolysin induced Ca2+ flux resulted in annexin binding to 
membrane phospholipids to cause the aggregation and membrane fusions necessary for 
effective streptolysin pore removal (Babiychuck et al 2011).  
The endocytosis of MAC lesions is a well-established phenomenon within the field of 
complement biology, with the internalisation and subsequent exocytosis of MAC lesions 
shown on neutrophils upon complement attack back in the 1980’s (Morgan et al 1987). The 
role of endocytosis in MAC lesion removal may be two-fold. Firstly, allowing the sorting and 
enrichment of MAC in to MVBs before their subsequent exocytosis, or alternatively allowing 
the internalised MAC to be degraded or potentially induce intracellular signalling events (De 
Wit et al 2015). Endocytosis of receptor: ligand complexes is a common feature in the 
mediation of cell signalling, which generally occurs via a Clathrin mediated endocytic pathway 
(Mbengue et al 2016). However, the processes mediating MAC internalisation and 
endocytosis are controversial, with both conventional Clathrin endocytic pathways and 
Clathrin-independent mechanisms dependent on lipid rafts containing Caveolin-1 and 
Dynamin-2 both being implicated (Kerjaschki et al 1989; Moskovich et al 2012). The latter 
paper implies that Clathrin has no role in MAC endocytosis, as siRNA knockdown of Clathrin 
had no effects on MAC endocytosis or cell death; further work is needed to understand this 
process more clearly. 
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1.6– Sublytic MAC mediated cell signalling 
 
Due to the defence mechanisms described above, nucleated cells exposed to MAC usually 
avoid the cytolytic effects suffered by bacteria or aged erythrocytes.  However, the 
disturbances to cellular physiology induced by sublytic MAC cause a range of responses, 
including the mediate of secretion, degranulation, adherence, aggregation, chemotaxis and 
proliferation (Morgan 1989; Zhu et al 2017).  
In an increasing and diverse range of pathologies, deposition of sublytic MAC is implicated as 
a driver of the inflammation; these include atherosclerosis, cancer, Alzheimer’s disease and 
RA (Lewis et al 2010; Pio, Ajona and Lambris 2013; Romero et al 2013). Unsurprisingly, given 
the range of potential effects of sublytic MAC, the mechanisms by which it induces 
pathologies is diverse. For example, in certain cell types sublytic MAC deposition induces 
apoptosis, resulting in tissue damage and loss of organ function. In a model of 
mesangioproliferative glomerulonephritis, sublytic MAC induced glomerular cell apoptosis 
through activation of Caspase 8 and upregulation of the IRF transcription factor (Liu et al 
2012). Similarly, in photoreceptor cells, sublytic MAC triggered apoptosis and increased 
sensitivity to necrotic pathways induced by staurosporine, a broad range kinase inhibitor (Shi 
et al 2015).  
In contrast, in other cell types, including aortic smooth muscle, endothelial cells and Schwann 
cells, sublytic MAC deposition inhibited apoptosis and induced proliferation (Tegla et al 2011). 
The induction of proliferation by sublytic MAC is mediated by several mechanisms, including 
RAS/RAF and AKT mediated pathways. Some reports suggest that intracellular signalling 
cascades are activated even before the completion of the MAC pore, with C5b-7 implicated 
in the activation of membrane phospholipases and cAMP signalling, although the exact 
mechanism of how the loosely membrane associated C5b-7 induced signalling events was not 
explored (Carney et al 1990). Further anti-apoptotic mechanisms induced by sublytic MAC 
include the induction of the RAS/RAF, ERK, p38MAPK, JNK and Gi / Go G-protein activation; 
these multiple pathways are summarised in Figure 1.12. Anti-apoptotic effects of MAC may 
correspond to the observed enhancement of cell cycle, involving increased CDK-2 and CDK-4 
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signalling, whilst reducing p21 cell cycle inhibitor mRNA expression (Rus, Nicolescu and Shin 
1996).  
Many of these signalling pathways are driven through differential cell type responses to 
sublytic MAC mediated elevation of intracellular Ca2+, caused by chemiosmotic gradient 
between the cytosol and the extracellular fluid, which becomes disrupted by the nonspecific 
MAC pore (Morgan 1989) . The level of elevation, the duration of Ca2+ flux and the cell specific 
signalling machinery mediates the effects Ca2+ and may determine which of these contrasting 
cell fates occurs. Whilst Calcium may activate a raft of associated kinases and signalling 
pathways, the direct binding of Calcium ions to protein structures can have large effects on 
pore both structure and function, which may have direct implication on activation of NLRP3 
and associated inflammasome components (Yaron et al 2015). 
 
 
Figure 1.12. Pro-survival signalling pathways activated in different cell types by sublytic MAC. The association of MAC with 
Giα subunits to drive RAS/RAF is still controversial, however the influx of calcium may also activate MAPK and PLC/IP3 
signalling (Image derived  from Tegla et al 2011). 
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The contributions of the pro-inflammatory effects of sublytic MAC and the anaphylatoxins to 
disease pathology are increasingly implicated in a broad spectrum of diseases. Complement 
knockout mice show decreased inflammation in models of inflammatory disease, such as 
collagen antibody-induced rheumatoid arthritis. In this model, clinical severity of this 
inflammatory autoimmune condition was compared between WT and C3aR -/-, C5aR -/- and 
C6 -/- mice, with the severity scoring decreasing by 52, 94 and 65% for each respective 
knockout (Banda et al 2012). These data highlight the importance of complement as a pro-
inflammatory driver of the innate immune system, in some cases to a pathological level.  
The signalling pathways induced by the anaphylatoxins and sublytic MAC are part of the 
larger, complex network of innate immune system driven signalling pathways. Within this 
network, complement signalling acts both synergistically and antagonistically with a range of 
other receptors including Toll like receptors (TLRs), Rig like receptors (RLRs), Nod like 
receptors (NLRs) and other effectors such as C-reactive protein (CRP). For the signalling 
impact of complement to be fully appreciated, the interactions with these other mechanisms 
need to be realised; therefore, anaphylatoxin and sublytic MAC cell signalling will be revisited 
once these others have been highlighted in the following section. Some of the diverse array 
of signalling pathways activated by sublytic MAC are shown in Figure 1.13. 
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Figure 1.13. Schematic of the range of cellular effects induced by sublytic MAC. Sublytic MAC deposition on the cell can 
mediate a range of effects through elevation of intracellular Ca2+, induction of cAMP signalling, PLC activation and NF-κB 
activation. Many of these pathways have implications in inflammasome activation and inflammatory cell signalling. Image 
sourced from Morgan et al 2016.  
 
 
1.7 - Nod like Receptors – background, signalling and disease. 
 
Nod like receptors (NLRs) are a versatile family of intracellular receptors with a broad range 
of functions, ranging from antigen presentation and modulation of inflammation to 
embryonic development and sensing cellular metabolic changes (Motta et al 2015). 
Evolutionarily, NLRs are well conserved and orthologs are found across much of the animal 
kingdom (Lange et al 2011). The NLR family in humans is diverse, comprising 22 members 
with specific functions dependent on ligand specificity and effector functions, each 
determined by individual domains in the molecular tripartite structure. Upon activation the 
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autoinhibited monomeric inflammasome-forming NLRs oligomerise to form the characteristic 
pinwheel-shaped active inflammasome structure, leading to cell signalling and cytokine 
secretion events (Lechtenberg et al 2014). 
As mentioned, numerous NLRs perform vital roles within the body; however, the most well 
studied, ubiquitously expressed and pathologically relevant NLR is NLRP3. Dysregulation of 
NLRP3 can perpetuate chronic inflammation through cytokine maturation and secretion and 
the induction of pyroptosis and is implicated in classical cryopyrinopathies such as Muckle-
Wells syndrome, neonatal-onset multi-system inflammatory disease (NOMID) and more 
common pathologies such as cardiovascular, metabolic and rheumatic conditions (Tong et al 
2015; Rheinheimer et al 2017; Zhou et al 2018). Due to this well documented role of NLRP3 
in the perpetuation of aberrant inflammation, it will be my focus experimentally over the 
course of the project.  
 
1.7.1 – NLR structure and function 
 
NLRs are comprised of a distinct tripartite structure, the Leucine rich repeat region (LRR), the 
nucleotide binding and oligomerisation domain (NACHT) and N terminal effector domain 
(normally a pyrin or a Caspase activation and recruitment domain – PYD and CARD 
respectively) which co-operatively determine both ligand specificity and the presence or 
absence of a linker between the inflammasome and respective effector Caspase, with NLRP3 
structure highlighted in Figure 1.14.  
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Figure 1.14. Tripartite structures of known inflammasomes with LRR, NACHT and PYD/CARD domains, with NLRP3 highlighted 
(Image edited  from Stutz et al 2009).  
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1.7.2 - The roles of the LRR in NLRP3 function 
 
The C terminal LRR is functionally responsible for PAMP / DAMP sensing and the specificity of 
the individual NLRs (He, Hara and Nunez 2015). The LRRs of NLRs and TLRs demonstrate some 
conserved secondary structural motifs, including a super helical arrangement of short parallel 
beta strands. The overall topology of LRRs in NLRs is a right-handed helix, as opposed to TLRs 
that are left handed helix or flat; all contain a highly conserved Leucine repeat (LxxLxLxxNx(x/-
)L) where L represents Leucine, N is Asn, Thr, Ser or Cys and X is a non-conserved residue. The 
general function of the LRR is to mediate homotypic protein-protein interactions, the nature 
of which in the case of inflammasome activators is still unclear (Kobe and Kajava 2001). 
However, the SGT-1/HSP70/HSP90 complex is fundamental for inflammasome activation and 
preferentially interacts with protein LRR regions. This may suggest that this chaperone 
complex may be intrinsically involved in assisting the protein refolding upon activation, or 
possibly acting as a linker in a complex with an activating protein such as AKT or MAP3K, which 
have been shown to associate with the SGT-1 complex when active (Mayor et al 2007).  
 
1.7.3 - NACHT function in NLRP3 activation 
 
The second main functional domain within the tripartite inflammasome structure is the 
central NACHT domain, responsible for the nucleotide binding and oligomerisation of NLRs 
(Duncan et al 2007). Although no 3D structures of the NACHT domains of NLRP proteins have 
been solved, the structurally and functionally similar NLRC4 and APAF1 NACHT domains have 
been recently elucidated and may offer new insight into NLRP protein activation and 
oligomerisation.  NLRC4 has been mapped to a resolution of 3.2 Ȧ (minus the CARD) 
demonstrating that, like APAF-1, NLRC4 monomers exist in an autoinhibited monomeric form 
with ADP bound to the NACHT domain and the LRR forming a loop spatially binding the 
nucleotide-binding and HD2 domains (Hu et al 2013). 
The NACHT of APAF-1 / NLRC4 were shown to contain a central NOD domain with 3 auxiliary 
helical NAD domains containing 12 conserved motifs relating to nucleotide binding and 
hydrolysis, including an ATPase specific and catalytic Mg2+ binding pocket that enables the 
 
 
37 
 
NLRs to associate with the STAND family of AAA+ ATPases (Zhang et al 2015). NLRP3 and 
NLRP12 also exhibit a specific ATPase activity, which has been shown to be necessary for 
functional inflammasome formation (Maharana et al 2015). Often, ATP binding or hydrolysis 
induces conformational changes in the both the local and overall structures of proteins; 
therefore, it has been hypothesised that the ATP/ADP bound state of the NLRs may regulate 
their activity (Duncan et al 2007).  
Unsurprisingly, due to the plethora of pathophysiological conditions in which inflammasome 
activation (particularly NLRP3) has been implicated, pharmaceutical modulation of 
inflammasomes is of intense interest. Notably, a range of vinyl sulphone anti-inflammatory 
compounds, including Bay 11-7082, which functioned through an unknown mechanism, have 
been shown to interact directly with the NACHT of NLRP3 (Juliana et al 2010).   
 
1.7.4 – The role of the PYD in NLRP3 activation 
 
The final major structural domain of NLRs is the N terminal effector domain which, depending 
on the NLR, is either a CARD or PYD. Both the NLRP1 and NLRC4 complexes contain the CARD 
domain, allowing direct interaction between the NLR and its Caspase effector (Lechtenberg 
et al 2014). The inflammasome forming NLRs, including NLRP3, lack a CARD domain and 
instead interact with the associated Caspase through the linker associated speck like protein 
(ASC). ASC is a 22 kDa, highly charged protein containing a pyrin domain (PYD) and Caspase 
activation and recruitment domain (CARD) which was observed to form intracellular specks 
in response to retinoic acid in HL-60 cells (Masumoto et al 1999). Later, it was established that 
ASC was the central linker in inflammasome formation by binding to the NLR PYD through 
homotypic interactions, and subsequently with Caspses through the CARD (Liu et al 2013). 
To date, no crystal structure or mutational analysis of NLR PYD domains have been described; 
however, NMR spectroscopic techniques have shed some light on a potential mechanism of 
PYD interactions. Charged regions are present on the PYD of ASC, with helices 1 and 4 being 
highly negatively charged and 2 and 3 highly positive, allowing PYD/PYD interaction between 
oppositely charged helices (Liepinsh et al 2003). Further, NMR studies on the NLRP12 PYD 
demonstrate that it forms a tightly packed 6 helical bundle with short loop regions, all 
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stabilised by a substantial hydrophobic core to give a stable tertiary structure, shown in Figure 
1.15 (Pinheiro et al 2011). The charge state of the PYD of NLRP3 seems to be crucial for 
oligomerisation to form an active inflammasome, with the phosphorylation state of Ser5 of 
crucial importance. The dephosphorylation of Ser5 by protein phosphatase 2 a (PP2a) was 
demonstrated to be sufficient to induce a permissive state for oligomerisation through 
allowing charge interactions in the PYD interface (Stutz et al 2017).  
 
 
 
 
 
 
 
 
Figure 1.15.  A ribbon diagram of the proposed lowest energy conformer of NLRP12 PYD demonstrating the charged α helices 
thought to be crucial for PYD:PYD interaction (B) The same image rotated through 90˚ and the hydrophobic core residues 
highlighted in Cyan stick form (C) (Image edited from Pinheiro et al 2011).  
 
1.8– Inflammasome priming – Signal one 
 
To activate the NLRP3 inflammasome, induce oligomerisation and effectively secrete IL-1β 
and IL-18, a two-step signalling process is generally required with the initial priming step 
induced by TLR, C5a receptor or cytokine receptor signalling. It was demonstrated that 
priming, predominantly through NF-κB signalling, was necessary, but not sufficient, to induce 
NLRP3 activation (Bauernfeind et al 2009). It was subsequently demonstrated that NF-κB 
induced an upregulation of the precursors pro-IL1β/pro-IL18 as well as NLRP3 itself, but not 
upregulation of the inflammasome components ASC or Caspase-1 (Hornung and Latz 2010). 
 
Stabilising 
hydrophobic core Highly charged 
α-helices 
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1.8.1 – Transcriptional priming through TLR4 
 
The prototypical cell signalling for priming of the NLRP3 inflammasome is mediated by TLR4 
activation by a range of ligands, including PAMPS such as the bacterial cell wall component 
lipopolysaccharide (LPS) and DAMPS including HMGB1 (Kim and Jo 2013). TLR4 is a single pass 
transmembrane receptor comprising a 608 aa extracellular domain, a transmembrane 
domain and a 187 aa intracellular domain (Kim et al 2007). The recognition and interaction of 
TLR4 with LPS is mediated by MD-2 which undergoes conformational change upon interaction 
with LPS, permitting phosphate groups on the LPS molecule to induce receptor 
multimerisation and signal transduction, shown in Figure 1.16 (Park et al 2009).  
 
 
 
Figure 1.16. The activation of the canonical NF-κB signalling pathway through TLR4. The activation of NF-κB to induce the 
expression of pro-IL1β, pro-IL18 and NLRP3 is generally necessary for effective inflammasome activation (Image content 
sourced from Lim and Staudt 2013). 
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TLR engagement induces the cytoplasmic TIR domain to recruit various signalling adaptors 
including MYD-88 and/or TRIF/TRAM (Lim and Staudt 2013). Dependent on the signalling 
adaptor engaged, a range of potential effectors can then be activated, including the IRAK 
kinase family and the ubiquitin ligases TRAF6 and Pellino 1 (Kawai and Akira 2010). The 
activation of these pathways then culminates in the engagement of NF-κB, JNK and p38 MAPK 
signalling pathways to regulate gene transcription (Figure 1.17). The induction of NF-κB 
signalling through TLR4 activation is via the canonical pathway; IKKβ is activated by 
phosphorylation and in turn phosphorylates IKKα Ser32 and Ser36, inducing IKKα proteasomal 
degradation and freeing NF-κB from the inhibitor complex. This then allows NF-κB P50/P65 
heterodimer translocation to the nucleus to induce the transcription of a host of pro-
inflammatory genes (Hoesel and Schmid 2013).  
Alongside the canonical priming mechanism through TLR4 engagement, other mechanisms of 
priming through TNFαR, C5aR and an autocrine loop through IL-1R signalling also exist, 
transduced through similar mediators to result in NF-κB mediated NLRP3 priming (He et al 
2016). These are summarised  in Figure 1.17.  
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Figure 1.17. Mechanisms of NLRP3 priming. NLRP3 priming occurs via the induction of NF-κB mediated transcription of 
NLRP3 and Pro-IL1β and Pro-IL18, as well as postulated direct effects on NLRP3 itself via post translational modifications. 
Alongside canonical TLR4 priming, IL-1R and TNFαR can mediate these effects through IRAK 1/4 , MYD88, FADD, Caspase-8 
and TRIF/TRAM related pathways. C5aR has been implicated to directly effect NLRP3 activation through ROS production 
and priming through P38 MAPK mediated NF-κB activation (Haggadone et al 2016; Groslambert and Py 2018)  
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1.9- Non-transcriptional priming of NLRP3 
 
The priming signal through the NF-κB signalling pathway was thought to simply induce the 
transcription of necessary components for inflammasome activation; however, activation of 
NF-κB also has a direct effect upon NLRP3 through the generation of reactive oxygen species 
(ROS), which in turn activate the BRCC3 de-ubiquitinase; the resultant de-ubiquitination of 
NLRP3 may yield a primed state (Juliana et al 2012). 
Further studies also demonstrate TLR priming is not strictly necessary; for example, 
simultaneous engagement of TLR4 and NLRP3 induced a strong Caspase-1 response in an 
IRAK-1 dependent manner in bone marrow derived macrophages (Lin et al 2013).  A central 
role for ERK1, ROS and the proteasome in inflammasome activation independent of 
transcription suggests that the priming step is more complex than just the transcription of 
inflammasome components (Ghonime et al 2014). 
 The evidence for the involvement of phosphorylation in the priming and activation of the 
NLRP3 inflammasome also includes a potential role for TAK1 and the MAPK family, with 
multiple studies highlighting TAK1/JNK and SYK as crucial for release of IL-1β through NLRP3 
activation; however, the data indicate a role for these kinases in the induction of ASC speck 
oligomerisation rather than direct interaction with NLRP3 (Okada et al 2014; Patel et al 2018). 
Moreover, TAK1 deficient murine BMDMs demonstrate spontaneous NLRP3 activation in the 
absence of conventional priming/activation stimuli, mediated through RIPK1 and 
spontaneous TNF-α autocrine signalling coupled with IKKα/β activation; these cells also 
demonstrated homeostatic hyperactivation of ERK, traditionally delineated as a downstream 
activated MAPK of TAK1, demonstrating that non-canonical mechanisms may mediate this 
effect (Malidreddi et al 2018). 
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1.10 – NLRP3 activation mechanisms – Signal two 
 
The NLRP3 inflammasome, once primed in either a transcription dependent or independent 
manner, can become activated by a plethora of activating stimuli which break down in to 
three main categories – intracellular ion fluxes, ROS generation and mitochondrial 
dysfunction and lysosomal rupture and damage (Zoete et al 2014). The effects of these stimuli 
on the structure and binding partners of NLRP3 are profound; however, how these diverse 
stimuli elicit the same response is unclear. The diversity of activating stimuli would suggest a 
conserved set of downstream mediators due to the improbability of NLRP3 directly 
recognising such diverse signals; however, these mechanisms remain obscure. A schematic 
illustrating the broad classes of NLRP3 activators is shown in Figure 1.18.  
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Figure 1.18 – Classes of NLRP3 activators. Broadly, NLRP3 activation is induced through cell membrane disruption through 
ionophores, frustrated phagocytosis / lysosomal disruption through crystalline substances or aggregated proteins or 
through extracellular ATP mediating P2XR7 activation. Alongside these external activators, the dysregulation of internal 
organelle homeostasis (through one of these stimuli or otherwise) may also drive inflammasome activation. The 
downstream events of these stimuli then broadly divisible in to ionic flux, ROS generation, lysosomal destabilisation and 
cathepsin release and organelle dysfunction. MAC cryo EM sourced from Menny et al 2018.  
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A leading hypothesis is that ion flux is a necessary and sufficient signal to induce NLRP3 
inflammasome activation; however, the exact nature of the flux, whether it is dependent on 
potassium efflux, calcium influx, or a combination of both, is still controversial (Chae et al 
2015; Katsnelson et al 2015; Yaron et al 2015). 
 
1.10.1 - Potassium efflux as an activator of NLRP3 
 
The hypothesis that potassium efflux is solely responsible for the activation of the NLRP3 
inflammasome is supported by the recent report systematically demonstrating that there was 
no role for Ca2+ influx in the activation of NLRP3 (Katsnelson et al 2015). It was demonstrated 
that nigericin-induced Ca2+ influx occurred downstream of Caspase-1 activation, likely due to 
the capacity of Caspase-1 to alter membrane permeability; depletion of Ca2+ from the 
medium, depletion of ER Ca2+ stores and Ca2+ specific ionophores were all without effect on 
IL-1β secretion. Furthermore, the group showed that the intracellular Ca2+ chelator BAPTA, 
previously shown to strongly inhibit NLRP3 activation, exerted pleiotropic inhibitory effects, 
including inhibition of NLRP3 activation in response to Nigericin even in Ca2+ depleted medium 
(Katsnelson et al 2015). The exact mechanism by which K+ efflux activates the inflammasome 
is as yet unclear. Many other groups have demonstrated NLRP3 inhibitory functions of the K+ 
channel inhibitor Glyburide and elevated extracellular K+ concentrations, making K+ efflux a 
strong candidate for NLRP3 activation (Lamkanfi et al 2009; Di et al 2018). 
 
1.10.2 - Calcium influx as an activation mechanism of NLRP3 
 
Despite the evidence described above, other groups have strongly conflicting data 
demonstrating a crucial and indispensable role for Ca2+ for inflammasome activation 
(Sutterwala et al 2014). For example, the intracellular calcium receptor (CASR) was necessary 
and sufficient to activate the NLRP3 inflammasome in the presence of elevated cytosolic Ca2+ 
calcium (Lee et al, 2012). Interestingly, they also reported a paradoxical response to increased 
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extracellular Ca2+, which inhibited NLRP3 activation by extracellular ATP but not flagellin or 
dsDNA, perhaps beginning to explain some of the discrepancies in the literature.  
Some groups have attempted to unify the contrasting theories on the role of ion fluxes in 
NLRP3 inflammasome activation utilising real time imaging to link the K+ and Ca2+ fluxes, 
showing that NLRP3 activation is dependent on both ions and proposing a model where K+ 
efflux was the regulator for Ca2+, which then in turn induced mitochondrial dysfunction and 
ROS generation to induce the final activation signal (Yaron et al 2015).   
 
1.10.3 - ROS generation, mitochondrial dysfunction and metabolic perturbation as NLRP3 
activators 
 
The concept that mitochondria may be intrinsically linked with NLRP3 activation has strong 
support, with the mitochondria acting as a nexus between Ca2+, ROS and cell metabolism – all 
of which have been shown to activate or regulate NLRP3 activation. The concept that ROS, 
predominantly produced by mitochondria, is an activator of the NLRP3 inflammasome is 
controversial, with studies presenting arguments both for and against the case (Zhou et al 
2011; Iyer et al 2013). Whether ROS act as an activator of NLRP3 or are generated as a 
consequence of the activation remains unclear, with real time ROS imaging being required to 
delineate the chronology of events.  
Other molecules associated with mitochondria, including Cardiolipin, MAVS, Mitofusins and 
mitochondrial DNA, have all been shown to act as activators of NLRP3; this, coupled with the 
demonstration that sphingolipids and other metabolic intermediaries can activate or 
downregulate the inflammasome, place the NLRP3 inflammasome at a crossroads of 
immunity, metabolism and cell signalling cascades, aligned with the mitochondria (Camell et 
al 2015; Gurung et al 2015). The recent demonstration that NLRP3 translocates to a 
mitochondrial proximal position upon priming is further evidence of the interactions between 
mitochondria and NLRP3 (Sutterwala et al 2018). The evidence that NLRP3 activation is 
heavily dependent on the metabolic state of the cell is gradually growing, highlighting a 
potential immunometabolic axis, the imbalance of which drives the inflammatory state. It has 
been demonstrated In vitro that elevated extracellular glucose (25 mM) induced an 
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upregulation of NLRP3 and IL-1β in murine podocytes, while NLRP3 or Caspase 1 deficiency 
ameliorated diabetic nephropathy in mouse models (Shahzad et al 2015). 
 
1.11 –Pore forming proteins as activators of NLRP3 
 
Whilst the focus of this thesis will be on the potential of the membrane attack complex to 
activate NLRP3, a range of other pore forming proteins have been demonstrated to be 
inflammasome activators, including nigericin, haemolysin, perforin and cholesterol 
dependent cytolysins (Mariathasan et al 2006; Chu et al 2009; Yao et al 2017; Muñoz-
Planillo et al 2009; Yao et al 2017).  
Nigericin has been established as a potent NLRP3, first demonstrated to induce mature IL-1β 
secretion in LPS primed macrophages (Mariathasan et al 2006).  In contrast to the other 
pore forming toxins, Nigericin is highly selective for monovalent cations, particularly K+, with 
a 45-fold higher affinity for K+ over Na+ and limited affinity for divalent cations other than 
Pb2+ (Prabhananda et al 1991; Hamidiana et al 2004). Therefore, the mechanism by which 
nigericin drives NLRP3 activation has been strongly associated with the efflux of K+ from the 
cell (Katnelson et al 2015). Despite this, other groups have suggested that mitochondrial  
ROS is the predominant activator of NLRP3, as ROS scavengers dose dependently inhibit 
nigericin mediated NLRP3 activation and mitochondrially derived ROS was shown to drive 
lysosomal destabilisation, with subsequent NLRP3 activation (Heid et al 2013). Although as 
mentioned, nigericin has limited capacity as a Calcium ionophore, Calcium mobilisation from 
intracellular ER stores has been demonstrated in response to nigericin, with ablation of ER 
release through 2-ABP (IP3 receptor antagonist and TRP channel inhibitor), U7312 
(Phospholipase C inhibitor) or Xestospongin C (IP3 receptor antagonist) pre-treatment 
statistically significantly inhibiting Caspase-1 cleavage and IL-1β release (Murakimi et al 
2012). 
The other pore forming proteins demonstrated to activate NLRP3 have less ionic specificity 
in comparison to nigericin, and therefore can induce primary Ca2+ flux across the cell 
membrane as well as mediating release from endoplasmic stores. Despite this, the 
staphylococcus derived α-haemolysin has only been demonstrated to activate NLRP3 by a K+ 
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dependent mechanism, although ROS scavengers or Ca2+ modulating agents were not tested 
(Muñoz-Planillo et al 2009; Craven et al 2009). Interestingly, elevated extracellular NaCl (130 
mM) did not affect α-haemolysin mediated NLRP3 activation, in contrast to data in this 
thesis for MAC mediated NLRP3 activation (Craven et al 2009). 
Contrastingly, cholesterol dependent cytolysins (CDLs) have had a demonstrable role for 
Ca2+ in NLRP3 activation, alongside K+. CDLs mediated NLRP3 activation in murine BMDMs 
was demonstrated to be at concentrations below a lytic threshold, inhibited by the addition 
of free extracellular cholesterol and pharmacological inhibitors of Cathepsins, PLA2, calcium 
chelators or elevated extracellular K+ (Chu et al 2009). In a similar manner, perforin 
activation of NLRP3 was also demonstrated to be dependent on both K+ efflux and Ca2+ 
influx in murine BMDMs, with calcium chelation, inhibition of the release of endoplasmic 
reticulum calcium stores and elevated extracellular KCl all statistically significantly inhibiting 
IL-1β secretion.  
Therefore, across a range of ionophores (with the exception of haemolysin, where the role 
of Ca2+ was not fully investigated) , both K+ efflux and Ca2+ have been implicated in 
mediating the activation of NLRP3, even in the case of Nigericin which has limited Ca2+ 
affinity. Further implicated pathways include ROS production and Cathepsin activation, with 
a summation of the cited literature shown in table 1. MAC mediated activation of NLRP3 will 
be addressed separately (section 1.18.2), however, MAC has been included in the table for 
completeness and to allow comparison with the other ionophores. 
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Ionophore 
name 
Ionophore 
selectivity  
Cell model(s) used 
Proposed 
mechanism(s) of 
NLRP3 activation 
References 
Nigericin K+>Na+>Ca2+ 
 primary murine 
dendritic cells and  
bone marrow derived 
macrophages 
K+ efflux, Ca2+ 
release from 
intracellular stores, 
ROS generation 
Murakimi et al 
2012, Katnelson 
et al 2015, Heid 
et al 2013  
Haemolysin Non-specific 
THP-1 cells, primary 
murine bone marrow 
derived macrophages 
K+ efflux 
Craven et al 
2009, Munoz-
Planillo et al 2009 
Cholesterol 
dependent 
cytolysins 
Non-specific 
Primary murine bone 
marrow derived 
macrophages 
K+ efflux, Ca2+ influx, 
Ca2+ independent 
PLA(2), Cathepsin B 
Chu et al 2009 
Perforin Non-specific 
Primary murine bone 
marrow derived 
macrophages 
K+ efflux, Ca2+ 
release from 
intracellular stores 
(Ca2+ total chelation 
was also inhibitory) 
Yao et al 2017 
Membrane 
attack 
complex 
Non-specific 
A549 lung epithelial 
cells, Primary human 
and mouse bone 
marrow derived 
macrophages, Primary 
murine bone marrow 
derived dendritic cells 
Ca2+ flux, Ca2+ 
release from 
intracellular stores, 
mitochondrial 
damage, K+ efflux, 
ROS production 
Triantafilou et al 
2013, Laudisi et 
al 2013, Suresh 
et al 2016 
 
Table 1: Pore forming proteins known to activate NLRP3. A range of pore forming ionophores have been demonstrated to 
activate NLRP3 in a range of cell types. Ionophore specificity, proposed mechanisms of NLRP3 activation and cell models 
used in cited papers.  
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1.12 - Negative regulation of NLRP3 activation 
 
Due to the potential for aberrant NLRP3 activation to perpetuate chronic inflammation, tight 
regulation beyond the two-step activation process is required. A range of regulatory 
mechanisms govern the NLRP3 inflammasome, varying from miRNA transcriptional regulation 
of components to inhibition of activation of the translated proteins forming the oligomeric 
complex.  
The regulation of the NLRP3 inflammasome by miRNA has been demonstrated by various 
groups with miRNAs 33, 132 and 9 amongst those implicated as negative NLRP3 regulators 
(Byeon et al 2017; Wang et al 2017; Xie et al 2018). The former two of these regulated IL-1β 
and IL-18 expression, whilst miRNA 9 regulated NF-κB through JAK / STAT signalling leading 
to inflammasome priming in an atherosclerosis model. 
Inhibition of NLRP3 assembly pertains directly to the modulation of MAC-mediated activation 
in primed cells. 5’ AMP activated protein kinase (AMPK) signalling is a negative regulator of 
NLRP3 activation, with AMPK acting as an indirect sensor of the cell metabolic state and 
becoming activated by elevated AMP:ATP ratios (Richter and Ruderman 2010). The induction 
of AMPK signalling can regulate NLRP3 through a variety of mechanisms, including the 
induction of autophagy, mediating mitochondrial plasticity and cell energy homeostasis and 
managing ER stress responses, all of which are implicated as NLRP3 activators (Cordero et al 
2018). In a similar manner, cAMP signalling can be an effective inhibitor of NLRP3 activation; 
cAMP directly binds NLRP3 and inhibits the ATPase NACHT domain, preventing 
oligomerisation and activation. This is particularly relevant given the ability of MAC to mediate 
activation of cAMP signalling and the PKA pathway, which may provide an effective “off 
switch” for MAC mediated NLRP3 activation (Halperin and Weller 1993).  
Finally, mechanisms of post translational modification such as ubiquitination and 
phosphorylation may also regulate the inactivation and dissipation of the NLRP3 
inflammasome. The ubiquitinating enzyme FBXL2 mediates the downregulation of NLRP3 
through Lys-689 ubiquitination; however, upon LPS stimulation FXBL2 itself becomes 
ubiquitinated and degraded through action of F-BOX 03, thus the inhibitory effect is removed 
(Jo et al 2017). Phosphorylation can also have inhibitory effects on inflammasome activation. 
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Phosphorylation of IKKα regulates NLRP3 oligomerisation through secondary ASC 
phosphorylation and decreased Caspase-1 recruitment. Direct phosphorylation of NLRP3 
through PKA phosphorylation of Ser295 can also reduce the ATPase capacity of the NACHT. 
Interestingly, CAPS associated mutations in NLRP3 localise around Ser295, suggesting 
hyperactivation and subsequent pathology may be regulated by the region (Mortimer et al 
2016).  
 
1.13– Inflammasome assembly and effects of IL-1β secretion 
 
As discussed previously, under normal cellular conditions NLRP3 folds into an auto-inhibited 
structure where the LRR domain interacts with the NBD and folds over the molecule, 
preventing nucleotide binding and activation (Ting et al 2008). This is corroborated by the 
evidence that missense Tyr859Cys mutations in the LRR domain found in atypical 
autoinflammatory disorder patients exhibit enhanced ASC speck formation and Caspase-1 
processing, indicating an important role of the LRR in setting the activation threshold of 
NLRP3 (Jeru et al 2010). Therefore, it appears that, upon activation, NLRP3 undergoes 
conformational change allowing the LRR to release the protein into an active formation and 
replacing the NACHT-bound ADP with ATP to allow formation of the multimeric 
inflammasome complex.  
It has been hypothesised that HSP90 and SGT1 cellular chaperones may be central to this 
process; indeed, the HSP90/SGT1 complex is indispensable for inflammasome activation 
(Mayor et al 2007). Furthermore, HSP90/SGT-1 associates with Ca2+ sensing proteins, 
including S100 and a diverse range of kinases and ubiquitin remodelling proteins, potentially 
linking some of the diverse activation stimuli of the NLRP3 inflammasome (Kadota et al 2010). 
One such kinase which has recently been highlighted as having a crucial role in NLRP3 
activation is NEK7, a member of the NIMA family of kinases which regulate cell cycle 
progression and is a crucial regulator of NLRP3. NEK7 is fundamental for survival, with NEK7 -
/- mice undergoing embryonic lethality. NEK7/NLRP3 interactions regulate inflammasome 
and speck assembly independent of NEK7 kinase activity (He et al 2016).  
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The binding of ATP to NACHT is the trigger required to allow the critical homotypic 
interactions between the pyrin domains of NLRP3 and ASC, essential for the formation of the 
mature inflammasome (Abderrazak et al 2015). The interaction between NLRP3 and ASC 
serves as a site of nucleation for further ASC/ASC interactions, allowing the formation of a 
filamentous ASC spindle which in turn allows the nucleation of Caspase-1 filaments, recruited 
to ASC via CARD domain homotypic interactions, shown in Figure 1.17 (Lu and Wu 2014). 
 
 
Figure 1.17. The formation of the multimeric NLRP3 inflammasome complex. Activated NLRP3 forms a point of nucleation for 
ASC oligomers via PYD/PYD homotypic interactions, which in turn provides nucleation for Caspase-1 fibrils through 
CARD/CARD interactions (Image edited from Lu et al 2014). 
 
The formation of the Caspase-1 fibrils catalyses the conversion of pro-Caspase-1 zymogen to 
the active Caspase p10/p20 heterodimer through autolytic cleavage (Franchi et al 2009). This 
activated caspase then performs the final and critical step in inflammasome activation, the 
proteolytic cleavage of the precursors pro-IL-1β and pro-IL-18 to yield the pro-inflammatory 
cytokines IL-1β and IL-18, alongside a range of non-canonical substrates (Sollberger et al 
2012).  Caspase-1 activation has also been implicated in other processes such as cell 
membrane repair through SREBP1 activation and interactions with caveolae and regulation 
of cellular metabolic processes, including glycolytic enzyme cleavage and regulation of 
triglyceride metabolism, independently of IL-1β or IL-18 (Kotas et al 2013).  
 
 
 
NLRP3 
ASC  
Caspase-1 
filaments 
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1.14 - Non-Canonical inflammasome activation 
 
Whilst the mechanisms underlying canonical NLRP3 activation are still unclear, non-
canonical activation mechanisms, where Caspase-11 in mice and Caspases 4 or 5 in humans 
are recruited to the complex in place of Caspase-1, are even more obscure. Non-canonical 
NLRP3 activation occurs during gram negative bacterial infection and its effects resemble 
canonical activation, with secretion of IL-1 family cytokines, Gasdermin cleavage and 
pyroptotic events (Pellegrini et al 2017). The realisation that non-canonical caspases may be 
important in NLRP3 activation was hindered by the proximity of Caspase-1 and Caspase-11 
on chromosome 10 in mice; Caspase-1 knockout mice also lacked Caspase-11. The 
generation of Caspase-1 null mice with functional Caspase-11 suggested that Caspase-11 
could not directly process the pro-cytokines but augmented the capacity of Caspase-1 to 
cleave pro-IL-1β in response to both canonical and non-canonical activators (Man et al 
2017). To further complicate matters, other groups have reported that human Caspases 4 
and 5 have some capacity to process IL-1β independently of Caspase-1 (Schmid-Burgk et al 
2015).  
1.15- IL-1β secretion and release of inflammasome components 
 
The exact mechanism by which IL-1β produced by the NLRP3 inflammasome is released from 
the cell to act as a pro-inflammatory cytokine are still obscure; the process does not follow 
the canonical ER/Golgi secretion system and numerous mechanisms have been proposed. 
These include endosomal/lysosomal populations of IL-1β being released when autophagy is 
inhibited, microvesicular shedding, and release from pyroptotic cells as membrane integrity 
decreased (Luheshi et al 2012). Alongside IL-1β and IL-18 secretion, ASC and Caspase-1 may 
be released from the cell; in primed macrophages activated with ATP or Nigericin, ASC foci 
capable of activating Caspase-1 were detected outside of the cell within 20 minutes of 
stimulation (Baroja-Mazo et al 2014). Furthermore, extracellular ASC foci may propagate 
other roles independently of NLRP3 and Caspase-1 through the mediation of apoptosis or 
nucleating further ASC foci in neighbouring cells through phagocytic uptake and propagation 
of NLRP3 inflammasome activation (Franklin et al 2014; Franklin et al 2018). Interestingly, this 
behaviour of ASC as a highly oligomeric, fibril-forming molecule is reminiscent of prionoid 
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proteins such as β-amyloid. Indeed, it has been shown that ASC released from cells upon 
pyroptosis can be a target for autoantibodies in autoinflammatory disease.  
 
1.16 - IL-1β signalling in health and disease 
 
IL-1β induces potent pro-inflammatory effects through binding its cell surface receptor; IL-1R 
has high intracellular domain homology with the TLRs, generating the TIR superfamily, critical 
mediators of innate inflammatory responses (Dunne and O’Neill 2003). Both IL-1α and IL-1β 
can bind the IL-1R to induce differing signalling responses (O’Neill and Greene 1998). The IL-
1R contains three extracellular IgG domains which when bound to ligand form a question 
mark shaped structure, enveloping and grasping the ligand in a similar manner to the 
interactions of the FGFR / FGF (Ve, Williams and Kobe 2015). However, unlike the binary FGFR 
– FGF complex, the IL-1R complex is heterotrimeric in nature, consisting of the primary 
receptor subunit, the ligand and a receptor accessory protein IL-1RAP which stabilises the IL-
1R as well as being crucial for the recruitment of intracellular effectors such as MYD-88 for 
effective signal transduction (Smeets et al 2005). 
IL-1R ligand binding triggers four identified signalling kinase cascades, NF-κB, ERK1, ERK2 and 
JNK (Dunne and O’Neill 2003),all of which have roles in priming of the NLRP3 inflammasome, 
demonstrating an element of self-propagation that might favour a chronic inflammatory 
state.  Aside from their roles in the activation of the inflammasome, these pathways are also 
central regulators of a range of other pro-inflammatory pathways including inducing IL-6, 
TNFα, cyclo-oxygenase’s and prostaglandins and matrix metalloproteases, some of the core 
signalling mechanisms for the inflammatory response (Tornatore et al 2012).  
Unsurprisingly, due to this diverse range of pro-inflammatory effects, IL-1β has been 
demonstrated to be central to the pathogenesis of a wide range of inflammatory diseases 
including rheumatoid arthritis, T2 diabetes mellitus and Alzheimer’s disease (Dinarello 2011; 
Parajuli et al 2013). Despite this, direct therapeutic mediation of IL-1β signalling has so far 
only had limited success, with the IL-1R antagonist Anakinra and the IL-1β specific mAb 
canakinumab both having limited effectiveness in multiple studies in a variety of conditions  
(Mertens and Singh 2009; Howard et al 2014). Direct modulation of the mechanisms 
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underlying IL-1β secretion may have potential as therapeutics in a range of conditions; 
indeed, MCC950, an orally active, specific inhibitor of both canonical and non-canonical 
NLRP3 inflammasome activation, attenuated disease in experimental models of multiple 
sclerosis and neonatal fatal cryopyrin associated periodic syndromes (Coll et al 2015). 
MCC950 inhibits NLRP3/Caspase-1 interactions; the generation of Caspase-1 P10/P20 was 
dose dependently inhibited while pro-Caspase-1 levels remained unchanged. No clinical trials 
of MCC950 are yet published, and there remains a major unmet therapeutic need for effective 
regulation of NLRP3 activation in a range of inflammatory conditions. 
 
1.17- NLRP3 mediated pyroptosis 
 
Programmed cell death is a necessity in tissue homeostasis and remodelling, however the 
induction of pyroptosis through NLRP3 activation, inflammasome formation and subsequent 
Caspase-1 cleavage differs from more controlled forms of cell death such as apoptosis (Miao 
et al 2011). Pyroptosis was discerned as a distinct form of cell death in studies investigating 
Salmonella typhimurium induced macrophage cell death; it differs from apoptosis in that 
inflammatory Caspases 1,4 and 5 are activated in humans as opposed to apoptotic Caspases 
2,3,6,7,8, and 9. Further differences include a lack of PARP1 and ICAD cleavage and 
morphological and functional differences with cell swelling and pore formation observed in 
pyroptotic cells (Abe and Morrell 2016).  
Pyroptosis is predominantly a response to infectious agents, including Salmonella and Shigella 
species in macrophages; however, a broadening role for pyroptosis in a variety of pathologies 
is emerging. Whilst the importance in disease and mechanisms of pyroptosis are still in the 
process of becoming understood, the biological role is to prevent the spread of bacterial 
infection in a two-fold manner, first by the direct disruption of the intracellular microbial 
niche through cell death and pyroptosis induced intracellular traps, and second by driving 
inflammation through the release of intracellular contents, which recruits circulating immune 
cells to the site of infection (Shao et al 2017).  
The mechanism by which pyroptosis occurs has glaring similarities to the formation of MAC 
on the cell surface, with an intracellular pore formed by the activated Caspase-1 substrate 
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Gasdermin D (GSDM D). Upon Caspase-1/4/5/11 activation through the formation of the 
respective inflammasome, GSDM D is cleaved, removing the autoinhibitory C terminal domain 
(Rathkey et al 2017). The active 30 kDa N terminal domain then oligomerises into 16mer pores 
of a diameter of 12-14 nm which result in lytic cell death through chemiosmotic flux, cell 
swelling and eventual lysis. The parallels between Gasdermin oligomerisation and MAC 
formation are clear; however, the membrane localisation (intracellular v extracellular 
formation) and pore size (12 nm v 24 nm) differ (Kayagaki et al 2015).  A schematic for 
Gasdermin D mediated pyroptosis is shown in Figure 1.18. 
 
 
 
Figure 1.18. Schematic diagram of Caspase-1 mediated pyroptosis. The activation of NLRP3 through  PAMP / DAMPs  results 
in inflammasome activation and oligomerisation. This in turn allows the autocatalytic cleavage of Caspase-1  in to its active 
form. Activated Caspase-1 may in turn may cleave substrate proteins, including Gasdermin D. Upon cleavage, GSDM D N 
terminal domains may oligomerise to form large pores in the cell membrane to allow cytokine release alongside inducing the 
osmotic lysis which is commonplace in pyroptosis (Image based on content  from Shao et al 2017).  
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Whilst pyroptosis is a distinctly different form of death to apoptosis, it shares many 
characteristics with other forms of inflammatory cell death, such as necroptosis. The 
induction of necroptosis is canonically through TNFαR signalling, the recruitment, 
dimerization and phosphorylation of RIPK1 and subsequent interaction with RIPK3. The 
formation of the RIPK1/RIPK3 complex allows phosphorylation and oligomerisation of MLKL, 
which integrates in to the cell membrane resulting in rupture and lytic cell death (Bergsbaken 
et al 2009).  
The similarities between pyroptosis and necroptosis may stem from the direct and indirect 
interactions between the two pathways. Many of the mechanisms mediating RIPK1 activation 
and subsequently activated by RIPK1 are shared with established NLRP3 pathways. K63 
ubiquitination is crucial for both NLRP3 and RIPK1 activation, a role for TAK1 has been 
established in the activation of both pathways, both pathways modulate NF-κB signalling and 
both undergo regulation through A20 activation (Yuan et al 2018). 
Unsurprisingly, direct modulation of NLRP3 activation by RIPK1/3 has also been described. 
The formation of phospho-MLKL on the surface in response to necroptotic stimuli induced 
NLRP3 activation in a Caspase-1 and potassium efflux dependent manner. Furthermore, many 
of the inflammatory effects of necroptosis on bystander cells, notably NF-κB activation, are 
dependent on NLRP3 activation, suggesting a pro-inflammatory, death inducing synergism 
between the pathways (Conos et al 2017). 
 
1.18- The role of complement in the activation of the NLRP3 inflammasome 
 
As previously discussed, the complement pathway and NLR inflammasomes are linchpins of 
the innate immune system, underpinning the body’s ability to induce and control 
inflammation in response to infection; however, either or both pathways may become 
dysregulated and be causative or contributing agents of disease. Unsurprisingly, a large 
degree of interaction and synergism has evolved between these two innate inflammatory 
pathways in order to mount an optimal response. Over recent years the extent of interaction 
between the two systems has become increasingly clear, with roles demonstrated for 
multiple complement components in the modulation of the inflammasome response.  
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1.18.1- Complement anaphylatoxins and NLRP3 activation 
 
The anaphylatoxins C3a and C5a have long been shown to be important mediators of 
inflammation through signalling through their respective receptors. However, recent 
advances have linked the anaphylatoxins with the priming and activation of the NLRP3 
inflammasome. C3a was shown to modulate the release of ATP from the cell when present 
alongside LPS, which in turn activated the inflammasome by the well described extracellular 
ATP / P2XR mechanism. This modulation was dependent on ERK1/2 signalling; however, the 
release mechanism of ATP from the cell remained elusive (Asgari et al 2013).  
The role of C5a in NLRP3 priming and activation is slightly better documented, with roles being 
demonstrated in AMD and photo-oxidative retinal damage, cholesterol and uric acid crystal 
induced NLRP3 activation and sepsis (Samstad et al 2015). In the uric acid crystal model of 
gout, C5a primed the inflammasome to induce a far more robust IL-1β response independent 
of phagocytic crystal uptake and dependent on K+ efflux, PLC signalling and Cathepsin B 
activity (An et al 2014). The potentiation of MSU crystal induced activation may well be 
attributable to the extensive interactions between C5a and TLR signalling, likely via activation 
of NF-κB signalling. C5a binding C5aR1 has been shown to induce NF-κB signalling in 
monocytes and robustly induce the expression of NF-κB mediated pro-inflammatory 
cytokines such as IL-8 and IL-6 (Hsu et al 1999). Therefore, the anaphylatoxins can deliver the 
central priming signal for NLRP3 activation, rendering cells sensitive to activating stimuli such 
as crystalline/prion structures inducing frustrated phagocytosis, extracellular ATP and pore 
forming toxins; the last of these can also be generated from complement activation in the 
form of the MAC. However, a separate study investigating the role of C5a in inflammasome 
priming and activation in a gout model suggested that C5a induced a strong oxidative burst 
through the generation of ROS, but had no direct effect on upregulation of NLRP3, ASC or 
Caspase-1, suggesting that C5a priming effects are mediated through ROS signalling.  
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1.18.2- The Membrane attack complex and NLRP3 activation 
 
The role of the MAC in activating the inflammasome is relatively poorly understood, with only 
four papers directly linking sublytic MAC formation to the generation of IL-1β and NLRP3 
activation (Triantafilou et al 2013; Laudisi et al 2013, Mosser et al 2016, Kumar et al 2018).   
The first paper from our group demonstrated that sublytic MAC deposition is capable of 
driving IL-1β secretion and NLRP3 activation in lung epithelial cells (Triantafilou et al 2013). 
The experiments demonstrated that the effect was C5, C6 and C9 dependent and also 
sensitive to heat inactivation, demonstrating that the effects were indeed MAC dependent. 
The mechanism by which sublytic MAC induced these effects was demonstrated through 
shRNA silencing to be NLRP3 and ASC dependent. The effects were also shown to be Ca2+ flux 
dependant and requiring Ca2+ release from intracellular stores through IP3/RYR channels; the 
induced ion flux resulted in mitochondrial dysfunction through Ca2+ uptake (Triantafilou et al 
2013). 
The conclusions of  our group (Triantafilou et al 2013) were supported by the demonstration 
that non-lethal MAC induced inflammasome activation in murine bone marrow derived 
dendritic cells in a Ca2+ and K+ dependent manner, through pre-treatment with BAPTA-AM 
and elevated extracellular KCl both statistically significantly inhibiting IL-1β release  (Laudisi 
et al 2013). The experimental model used by Laudisi et al circumvented the possible effects 
of using polyclonal antiserum to sensitise cells to complement and any possibility of antibody 
or CD59 mediated signalling events having roles in NLRP3 activation using heterologous 
serum (rabbit serum titrated on mouse bone marrow derived dendritic cells). 
Further evidence supporting non-lethal MAC induces NLRP3 activation was demonstrated in 
LPS primed, murine bone marrow derived macrophages (Mosser et al 2016). The activation 
of complement by inulin, zymosan and Leishmania major in the presence of complete serum, 
but not heat inactivated or complement terminal pathway depleted serum produced robust 
IL-1β responses. Furthermore, the reactive lysis system of purified complement components 
was shown to induce IL-1β release upon the formation of complete MAC (C5b-9) but not any 
intermediate states. The molecular mechanisms proposed for the release of IL-1β  were K+ 
efflux, including the inhibition of K+ gated channels, and ROS production, whereas a role for 
Ca2+ was not explored (Mosser et al 2016).   
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Finally, the significance of complement mediated NLRP3 activation was demonstrated in vivo 
in a mouse model of uveitis, where C9 -/- mice demonstrated reduced IL-1β, NLRP3 and 
Caspase-1 at the protein level relative to wild type, although histological retinal damage was 
not significantly changed (Kumar et al 2018). Interestingly, treatment with a lentivral 
expression vector generating soluble CD59 caused reduction in inflammasome activation (IL-
1β and Caspase P20) but also reduced the histological damage of the disease, suggesting 
further anti-inflammatory roles for CD59 beyond only regulating complement terminal 
pathway and subsequently inflammasome activation (Kumar et al 2018).  
Therefore, the published literature from our group and others linking  sublethal MAC and 
NLRP3 activation is predominantly concordant, with ion fluxes, ROS production and 
mitochondrial dysfunction being the demonstrated mechanisms (Triantafilou et al 2013, 
Laudisi et al 2013, Suresh et al 2016). How the perturbations in Ca2+ / K+ influence NLRP3 
remain unclear across the literature surrounding inflammasomes, multiple mechanisms likely 
exist. Furthermore, the mechanism by which complement can potentially both prime and 
activate the inflammasome in A549 cells is still unclear (Triantafilou et al 2013). A summary 
schematic of the proposed mechanisms of MAC induced NLRP3 activation from the current 
literature is shown in Figure 1.19.  
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Figure 1.19. Schematic of mechanisms of sublytic MAC mediated NLRP3 activation demonstrated in the published literature. 
A combination of Ca2+ influx and secondary release from intracellular stores, K+ efflux and ROS mediated NLRP3 activation 
have all been demonstrated to have a role in activation (Triantafilou et al 2013; Laudisi et al 2013; Mosser et al 2016). MAC 
image sourced from Menny et al 2018.  
 
1.19- Rheumatoid Arthritis 
 
Rheumatoid arthritis (RA) is the most common inflammatory joint disorder, affecting around 
1% of the UK adult population; however, with the aging western population these figures are 
expected to continue to rise (Sacks et al 2010; Humphreys et al 2012). RA is currently 
diagnosed and defined by the 2010 ACR scoring system which accounts for the number and 
sites of joints experiencing synovitis, serological abnormalities, elevation of acute phase 
response proteins and the duration of symptoms (Aletaha et al 2010). If left untreated, the 
disease manifests in inflammatory and debilitating changes to the joint culminating in bone 
and cartilage erosion, synovial hyperplasia and neovascularisation, chronic inflammation and 
stretching and deformity of tendons (Venables and Maini 2015).  
1 – MAC 
induced event 
2 – How MAC induced 
events may activate NLRP3 
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Current treatment for RA focusses on the class of drugs known as DMARDs (Disease Modifying 
Anti-Rheumatic Drugs) – which have been the mainstay of RA treatment since the 1970’s 
(Kahlenberg and Fox 2011). The most commonly administered DMARD is methotrexate (MTX) 
which can be taken orally or subcutaneously at a relatively low dose (10-25 mg / week) and is 
generally well tolerated with limited side effects, although GI, bone marrow and liver toxicity 
can occur in rare cases. The effectiveness of MTX is substantial in a subset of RA patients, with 
one third of patients demonstrating no radiographical progression after a year of MTX 
treatment, which can be further enhanced when combined with targeted biological therapies 
(Weinblatt 2013). Despite MTX being frequently prescribed, the exact anti-inflammatory 
mechanism it exerts is unclear. Originally, it was believed the antagonism of folate 
biosynthesis induced by MTX would inhibit the proliferation of the pro-inflammatory cells 
mediating RA; however, further theories including inhibition of toxic spermine synthesis, 
depletion of intracellular glutathione and increase of extracellular adenosine have all been 
proposed (Cronstein 2005).   
The localised changes in the morphology and inflammatory state of the joint are preceded by 
serological changes such as anti-citrullinated protein antibody (ACPA) and rheumatoid factor 
(RF) immune complexes, indicating that the scope of the disease exceeds the affected joints 
(Shi et al 2014). The evidence for RA to be considered a systemic inflammatory condition 
rather than a localised joint pathology is strong, with extra-articular manifestations such as 
cardiovascular, haematological and renal co-morbidities more frequent in aggressive RA 
(predominantly RF/HLA-DR4 positive patients) (Cojocaru et al 2010).  
The aetiology of RA is still unclear; although a range of genetic and environmental factors 
have all been associated with the induction of RA, no defining mechanism has yet been 
proposed. The most strongly associated genetic factor for RA is within the human leukocyte 
antigen (HLA) cluster, involved in antigen presentation to T cells. The highly polymorphic N 
terminal HLA region was found to be most associated with RA, with mutations in residues 70-
74 being dubbed the susceptibility epitope (SE) and enabling the presentation of self-derived 
peptides as auto-antigens, including citrullinated cartilage and synovial components (Scally et 
al 2013). However, HLA mutations alone are not sufficient to induce the disease phenotype 
(not all individuals with the SE go on to develop RA) – highlighting further factors including 
smoking, obesity and chronic systemic inflammation (Crowson et al 2013).  
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The “normal”, healthy synovium functions to encapsulate and protect the joint, as well as 
providing lubrication in the form of synovial fluid and supplying nutrients to the cartilage. It 
is a loose array of cells embedded in extracellular matrix (ECM) with roughly equal 
proportions of fibroblast like synoviocytes (FLS ) and macrophage like synoviocytes (Bartok 
and Firestein 2009). Under non-pathological conditions, FLS line the joint in a layer 1-2 cells 
deep, are relatively inactive in terms of secreted enzymes and cytokines and have a relatively 
low turnover rate due to a propensity to resist apoptosis (Firestein 2003). 
 
 
 
 
 
Figure 1.20. Electron micrograph demonstrating intimal synovial lining hyperplasia in RA – the FLS become activated and 
display an aggressive, invasive and hyperplastic phenotype relative to an OA joint (Image edited from Firestein 2003).  
 
This ordered architecture becomes highly hyperplastic and disordered in the inflammatory 
RA phenotype, with massive increases of FLS in the intimal layer, up to 20 cells thick, as well 
as invasion into the local cartilage resulting in joint destruction. Alongside this, osteoclasts 
become activated and differentiated through the pro-inflammatory cytokine environment 
through the actions of RANKL, IL-17, TNFα and IL-1β resulting in localised bone erosion and 
resorption, further compromising joint integrity (Schett 2007). Furthermore, once the 
inflammatory state is established in the joint chemotactic signalling induces immune cell 
Osteoarthritis synovium (non-
hyperplastic) 
Rheumatoid hyperplastic synovium 
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infiltration, including B and T cells, mast cells and macrophages, which exacerbate the 
condition through recognition of autoantigens and inflammatory cytokine secretion (Kinne 
2000; Mellado et al 2015).  
The initial event mediating this transition from the healthy synovium to that seen in RA is 
unclear, however it appears to precede adaptive immune cell infiltration into the joint and 
therefore may well be mediated by the innate immune system interacting with the resident 
synovial cells (Burmester et al 2014).  
 
 
Figure 1.21. A potential chronology for the series of events underlying RA, with the innate immune system and the local 
synovial cells being central to the initiating events of the condition. Highlighted boxes denote stages in RA pathology in which 
NLRP3 or complement have been implicated (Image edited from Burmester et al 2014). 
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As previously mentioned, complement activation is one of the fundamental branches of the 
innate immune system, a potent mediator of inflammation; it is therefore, unsurprisingly, 
implicated in the pathogenesis of RA. Reports of a role of complement in RA date back to the 
1980’s, when it was found that most RA patients had elevated complement activation 
markers C3dg and sC5b9 in the synovial fluid, and around a third had elevated levels in the 
serum (Mollnes et al 1986).  Since then, a plethora of studies have found links between 
complement activation and RA, including the realisation that complement components are 
locally synthesised within the joint, predominantly by macrophage like synoviocytes, and that 
complement gene expression is upregulated in RA compared to healthy and OA synovium 
(Firestein et al 1991; Neumann et al 2001). The concept that complement is not merely 
upregulated but has a central role in the pathogenesis of RA is supported by studies in mouse 
collagen induced arthritis  (CAIA) models where histopathology scores were reduced by 52%, 
94% and 65% respectively for C3aR, C5aR and C6 knockout mice (Banda et al 2012; Mehta et 
al 2015). These data collectively show that, in mouse models at least, both the chemotactic 
anaphylatoxins (C5a and C3a) and the membrane attack complex (inhibited in C6 deficiency) 
have substantial roles in arthritis.  
As previously discussed, the complement system is capable of interacting with and activating 
other innate immune inflammatory pathways, including the NLRs. The NLRs and their 
predominant activation products IL-1β and IL-18 have also been shown to have a central role 
in RA, although attempts at therapeutic modulation of these pathways has so far only had 
modest efficacy. The observation that IL-1β levels were elevated and correlated with some 
disease parameters in RA dates back to the early 1990’s; synovial fluid IL-1β concentration 
was found to be 10-fold higher in RA relative to OA and correlated to morphological patterns 
in the joint (Kahle et al 1992). Upregulation in IL-1β is not concomitantly matched with 
increases in its receptor antagonist IL-1Ra, leading to dysregulation of IL-1β signalling. 
However, when therapeutic intervention in IL-1β signalling was attempted using the IL-1β 
receptor antagonist Anakinra only modest clinical improvements in ACR20 were achieved 
(15% greater than placebo controls), considerably less effective than biologics targeting other 
systems such as TNFα (Mertens and Singh 2009). This lack of efficacy of Anakinra may be 
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because IL-1β can exert cellular effects through binding a relatively small number of IL-1R on 
a cell, making adequate dosing of a competitive IL-1β receptor blocker difficult (Kay and 
Calabrese 2004). Recent advances in the understanding of IL-1β secretion and maturation has 
led to the development of the previously mentioned MCC950, a specific inhibitor of the NLRP3 
inflammasome, which could potentially be a far more efficacious method of therapeutic 
intervention, alone or potentially coupled with receptor antagonism.  
The potential of IL-1β and NLRP3 to induce RA was recently demonstrated in a mouse model 
where TNFAIP3 (Also known as A20), which has multiple SNPs linked to RA, was demonstrated 
to be a negative regulator of NLRP3 and IL-1β in mice, with A20 -/- mice exhibiting polyarthritis 
resembling RA. These symptoms were not rescued by deletion of the TNFαR but were rescued 
by IL-1βR / NLRP3 / Caspase-1 knockout, indicating that the effects observed were induced 
by the NLRP3 / IL-1β signalling axis (Vande Walle et al 2014). This is also reinforced by human 
genetic studies associating NLRP3 polymorphisms such as rs35829419 C>A with an increased 
risk of RA (Wang et al 2015).  
Therefore, understanding the interplay between the complement and NLR systems may be 
crucial to understand the mechanisms involved in the early pro-inflammatory and 
chemotactic events underlying the induction of RA.  
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1.20– Project aims and objectives 
 
In the body of research described in this thesis I intend to dissect the molecular mechanisms 
underpinning the observations that sublytic MAC can activate NLRP3 and highlight the 
individual proteins and pathways which transduce these signals from the MAC to the 
intracellular inflammasome complex. This will be performed in both primary cells and cell line 
models. The overarching aim is to highlight signal transduction pathways linking sublytic MAC 
deposition and NLRP3 activation, the amelioration of which may offset MAC induced 
inflammation in disease. Furthermore, it has become apparent that NLRP3 and complement 
have further interactions, through both susceptibility to MAC mediated death and regulator 
expression in synovial cell lines. These new areas of interaction remain largely unexplored and 
will begin to be demonstrated and discussed in this body of work. 
 The hypothesis underpinning this work is that there are conserved signalling mechanisms 
linking MAC deposition and NLRP3 activation, and that further, currently undefined, links 
between the two systems exist. 
Therefore, the key aims of this body of work are to: 
1) Demonstrate sublytic MAC generation and determine the effects of sublytic MAC on 
NLRP3 activation and IL-1β secretion; 
2) Address the broad molecular mechanisms by which sublytic MAC activates NLRP3;  
3) Investigate how these triggers may induce NLRP3 activation through intracellular 
signalling cascades and modulate MAC mediated inflammasome activation; 
4) Investigate the broader interactions of NLRP3 and MAC, particularly in complement 
regulator expression and MAC mediated cell death. 
 
 
 
 
 
 
 
68 
 
2 – Materials and Methods 
2.1 -Lists of consumables, antibodies and cell signalling inhibitors and buffer recipes: 
 
Table of buffer recipes: 
  
Buffer name Chemical composition 
1x PBS 
0.137 M NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4 , 1.8 mM KH2PO4 , pH 7.4  
Western blot running buffer (1x) 
25 mM TRIS, 191 mM Glycine, 1% 
(w/v) SDS, pH 8.3 
Western blot transfer buffer (1x) 
25 mM TRIS, 191 mM Glycine, 20% 
v/v Methanol, pH 8.3 
Reducing SDS PAGE buffer 
125 mM TRIS, 20% v/v Glycerol, 
4% w/v SDS, 0.05% w/ 
Bromophenol blue, 5% v/v β-
Mercaptoethanol, pH 6.8 
CFD buffer (Oxoid) 
1 tablet per 100 ml of distilled 
water - 0.575 g/l Barbitone, 8.5 g/l 
NaCl, 0.168 g/l MgCl2 , 0.028 g/l 
CaCl2, 0.185 g/l soluble Barbitone, 
pH 7.4  
Alternative pathway buffer CFD buffer + 10 mM EGTA, pH 7.4 
TAE buffer (50x) 
242 g TRIS,  18.61 g EDTA, 57.1 ml 
Glacial Acetic acid in 1 L ddH2O, 
pH 8.5 
PBS-T 
1x PBS , 0.05 – 0.1 % v/v TWEEN 
20, pH 7.4 
FACS buffer 
1x PBS, 1& w/v BSA, pH 7.4, 0.22 
µM filtered 
ELISA reagent diluent 
1x PBS, 1% BSA, pH 7.4, 0.22 µM 
filtered 
HiTRAP Buffer B 
0.1 M Sodium acetate (C2H3NaO2), 
0.5 M NaCl, pH 4 
AKTA affinity elution buffer 
 0.1 M Glycine, 10 mM TRIS, pH 3, 
0.22 µm filtered 
AKTA affinity running buffer 
10 mM TRIS, 150 mM NaCl, pH 7.4, 
0.22 µm filtered 
HiTRAP Buffer A 
0.5 M ethanolamine, 0.5 M NaCl, 
pH 8.3 
HiTRAP ligand binding buffer 
0.2 M NaHCO3, 0.5 M NaCl, pH 
8.3, 0.22 µm filtered 
Western blot stripping buffer 
200 mM Glycine, 1% w/v SDS, 1% 
v/v TWEEN, pH 2.2 
3 A cell media supplement 
1 mM Sodium pyruvate, 2 mM L-
Glutamine, 50 µM Penicillin 
Streptomycin 
Table 2: Commonly used buffer recipes for experiments performed within the thesis 
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Table 3: List of consumable, kits and reagents used within the thesis. 
Kit / Reagent Source Product number 
Human IL-1β ELISA Duoset R&D systems DY401 
LDH cell viability assay kit Thermofisher 88954 
ROS / RNS assay kit Abcam ab139476 
Fluo-3-AM Calcium sensitive dye Molecular Probes 
F-21395 
Propidium Iodide  Sigma Aldrich  
P-4170 
Western blot film GE Healthcare 
28906838 
Western blot ECL reagent Thermofisher 32106 
RIPA lysis buffer Thermofisher 8990 
Protease Inhibitor tablets Roche 4693159001 
Pre-cast 4-20% gradient SDS PAGE 
gels BioRad 
4568094 
Pageruler Plus pre-stained protein 
ladder Thermofisher 
26619 
RPMI cell media Gibco 11530586 
Foetal Calf Serum (FCS) Thermofisher 10500056 
Complement Fixation Diluent (CFD) 
Oxoid BR0016 
HiTRAP NHS activated affinity 
columns  GE Healthcare 
17071601 
Lipopolysaccharide (LPS) Sigma Aldrich L3024-5MG 
Complement C5a Comptech A144 
Complement Factor B Comptech A135 
Complement Factor D Comptech A136 
Cobra Venom Factor Sigma Aldrich 233552-M  
Triton X 100 Sigma Aldrich T8787-50ML 
Guinea Pig red blood cells in 
Alsever's solution 
TCS Biosciences PB029AP 
Sheep red blood cells in Alsever's 
solution 
TCS Biosciences SB0629 
Lipofectamine 2000 Thermofisher 11668027 
NLRP3 gRNA Thermofisher A35509 
Cas9 mRNA Thermofisher A29378 
Dimethyl Sulphoxide (DMSO) Sigma Aldrich 
D2650-100ML 
Mass ruler mixed range DNA ladder Thermofisher 
SM0403 
One step RT PCR reagent set Invitrogen 12574018 
Mammalian Cell miniprep Kit Sigma Aldrich RTN70-1KT 
pCW-CAS9 Expression Vector Addgene 50661 
Puromycin Invivogen ant-pr-1 
Doxycycline Hyclate Sigma Aldrich D9891-1G 
Bovine Serum Albumin (BSA) Sigma Aldrich  A7906 
Skimmed Milk Powder Sigma Aldrich 70166-500G 
Micro BCA assay Kit Thermofisher 23235 
TMRE mitochondrial stress kit Abcam ab113852 
Caspase-glo 1 activity assay Promega G9951 
Propidium Iodide Sigma Aldrich P4170-10MG 
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Compound 
name 
Target  
Carrier 
Solvent 
Stock 
concentration 
Working 
concentration Supplier 
Catalogue 
number 
MCC950 NLRP3 DMSO 20 mM 10 µM  Invivogen inh-mcc 
Ac-YVAD-CMK Caspase 1 DMSO 10 mM 55 µM  Invivogen inh-yvad 
Z-VAD-FMK 
Pan 
Caspase 
DMSO 20 mM 20 µM Invivogen tlrl-vad 
LY294002 PI3K DMSO 2 mM 100 µM Invivogen tlrl-ly29 
Perifosine AKT DMSO 10 mM 50 µM Invivogen tlrl-peri 
Necrostatin 1 RIPK1 DMSO 5 mM 50 µM 
Sigma 
Aldrich 
N9307 
C16 PKR DMSO 10 mM 50 µM 
Sigma 
Aldrich 
I9785 
H18 PKA DMSO 5 mM 50 µM Tocris 2910 
BAPTA-AM 
Intracellular 
Calcium 
DMSO 2 mM 100 µM Tocris 2787 
Xestospongin 
C 
IP3R 
Calcium 
channels 
DMSO 2 mM 10 µM  Tocris 1280 
AG490 JAK2 DMSO 10 mM 50 µM Invivogen tlrl-ag4 
Geldanamycin HSP90 DMSO 1 mM 10 µM  Invivogen ant-gl-5 
Everolimus mTORC1 DMSO 18 µM 300 nM Invivogen tlrl-eve 
PD98059 ERK 1/2 DMSO  50 µM Invivogen tlrl-pd98 
NAC 
Intracellular 
ROS 
H2O 200 mM 5 mM 
Sigma 
Aldrich 
A7250 
SP600125 JNK DMSO 10 mM 50 µM Invivogen tlrl-sp60 
AKT 1/2  AKT DMSO 20 mM 10 µM  
Sigma 
Aldrich 
A6730 
LB100 PP2A DMSO 5 mM 5µM  
Selleck 
chem 
S7537 
 
Table 4: List of cell signalling inhibitors used in experiments. All DMSO reconstituted inhibitors were made under sterile 
conditions using tissue culture grade DMSO. All stock solutions of inhibitors were aliquoted and stored at -20°C prior to use. 
When stated in experiments, vehicle  controls were used with the highest concentration of DMSO solvent to be used as a 
solvent for any compounds in that assay (between 1:100 and 1:1000 dilution  v/v) 
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Antibody target Supplier Host species Catalogue number 
COS-1 antiserum 
(polyclonal 
antiserum against 
COS-1 kidney cell 
line derived from 
Cercopithecus 
aethiops) 
In house Rabbit N/A 
Anti-Human C3b 
FITC 
Biolegend Mouse 846108 
BRIC 229 anti-
CD59 
Bristol Regional 
Immunohematology 
Centre 
Mouse N/A 
BRIC 225 anti-
CD55 
Bristol Regional 
Immunohematology 
Centre 
Mouse N/A 
Anti-FLAG epitope 
antibody 
Thermofisher Mouse MA1-91878 
Eculizumab - anti-
C5 antibody 
Alexion Humanised mouse N/A 
SKY 59 anti-C5 
antibody 
Roche (see publication 
Fukazawa et al 2017) 
Humanised Rabbit N/A 
Anti-C6 (27D1) In house Mouse N/A 
Anti-C7 (23D10) In house Mouse N/A 
Anti-C8 (J1) In house Mouse N/A 
Anti-C9 (B7) In house Mouse N/A 
Anti-Caspase-1 
P10 
Santa-Cruz biotech Mouse SC-56036 
Anti NLRP3 CST Rabbit 13158S 
Anti IL-1β CST Mouse 12242S 
Anti β actin HRP 
conjugate 
Thermofisher Mouse MA5-15739-HRP 
MEM43 anti-CD59 
Grown in house 
(Originally from Vaclav 
Horejsi, Prague, Czech 
Republic) 
Mouse N/A 
Cholera toxin B 
subunit Alexa 488 
conjugate 
Thermofisher N/A C34775 
Anti Mouse Alexa 
488 
Thermofisher Goat A-11001 
Anti Mouse Alexa 
546 
Thermofisher Goat A-11030 
Anti-Mouse HRP Jackson Labs Goat 115-035-003 
Anti-Rabbit HRP Jackson Labs Goat 111-035-144 
 
Table 5: Table of primary and secondary antibodies used in the thesis. 
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2.2 - Cell culture techniques and conditions – THP-1 cell line 
 
THP-1 cells were a kind gift from Prof Phil Taylor (Cardiff). THP-1 cells are a spontaneously 
immortalised monocyte cell line derived from a childhood M5 leukaemia patient and 
represent a well-established In Vitro model for monocytic cells (Bosshart and Heinzelmann 
2016). Cells were cultured in upright, sterile T175 flasks in  complete medium (RPMI medium 
+ 10% v/v FCS and 3A supplement), with medium being replaced or cells passaged every 2-3 
days. Cells were maintained at densities no greater than 1x106 cells ml-1 in culture in a sterile 
incubator at 37˚C in 5% CO2. To passage, cells were centrifuged at 300 x g for 5 minutes and 
the media aspirated, cells resuspended in complete medium and split into fresh T175 flasks 
in a 1:4 ratio. To freeze cells down for storage, the centrifuged cell pellet was resuspended in 
cryotubes in freezing medium (10% v/v DMSO, 90% FCS v/v), placed in a cell freezing container 
containing methanol, and transferred to -80˚C freezer overnight prior to long term storage in 
liquid nitrogen.  
 
2.3 - Cell culture techniques and conditions – SW 982 cell line 
 
SW 982 synovial cells were received as a kind gift from Prof Kathy Triantafilou (Cardiff). The 
SW 982 line is derived from synovial sarcoma cells and has been validated as a model for RA 
studies (Chang et al 2014).  Cells were cultured in complete medium (RPMI medium + 10% 
FCS and 3A supplement). Cells were passaged every 2-3 days upon reaching 80-90% 
confluency. To passage these adherent cells, media was aspirated, cell monolayers were 
washed with 5 ml of sterile PBS and 3 ml of Trypsin-EDTA added for 5 minutes at 37˚C. The 
flasks were agitated and visually checked for cell de-adherence using a light microscope. 
Trypsin  was then neutralised using 12 ml of media +10% FCS to prevent cell damage, cells 
centrifuged at 300 x g for 5 minutes and the supernatant aspirated. Cells were split in a 1:2 
ratio to facilitate cell to cell contact, which helps maintain cell phenotype and growth. To 
freeze cells for long term storage, cells were harvested as above, and the same 
cryopreservation protocol was used as for THP-1 cells. 
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2.4 – Cell culture techniques and conditions – Thawing of frozen cell stocks 
 
To bring up cells from frozen cell stocks, aliquots from liquid nitrogen were rapidly defrosted 
at 37˚C in a water bath. Defrosted cells were immediately centrifuged at 300 x g for 5 minutes 
to remove the freezing media and minimise DMSO cytotoxicity. The freezing media was 
aspirated, and cells resuspended in 5 ml of appropriate media. Resuspended cells were then 
seeded into flasks as with normal tissue culture protocols. 
 
2.5 - Isolation of primary monocytes and differentiation to macrophages 
 
Primary monocytes were enriched from 20 ml of concentrated donor blood cells from the 
GSK BDU based on CD14 expression. Ficoll (15 ml) was added to two Accuspin 50 ml tubes 
and centrifuged for 5 minutes at 300 x g at room temperature to allow the Ficoll to flow 
through the membrane. The cone tubing was then cut, and the blood collected into a 50 ml 
Falcon tube, with the cone subsequently being flushed using 10 ml of PBS to ensure maximal 
recovery. The volume of collected blood (circa 20 ml) was made up to 40 ml in sterile PBS and 
inverted to mix, then gently layered on top of the Ficoll in the Accuspin tubes and centrifuged 
at 400 x g for 20 minutes at room temperature without a deceleration brake.  
The PBMC layer at the interface of the plasma and Ficoll was then removed using a sterile 
Pasteur pipette and transferred to a fresh Falcon tube before being made up to 50 ml using 
sterile PBS. Cells were then centrifuged at 300 x g for 10 minutes, the supernatant discarded, 
and pellets resuspended in a final volume of 50 ml of sterile PBS. After a second centrifugation 
step at 300 x g for 10 minutes, supernatant was discarded, and the cells resuspended in 1 ml 
of ice-cold MACS buffer (5 mM EDTA, 0.05% BSA in PBS without Ca2+ and Mg2+). Anti CD14 
magnetic beads (100 µl) were then added to the cell suspension and incubated for 15 minutes 
at 4˚C. Miltenyi columns were prewashed with MACS buffer and placed on the magnetic stand 
before the cell suspension was loaded; cells bound to CD14 beads were trapped in the 
columns by the magnetic field. The columns were removed from the magnetic stands, cells 
 
 
74 
 
eluted by washing with 3 x 5 ml of Miltenyi buffer and collected in fresh Falcon tubes. The cell 
suspensions were then centrifuged at 300 x g for 5 minutes with a deceleration brake, the 
supernatant aspirated and the cells resuspended in 10 ml of RPMI media + 5% v/v FCS. Cell 
number and viability was determined using the Vicell cell counter, with around 1x108 cells 
recovered. Viability was recorded at 99% by Trypan blue exclusion. Cells were then diluted to 
1x106 cells ml-1 in cell media with 100 ng/ml M-CSF and 1x pen/strep to induce cell 
differentiation into macrophages and plated in to 24 well plates for 5 days to mature.  
 
2.5 – Purification of complement terminal pathway components 
 
Donor plasma was received from the Wales Blood Bank in expired platelet bags. Plasma was 
rendered acellular by centrifugation at 3000 x g for 15 minutes and the plasma aspirated from 
the pellet. The plasma was 0.22 µm filtered before loading on to the AKTA FPLC. All 
complement components were purified using affinity chromatography on columns generated 
through the coupling of in-house anti complement terminal pathway antibodies to HiTRAP 
NHS activated columns. Between 50 and 100 ml of donor plasma was loaded on to the column 
per purification run, with run through plasma being collected and run over the column again 
to maximise purification yields. 
 HiTrap affinity columns were activated using ice cold 1 mM HCl before washing with coupling 
buffer. Monoclonal antibodies against terminal pathway components in coupling buffer were 
then added to the column and incubated for 4 hours at 4˚C. After washing and blocking of the 
column using alternate perfusions of HiTRAP Buffer A and Buffer B, the column was stored in 
10 mM TRIS, 0.02% NaN3 until use. Coupling efficiency was determined through measurement 
of 280 nm absorbance of antibody solution prior to and post coupling and was generally 
around 90%. For protein purifications, the AKTA FPLC was equilibrated in 10 mM TRIS, 150 
mM NaCl pH 7.4. The affinity column was then inserted into the system and five column 
volumes (CVs) of 10 mM TRIS, 150 mM NaCl pH 7.4 buffer were applied at a low flow rate  of 
0.5 ml minute-1 to equilibrate the column matrix. Filtered (0.22 µm) pooled human plasma 
was loaded on to the column, followed by  5  CV’s of running buffer to remove any non-
specifically bound protein. Bound protein was then eluted using 0.1 M Glycine, 10 mM TRIS 
 
 
75 
 
pH 3 and collected in  1 ml fractions. These were immediately neutralised with the addition 
of 100 µl of 1M TRIS pH 10. The protein-containing eluted fractions were identified by 
absorbance or protein assay, then pooled and dialysed overnight at 4˚C in to CFD buffer. The 
dialysed protein was then tested for protein content using absorbance at 280 nm on a 
Nanodrop or Pierce protein assay, purity and identity by SDS PAGE, Western blotting and 
ELISA based methods, and function using haemolytic assays. Functional, pure protein was 
stored at -80°C in aliquots to prevent excessive freeze thaw cycles at a concentration of 
greater than 1 mg/ml in CFD buffer. 
The affinity column was then re-equilibrated by washing in five CV’s of running buffer before 
storage in 10 mM TRIS, 0.02% NaN3 , pH 7.4 at 4˚C. The AKTA system was then washed into 
water and finally 20% v/v ethanol solution for storage. Due to the viscosity of  plasma, the 
system required frequent cleaning using water and 0.5 M sodium hydroxide to prevent 
residue build up, as well as online filter replacement after every few runs.  
 
2.6 - Purification of Cobra Venom Factor (CVF) 
 
CVF is a 144 kDa protease with C3 and C5 convertase activity found in Cobra venom. Whole 
cobra venom was previously purchased from Sigma and stored at -80˚C until use. The 
lyophilised venom was reconstituted in 10 mM TRIS buffer pH 7.4 with 10 mM EDTA to 
prevent any degradation by Ca2+-dependent venom proteases. The reconstituted venom was 
centrifuged at 10,000 x g in a 100 kDa cut off Vivaspin 500 spin column; removing all proteins 
below 100 kDa, whilst concentrating those heavier than 100 kDa. The concentrated protein 
was then reconstituted to 1 ml using  10 mM TRIS buffer without EDTA. The cobra venom was 
then loaded onto a MONOQ ion exchange column on the AKTA purification system via the 
sample injection loop and flushed through with TRIS running buffer. A linear elution gradient 
of 0-100% 0.5 M NaCl over 20 CV’s was used to elute the proteins dependent on charge.  
Eluted, protein-containing fractions were then collected and kept separate for assaying CVF 
functionality by haemolytic assays. A NHS – CVF control was used to ensure no spontaneous 
haemolysis of GPE’s by NHS, but phospholipases were not removed, which may explain the 
haemolytic properties of the void volume elution peak in later experiments (Figures 3.6 and 
 
 
76 
 
3.7) (Vogel and Müller-Eberhard 1984). Functionally positive fractions were subsequently 
pooled and dialysed into CFD overnight at 4˚C before SDS PAGE and Coomassie staining to 
verify protein identity. CVF containing fractions were then pooled and protein concentration 
measured using the micro BCA system.  
The AKTA system was subsequently returned in to water and ethanol and the MONOQ column 
stored in 20% ethanol until further use.   
 
2.7 - Micro BCA assay for protein quantification 
 
To accurately determine complement protein or CVF concentrations, the Pierce Micro BCA kit 
from Thermofisher was used. BSA standards were generated in PBS from 200 to 0.5 µg/ml. 
Then the amount of working reagent required for the assay was calculated (150 µl of working 
reagent / well in a 96 well plate format). The working reagent was then generated using a 
25:24:1 ration of kit reagents A, B and C respectively. The samples of unknown concentration 
were  diluted 1:10, 1:50 and 1:100  in PBS in triplicate to ensure distribution within the 
working range of the assay. Diluted samples and standards were added to the Nunclon 96 
well, clear, flat bottomed plate at 150 µl / well. The working reagent was then added at 150 
µl / well and mixed vigorously on a plate shaker for 30 seconds before sealing the plate and 
incubating at 37˚C for 2 hours. The plate was cooled to room temperature for 10 minutes 
before reading the absorbance at 562 nm in a plate reader. The blank absorbance values were 
subtracted from the other wells before fitting a polynomial standard curve to the standard 
samples and interpolating the unknown samples to the curve.  
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2.8 - Generation of C5b6 complexes 
 
To have a functional reactive lysis system for stimulations purified C5b6 complex was required 
as an initiator for subsequent C7, C8 and C9 binding to generate fully formed MAC. The 
purification of C5b6 was performed through firstly purifying C5, C6 and CVF as previously 
described to provide the raw materials for the reaction, alongside commercial FB and FD 
(Comptech). The protocol used was derived from a published paper and scaled down to the 
protein quantities available (DiScipio et al 1983). CVF (100 µg), Factor B (10 µg/ml) and Factor 
D (1 µg/ml) were mixed in CFD buffer and incubated for 1 hour at 37˚C in a water bath to 
allow the formation of CVFBb complexes, an alternative pathway C5 convertase analogue. 
The newly generated CVFBb complexes were added to 1 mg of C5 and C6 in CFD buffer and 
incubated overnight at 37˚C to allow cleavage of C5 and subsequent C5b C6 binding. The 
overnight reaction mixture was then dialysed into 10 mM Tris buffer for 4 hours to allow 
purification of C5b6 by ion exchange chromatography. The CVFBb generated C5b6 reaction 
mixture was concentrated to 200 µl volume using a 100 kDa cut off Vivapsin concentrator. 
This was then loaded via the sample loop on to the Mono Q anion exchange column and 
eluted with a linear gradient of 10 mM to 1M NaCl. The eluted C5b6 fractions were assayed 
for haemolytic activity and checked for purity by SDS PAGE. Pure, functional C5b6 was then 
aliquoted and stored at -80 ˚C until use 
 
2.9 - Coomassie staining of protein preparations 
 
To verify protein purity and molecular weight SDS PAGE and Coomassie staining was used. 
Precast 4-20% BIS-acrylamide gradient gels, or hand-cast 10% acrylamide gels with a 4% 
stacking gel were used for electrophoresis.  Samples were diluted to load 2 µg of protein per 
lane under reducing or non-reducing loading buffers. All diluted samples were heated to 
induce protein denaturation at 90˚C for 10 minutes in a heat block. To determine molecular 
weights of protein bands, the Pageruler plus pre-stained molecular weight marker 
(Thermofisher) was used, with 7.5 µl of pre-stained ladder loaded in lane one per gel.  SDS 
PAGE was subsequently performed at 120 V for one hour or until the Coomassie dye front 
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reached the bottom of the gel. Gels were then stained using Coomassie dye solution (50% 
methanol, 50% H2O v/v, 0.02% Coomassie powder w/v) for a minimum of 1 hour at room 
temperature with gentle agitation. The gels were then removed from the staining trays and 
added to the de-stain solution (50% H2O, 40% Methanol, 10% glacial acetic acid v/v), changing 
the wash every 15 minutes until the background gel stain was removed. The gels were then 
imaged using the Thermofisher MyECL imaging system.  
 
2.10 – Haemolytic assays 
2.10.1 Reactive lysis Haemolytic assay 
 
To determine the functional activity of purified complement terminal pathway components 
and Cobra venom factor, haemolytic assays were used. Guinea pig erythrocytes in Alsever’s 
solution were inverted to ensure even distribution of cells before 1 ml was taken from the 
stock and added to 20 ml of APB. The cell suspension was subsequently centrifuged at 300 x 
g for 5 minutes to pellet erythrocytes. The APB supernatant was aspirated, and the 
erythrocyte pellet resuspended in 20 ml of APB, and the process repeated until the 
supernatant was clear and colourless indicating no background haemolysis. An aliquot (400 
µl) of the set erythrocyte pellet was then aspirated and added to 20 ml of pre-warmed (37°C) 
APB to generate a 2% erythrocyte suspension. To perform the assay, 50 µl of 2% erythrocyte 
suspension was added per well in a 96 well, U bottomed plate. 50 µl of APB was then added 
to each well. Purified terminal pathway components diluted in CFD buffer were then 
sequentially added and the reaction volume made up to 150 µl with APB. In all assays, C5b6 
or C56 was first added at the concentration stated (titrated up to 0.5 µg/ml for C5b6 and 10 
µg/ml for C56) and incubated for 10 minutes at room temperature; C7 was subsequently 
added in at least two times molar excess compared to C5b6 (5 µg/ml) and incubated for a 
further 15 minutes at 37˚C. C8 and C9 were then added at roughly equimolar levels to C7 (5 
µg/ml) for a further 45 minutes at 37˚C. The negative control comprised 50 µl of erythrocytes 
in 100 µl of APB; the positive (100% lysis) control comprised of 50 µl of erythrocytes  in 100 
µl water + 1% TWEEN. For validation of terminal pathway component function, C7 + C8 + C9 
were added in the absence of C5b6.  
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After incubation to allow MAC mediated erythrocyte lysis, 96 well U bottomed plates were 
centrifuged at 300 x g for 5 minutes to pellet non-lysed erythrocytes and debris.  100 µl of the 
resultant supernatant was then carefully aspirated and transferred to a 96 well flat-bottomed 
plate. Absorbance was then measured at 405 nm, the closest available wavelength to the 
haemoglobin absorbance wavelength of 412 nm on the Magellan plate reader, and red cell 
cell lysis subsequently quantified relative to positive and negative controls. 
To confirm the necessity of sequential addition of complement terminal pathway components 
to allow MAC formation on the cell surface, C5b6, C7, C8 and C9 were pre-incubated together 
for 30 minutes at 37˚C at the same concentration as in the reactive lysis assays above. The 
incubated components were then added to Guinea pig erythrocytes and incubated for 45 
minutes at 37˚C as previously described for reactive lysis haemolytic assays and haemolysis 
measured in the same manner. Percentage haemolysis was calculated by:  
Percentage haemolysis = ((Absorbance sample- negative control)/( Positive control- negative 
control)) x 100 
Negative control = Erythrocytes in AP buffer 
Positive control = Erythrocytes in H2O + 1% v/v TWEEN 20 
 
2.10.2 Cobra venom factor haemolytic assay and classical pathway assays 
 
A variation of the reactive lysis assay was performed to determine the functionality of purified 
CVF. A titration of protein-containing fractions from the cobra venom MONOQ  elution (7.5% 
- 0.1% v/v) was added to Guinea Pig erythrocytes in a 96-well U-bottomed plate with a 
constant dose of 10% final volume (15 µl) NHS. The remaining assay volume up to 150 µl was 
made up with APB. The plate was incubated at 37°C for 45 minutes,  as described for the 
reactive lysis system. NHS only and MONOQ elution fraction only controls were included and 
haemolysis contingent on CVF activation of complement measured, alongside positive and 
negative controls of APB and 1% Triton X respectively. After CVF + NHS incubation with Guinea 
Pig erythrocytes, the U-bottomed plate was centrifuged, supernatant transferred, and  
haemolysis measured at 405 nm as previously described.  
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To determine the efficiency of complement component depletion from NHS, a classical 
pathway haemolytic assay was employed. Guinea pig erythrocytes were replaced with Sheep 
erythrocytes which are more resistant to complement mediated lysis and do not lyse directly 
with NHS. Sheep erythrocytes were therefore sensitised to human complement using anti-
Sheep erythrocyte antibody (Amboceptor), diluted 1:2000 and added in equal volumes to a 
2% suspension of Sheep erythrocytes in CFD for 30 minutes at 37oC. After washing, the 
sensitised cells were incubated with a titration of NHS, or the comparable complement 
depleted serum with or without reconstitution with purified complement proteins for 30 
minutes at 37°C; haemolysis was measured as above, and data analysed to confirm efficiency 
of depletion and capacity to restore lytic activity with complement component restoration. 
Percentage haemolysis was calculated by: 
Percentage haemolysis = ((Sample - Negative control) / (Positive control - Negative control)) 
x 100 
Negative control = Sensitised erythrocytes in CFD buffer 
Positive control = Erythrocytes in H2O + 1% v/v TWEEN 20 
 
2.11 – Determining cell viability through Propidium Iodide staining 
 
To ensure that experimental doses of MAC were sublytic, PI staining was performed by flow 
cytometry or plate-based fluorescence assays. For flow cytometry, cells were seeded at 1x106 
cells / ml in sterile 96 well U bottom plates in complete medium. Media was then replaced 
and cells sensitised  to complement with  a titration of the in-house heat inactivated COS-1 
antiserum (rabbit polyclonal antiserum against the COS-1 kidney cell line from Cercopithecus 
aethiops, previously heat inactivated) for 20 minutes at room temperature prior to 
centrifugation at 300 x g and washing of the cells with 200 µl of sterile PBS. Cells were 
resuspended in complete medium and pooled NHS or C5 depleted serum was titrated on the 
cells to provide a source of complement. Complement titrations were incubated for 1 hour at 
37˚C to allow complement mediated cell death.  Cells were centrifuged at 300 x g and washed 
twice in 200 µl of sterile PBS. The cell pellet was then resuspended in 200 µl of FACS buffer 
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and cells stained using 10 µg/ml PI  in the dark for 10 minutes at room temperature before 
running on the FACS Calibur flow cytometer. Relevant controls of unstained, unstimulated, 
antiserum only or NHS only, and positive control of cells incubated with 2% v/v Triton X were 
utilised to enable quantification of cell death and ensure complement dependence. PI 
fluorescence was measured in the FL2 channel on the flow cytometer on a log10 scale and 
analysed on Flowing software 2.0. Percentage cell death was calculated by subtracting 
unstained and unstimulated positive PI staining from the stimulated value. PI positivity was 
based on the gate around the Triton X-100 positive control.  
Percentage complement mediated cell death was calculated as percentage cells falling in the 
PI positive gate and the following formula: 
((Sample - Negative control) / (Positive control - Negative control)) x 100 
 
Negative control = Unstimulated cells 
Positive control = Cells + 1% v/v Triton X-100 
  
A representative FSC/SSC scatterplot and gating is shown below in Figure 2.1. 
 
 
Figure 2.1. Representative FSC/SSC scatterplot with gating around intact cells 
For measurement of reactive lysis mediated cell death on THP-1 cells, the reactive lysis 
haemolytic protocol described above was used for the formation of the MAC; cells were then 
resuspended in FACS buffer containing PI and viability assessed as above by flow cytometry 
analysis. A dose of C5b6 that, with the other terminal pathway components in molar excess, 
yielded cell death below a 5% threshold was defined as sublytic and subsequently utilised in 
stimulation experiments.  
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For kinetic, plate-based killing assays, the Clariostar fluorescent plate reader was used. SW 
982 cells were seeded at 2x104/ well in 200 µl of complete medium in opaque, sterile plates 
and left overnight to adhere to the plate under normal cell culture conditions. On the day of 
the experiment, complete medium was replaced, and cells were sensitised to complement 
using COS-1 antiserum as previously described. Cells were washed using 1x sterile PBS and 
before 200 µl of complete medium was added, alongside 10 µg/ml PI and the plate 
transported to the clariostar plate reader. The plate reader was configured with an excitation 
/ emission profile of 480 / 630 nm respectively and a gain of 800. Baseline PI fluorescence was 
measured  from the cells (prior to the addition of NHS, HI NHS, complement depleted NHS or 
Triton X at the given final concentrations (% v/v). The PI fluorescence at time 0 was subtracted 
as a baseline, with subsequent changes measured over the course of up to 1 hour. 
Fluorescence curves were then generated in MARS data analysis software and transposed 
into GraphPad PRISM. 
Percent cell death was calculated using the equation: Percentage cell death = ((Sample– 
Negative control) / (Positive control – Negative control)) x 100 
Negative control = reading for the well at time 0 (prior to NHS addition) 
Positive control = Cells + 1% v/v Triton X-100 
 
2.12 – Measuring cell viability through Lactate Dehydrogenase release (LDH) 
 
To eliminate any possibility that non-viable adherent cells were lost during the PI workflow, 
such as during the washing step prior to de-attachment from the growing surface, an LDH 
viability assay was used (Thermofisher). The lyophilised LDH reagent was dissolved in 11.4 ml 
ddH2O and added to 0.6 ml of LDH buffer immediately prior to the experiment. Any unused 
reagent was stored at -20˚C protected from direct light until use. Following manufacturer’s 
instructions, cells were seeded in a sterile 96 well, flat bottomed plate overnight at a density 
of 2x104 cells per well in 200 µl of complete medium. These cells were then washed with 1x 
sterile PBS and 200 µl of complete media replaced on the day of the experiment. The cells 
were subsequently sensitised to complement with COS-1 antiserum in complete medium as 
described previously. After sensitisation, cells were washed in 1x PBS and resuspended in  200 
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µl of complete medium. NHS, C5 depleted NHS or HI NHS were then titrated on the cells for 
1 hour to induce complement mediated cell death. In instances where cell signalling inhibitors 
were utilised to modulate cell death in response to complement, these were applied for 30 
minutes prior to the antiserum sensitisation step. Positive and negative controls of 1x (final 
concentration) lysis buffer and sterile water respectively were added to the complete 
medium, alongside appropriate serum only, antiserum only and unstimulated controls. Cell 
death was quantified relative to the negative and positive controls using the same equation 
as with PI staining, with the slight modification that the negative control used was a serum 
only sample as NHS gives a background signal in an LDH assay.  
After the one-hour stimulation for complement mediated cell death, 50 µl of cell supernatant 
was aspirated per well from samples and controls and mixed with 50 µl of the assay working 
reagent in a fresh, flat bottomed, clear 96 well plate for 30 minutes at room temperature 
protected from light. The reaction was stopped through the addition of 50 µl of 1M acetic 
acid, absorbance read at 492 nm on the Magellan plate reader and cell death was quantified 
relative to the negative and positive controls using the equation given above, and killing 
curves generated in GraphPad PRISM.  
The calculation used to determine percentage cell death by LDH release was therefore: 
Percentage LDH release = ((Sample - Negative control) / (Positive control - Negative control)) 
x 100 
 
Negative control = Cells + NHS without sensitising antibody 
Positive control = Cells + 1x final concentration lysis buffer 
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2.13 - Cell stimulation using reactive lysis system generated sublytic MAC 
 
In assays where complement mediated inflammasome activation was investigated, 2x105 
cells  (THP-1 monocytes or monocyte derived macrophages) were seeded in 96 well or 24 well 
plates in 200 µl or 500 µl of complete media, at concentrations of 1x106 and 4x105 cells /ml 
respectively). Cells were subsequently primed with 25 ng/ml C5a (Native protein purified from 
pooled human serum, Comptech) for 4 hours prior to MAC assembly. C5b6 (titrated up to 3 
µg/ml) was then deposited on the cells at the stated dose for 10 minutes at room temperature 
to allow cell membrane binding,  C7 was then added  for 15 minutes at 37˚C  at over two times 
molar excess relative to C5b6 (5 µg/ml to all samples) to ensure that the initiation of MAC 
formation was the titrated C5b6. After C7 binding, cells were centrifuged at 300 x g and 
medium aspirated and replaced. The wash step performed was to eliminate C5b67 soluble 
complexes which may bind the subsequently added C8 and C9 proteins, allowing lower doses 
of complement components to be utilised and optimising the system. C8 and C9 were again 
added in two times molar excess relative to the C5b6 initiating complex (5 µg/ml for both) 
and subsequently incubated for the stated times for the experimental stimulation. All times 
stated are relative to the final addition of C8 and C9 rather than the initiation of complex 
formation with C5b6.  
After incubation with sublytic MAC,  THP-1 monocytes were centrifuged at 300 x g, cell 
supernatant aspirated, and the pellet washed with sterile PBS. Adherent monocyte required 
no centrifugation and supernatant was directly aspirated. Cells were then lysed using RIPA 
buffer + protease inhibitor cocktail and agitated on a plate shaker for 15 minutes prior to 
centrifugation at 10,000 x g to remove cell debris and allow lysate to be transferred to fresh 
Eppendorf tubes. Both lysates and supernatants were stored at -20˚C prior to analysis. A 
schematic overview of the stimulation procedure is shown Figure 2.2. 
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Figure 2.2 – Schematic of reactive lysis stimulation protocol for THP-1 monocytes and primary macrophages. 
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2.14 - Cell stimulations using Classical pathway generated sublytic MAC 
 
THP-1 cells were harvested and seeded at 2x105 cells per well at a concentration of 1x106 
cells / ml  in a sterile 96 well U bottom plate in complete medium. To prime NLRP3 
activation, LPS (Sigma) was added to the cells at 100 ng/ml for 4 hours at 37˚C to prime 
inflammasome activation. If cell signalling inhibitors were then used to investigate 
mechanisms of NLRP3 activation, THP-1 cells were washed with 1x sterile PBS and 
resuspended in 200 µl of complete medium and the inhibitors, at the stated doses (300 nM 
– 100 µM, dependent on the inhibitor working concentration as described in reagent 
manufacturer’s instructions), were applied for 45 minutes at 37˚C after priming but prior to 
cell sensitisation to complement. Cells were washed in 1x sterile PBS and resuspended in 
200 µl complete cell media  before sensitisation to complement using COS-1 antiserum as 
previously described. Cells were subsequently washed in 1x sterile PBS and resuspended in 
200 µl of complete medium and NHS, HI NHS or complement component depleted NHS 
added at a sublytic dose for  1 hour.  Cells were then centrifuged at 300 x g, supernatant 
aspirated, and cells lysed as described in the previous section. A schematic for the Classical 
pathway system is shown in Figure 2.3. 
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Figure 2.3. A schematic overview of the classical pathway stimulation procedure using COS-1 antiserum and  NHS. 
 
 
 
2.15 – Flow cytometry staining for complement activation 
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2.15.1 Flow cytometry staining for C3b deposition 
 
To demonstrate that complement was the responsible factor for the observed effects, 
staining for complement components by flow cytometry was used. THP-1 cells were seeded 
at 2x105 cells / well at a concentration of 1x106 cells/ml in 96 well, sterile U-bottom 96 well 
plates in complete cell media. Cells were sensitised to complement as previously described 
using  COS-1 antiserum at titrated doses for 20 minutes at room temperature. Cells were 
subsequently washed with 1x sterile PBS and resuspended at 1x106 cells/ml in complete 
medium prior to addition of NHS / C5 depleted serum at the denoted concentration for 1 hour 
at 37˚C. Cells were washed in 1x sterile PBS and resuspended in 100 µl FACS buffer, prior to 
staining on ice, protected from light with anti-C3b monoclonal FITC conjugate (Biolegend) 
diluted 1:50 in FACS buffer for 30 minutes. Cells were washed twice with sterile PBS, 
resuspended in 200 µl of FACS buffer and assayed for fluorescence on the FACS Calibur using 
the FL1 channel and mean fluorescence quantified. Data were subsequently analysed on 
Flowing Software 2.0 and GraphPad PRISM 5.  
For C3b staining on SW 982 cells, cells were first trypsinised (1x Trypsin, 10 mM EDTA solution, 
Gibco) to disassociate the cells from the flask. This step was essential as disassociation with 
10 mM EDTA was slow and trypsinisation after complement deposition degraded C3b on the 
cell surface and ablated FACS signals.  2x105 cells were then resuspended per sample in 200 
µl of complete medium in 96 well U bottom plates prior to complement activation and 
deposition as previously described. SW 982 cells were stained, washed and analysed in an 
identical manner to THP-1 cells.  
 
 
 
 
 
2.15.2 Flow cytometry staining for C9 deposition 
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To stain for C9 (as a surrogate for MAC) deposition, a similar protocol was used. 2x105 THP-1 
cells were seeded per sample at 1x106 cells/ml, prior to sensitisation and stimulation with 
complement as previously described for 5 minutes. After 5 minutes, cells were centrifuged at 
300 x g and fixed in 4% PFA solution at 4°C for 20 minutes. The shorter incubation and 
requirement for cell fixing is reflective of the more transient nature of C9/MAC deposition on 
the cell surface, in contrast to C3b which is retained for longer periods (Morgan 1988).  Cells 
were stained for C9 deposition using in house B7 anti-C9 neo-epitope antibody (10 µg/ml) or 
appropriate isotype control for 20 minutes at room temperature. Cells  were subsequently 
centrifuged at 300 x g and washed twice with 1x sterile PBS. Cell were then incubated with 
the appropriate secondary antibody, anti-mouse IgG Alexa 546, for a further 20 minutes. Cells 
were washed twice in FACS buffer and then analysed for fluorescence using FACS Calibur as 
described above. 
 
2.16 - Determining cell surface complement regulator expression 
 
SW 982 synoviocytes were seeded in 6 well plates overnight at 1x106 cells per well and a 
concentration of 1x106 cells / ml. Cell medium was replaced on the day of the experiment and 
any cell signalling inhibitors added for 1 hour at the designated dose. Cells were then washed 
with 1 ml of sterile PBS per well, before trypsinisation with 0.7 ml Trypsin per well at 37˚C for 
10 minutes. The trypsin was subsequently neutralised with 0.7 ml of complete medium per 
well  before cells were transferred to sterile Eppendorf tubes and centrifuged at 300 x g for 
five minutes and supernatant aspirated. Cells were then fixed in 4% PFA solution for 20 
minutes at 4˚C to preserve expression profiles through the staining process, washed and 
resuspended in 200 µl FACS buffer prior to staining. For intracellular antigens, cells were 
stained in FACS buffer containing 0.1% v/v Triton X for both primary and secondary 
antibodies. CD59 was detected with the mouse monoclonal antibodies BRIC 229 or MEM 43, 
whilst CD55 was detected using BRIC 215. All antibodies were used at 10 µg/ml, for 30 
minutes on ice in FACS buffer. Cells were then centrifuged at 300 x g and washed with sterile 
PBS before incubation with appropriate conjugated secondary antibodies at 1:100 dilution in 
FACS buffer for 30 minutes on ice and protected from light. Cells were again washed in 1x 
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sterile PBS and resuspended in 200 µl of FACS buffer prior to data acquisition on the FACS 
Calibur. Data were analysed using Flowing Software 2.0 and GraphPad PRISM 5. 
 
2.17 – Investigating the role of CD59 in C3b deposition and cell death 
 
To investigate the role of CD59 in regulating C3b deposition and cell death, THP-1 monocytes 
were seeded in complete cell media at 1x105 cells per well  at a concentration of 1x106 cells 
/ ml in a sterile 96 well U bottom plate. Cells were sensitised to complement as previously 
described using COS-1 antiserum, with and without CD59 function blocking antibody BRIC 229 
at 10 µg/ml. Cells were then centrifuged at 300 x g, washed in 1x sterile PBS and resuspended 
in  complete cell medium and MAC generated using titrations of NHS or C5 depleted serum 
as a control for 1 hour at 37˚C. The attacked cells were then washed and stained for cell death 
with 10 µg/ml Propidium Iodide for 10 minutes at room temperature and for C3b deposition 
as described above using anti C3b-FITC antibody (Biolegend) on ice for 30 minutes. Cells were 
then washed with 200 µl of sterile PBS twice before transfer to FACS tubes and running on 
the FACS Calibur flow cytometer. Subsequently, the data were analysed using Flowing 
software 2.0 and GraphPad PRISM 5.  
 
2.18 - Confocal microscopy imaging of complement regulator expression and complement 
cell surface deposition 
 
To further demonstrate different levels of complement regulator and terminal pathway 
product deposition on the cell surface, confocal microscopy was used to visualise cells. WT 
and NLRP3 -/- SW 982 synovial cells were seeded at 4x104 cells per well in an 8 well glass 
chamber slide and allowed to adhere to the glass overnight at 37°C. Cells were washed with 
300 µl 1x sterile PBS prior to fixation with 4% PFA for 20 minutes at room temperature. Cells 
were washed prior to staining with primary antibody. In the case of CD59 surface staining, no 
permeabilizing agent was used, however, when intracellular expression was investigated 
0.1% v/v Triton-X 100 was included in the primary and secondary antibody solutions. Primary 
antibody was diluted to appropriate concentration (20 µg/ml in the case of MEM43) in PBS, 
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0.2% w/v BSA, 0.2% w/v NaN3. Cells were incubated with primary antibody for 2 hours at 
room temperature. Cells were thoroughly washed with sterile PBS prior to secondary 
antibody addition at 4 µg/ml in PBS, 0.2% w/v BSA for 2 hours at room temperature protected 
from direct light. Directly conjugated Cholera Toxin B subunit Alexa 488 (Thermofisher) was 
used to detect lipid raft membrane regions through binding to the GM1 sphingolipid at the 
same time as secondary antibody at 1 µg/ml final concentration. Cells were again washed 
thoroughly with 3x 300 µl of sterile PBS, then incubated with a 1:2000 dilution of TOPRO, a 
carbocyanine nuclear stain, in PBS for 10 minutes at room temperature protected. 
The cell casket was removed, the glue lifted using a razor blade and peeled off evenly to allow 
mounting. A drop of vectashield was applied over each well and a coverslip applied over each 
half of the slide. This was pressed down using a pipette tip and excess vectashield removed 
using tissue. The coverslip was fixed using nail varnish and allowed to dry.  
Cells were imaged using the ZEISS confocal microscope using a 1.4 NA 63x Zeiss objective lens. 
The system was equilibrated, the far-red, red and green laser gains were optimised for each 
experiment, and images visualised and saved using the Zen Black software. Colocalisation of 
markers was performed using the Zen Blue software, with a Pearson’s co-efficient greater 
than 0.5 taken as significant colocalization.  
 
2.19 - Western blotting 
 
Cell lysates were collected as previously described in the cell stimulation protocols. Cell lysate 
was aliquoted then mixed in equal volume with 2x reducing Western blot loading buffer, 
boiled at 90˚C for 10 minutes to ensure protein denaturation and allowed to cool prior to 
loading. Precast gels (4-20% gradient BioRad gels) or hand cast gels (10-15% running, 3.5%-
4.5% stacking) were then loaded in separate wells with 5 µl of chromogenic molecular weight 
ladder and 25 µl of cell lysate + loading buffer. Gels were run in SDS PAGE running buffer for 
a minimum of one hour at 120 V constant voltage at room temperature or until the gel dye 
front reached the bottom of the gel.  
For gel transfer to nitrocellulose membrane a wet transfer system was used. Sponges, filter 
paper and nitrocellulose membrane were soaked in transfer buffer and then assembled 
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sequentially in the cassette, with a roller used to eliminate bubbles. The cassette was placed 
in the transfer buffer filled transfer tank and an ice block added to cool the buffer; voltage 
was set at 100 V for one hour. Complete transfer of the chromogenic ladder was checked to 
confirm effective protein transfer to the membrane. 
Membranes were then blocked for a minimum of 1 hour at room temperature with 5% non-
fat dry milk powder in 1x PBS + 0.1%  v/v TWEEN to prevent nonspecific antibody binding to 
the membrane. Primary antibodies were incubated with the membrane overnight at a 1/1000 
dilution at 4˚C in 5% w/v BSA in 1x PBS + 0.1% TWEEN with constant gentle agitation. Primary 
antibodies were reused up to three times with storage at -20˚C. Membranes were 
subsequently washed three times with 1x PBS + 0.1% TWEEN for 5 minutes at room 
temperature to remove any nonspecific primary antibody binding. The appropriate secondary 
antibody was then added in PBS, 5% w/v BSA, 0.1% TWEEN and incubated for 1 hour at room 
temperature with constant gentle agitation. Membranes were then washed three times (10 
minutes each) in 1x PBS + 0.1% TWEEN and a final 10-minute wash in 1x PBS, then probed 
using ECL reagents as per the manufacturer’s instructions. The membrane was soaked in  ECL 
detection reagent and excess was removed by blotting; the membrane  was then wrapped in 
clingfilm and images captured using the Thermofisher MyECL system or through exposure to 
autoradiography film. Molecular weights of protein bands were measured relative to the 
markers and band density assessed by densitometry (ImageStudio lite; Licor). 
One set of Western blot experiments (IL-1β in cell lysates from primary macrophages 
stimulated with reactive lysis) was performed at the GSK site in Stevenage and therefore had 
a modified protocol. Differentiated primary macrophages were stimulated with C5a and 
reactive lysis MAC as described and 1x106 cells were lysed in 200 µl of RIPA buffer with 
protease inhibitor cocktail. Cell lysate was loaded on 4-12% gradient BIS-TRIS gels and run 
under a constant Voltage of 120V for 1 hour. 5µl of Chameleon molecular weight marker was 
loaded in lane 1 of each gel. Protein was transferred to PVDF membrane using the semi-dry 
Invitrogen power blotting system for 8 minutes. Membranes were washed in PBS 0.1% v/v 
TWEEN as previously described and blocked in PBS + 5% w/v BSA for 1 hour. To probe for IL-
1β, mouse anti human IL-1β (CST) was diluted 1:1000 in PBS 5% w/v BSA for 1 hour at room 
temperature and rabbit anti human β-actin (1:10,000 – CST). Membranes were subsequently 
washed with PBS 0.1% V/V TWEEN and probed with the respective LICOR secondary 
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antibodies (Goat anti-rabbit 800 CW and Donkey anti-mouse 680 CW) for 1 hour at room 
temperature. The two secondary antibodies allow detection of IL-1β and β-actin on the 
membrane simultaneously at the respective wavelengths. Membranes were washed 3 x 15 
minutes in PBS + 0.1% V/V TWEEN before a 30-minute wash in deionized H2O. All steps after 
the addition of the secondary antibodies were performed protected from direct light. Washed 
membranes were then visualised at 680 and 800nm on the ODYSSEY system and images at 
each wavelength saved. 
 
2.20 - Quantification of IL-1β secretion by ELISA 
 
To measure mature IL-1β secretion from cells, a duo set kit from R&D systems was used as 
per the manufacturer’s instructions. A 96 well Nunclon plate was coated with a 1/120 (v/v) 
dilution of capture antibody in PBS for 2 hours at 37˚C or overnight at room temperature. The 
plate was then washed twice using PBS + 0.05% TWEEN, blocked with 300 µl per well of PBS 
+ 1% w/v BSA for 1 hour at 37˚C and washed again. A dilution series of IL-1β standard from 
500-7.2 pg/ml was generated in cell culture medium and 100 µl added to wells in duplicate to 
generate a standard curve. Diluted sample supernatants (100 µl) were added to sample wells 
and incubated for 1 hour at 37˚C. Wells were washed and detection antibody (100 µl/well at 
1/60 (v/v) in  PBS + 1% BSA) added for 1 hour at 37˚C. After washing, 100 µl of Streptavidin-
HRP (1/40 (v/v) in  PBS + 1% BSA) was added per well for 20 minutes at 37˚C. Wells were again 
washed and 100 µl of TMB substrate solution added per well for 20 minutes at room 
temperature. The chromogenic reaction was stopped by addition of 50 µl per well of 10% v/v 
H2SO4. The colour change was subsequently read at 490 nm on the Magellan plate reader. A 
standard curve was then generated, and sample unknown values interpolated using PRISM 5 
analysis software. 
 
 
2.21 – CaspaseGlo assay for Caspase 1 activation 
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Alongside IL-1β secretion, the cleavage of Caspase-1 is an important marker for NLRP3 
activation. While this can be detected by western blotting for Caspase activation fragments, I 
selected a semi quantitative technique, the CaspaseGlo kit from Promega. This assay utilises 
a synthetic Caspase-1 substrate which, when cleaved by Caspase-1, generates a luminescent 
signal, which is used to quantify levels of Caspase activation relative to controls. A schematic 
of the reaction is shown in Figure 2.4. 
 
 
 
 
 
 
 
 
 
Figure 2.4.  Schematic of the luminescent reaction used to generate Caspase-1 glo signal. The synthetic Caspase-1 substrate 
Z-WEHD is cleaved by the activated Caspase, generating Aminoluceferin, which in turn emits a quantifiable luminescent 
signal proportional to the amounts of activated Caspase-1. Image sourced from Promega website. 
 
THP-1 cells were seeded at 2x105 / well in a 96 well, U bottomed plate while SW 982 cells 
were seeded  directly to opaque, sterile plates. THP-1 and SW 982 cells were sensitised to 
complement deposition and subjected to sublytic complement deposition using NHS or C5 
depleted serum for one hour. The cells were then added to the Caspase-1 luminescent 
substrate and incubated in the dark at room temperature for 90 minutes prior to transfer to 
white, flat bottomed, sterile 96 well plates; luminescence values were recorded on the 
Clariostar plate reader. Data was then analysed in GraphPad Prism 5 software. 
2.22 - Measuring calcium flux in response to sublytic MAC 
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THP-1 monocytes were cultured in complete medium; 2x105 cells/well were seeded in U 
bottomed 96 well plates. The fluorescent Calcium binding dye Fluo-3-AM (Thermofisher) was 
reconstituted in DMSO to make a 221 µM stock, before adding to the cells at a 1:100 final 
dilution (2.2 µM) and incubating for one hour at 37˚C away from direct light. The lipophilic 
dye was taken up by the cells and trapped by cytosolic esterase cleavage of the AM (acetoxy-
methyl) group (Figure 2.4). The cells were then sensitised to complement as previously 
described, washed and resuspended in 200 µl of CFD buffer +/- 10 mM EGTA. Cells were 
exposed to NHS or C5 depleted serum and incubated at room temperature to allow quick 
loading on the cytometer or plate reader for the designated length of time before running on 
the flow cytometer and measurement of FL1 fluorescence.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Schematic of methyl ester loading to the cell. Cell permeable, non-polarised methyl esters are added to the cells 
and incubated for 30 minutes – 1 hour at 37°C to allow the uptake across the cell membrane. Upon entering the cell, esterase 
cleavage generates a polarised molecule which is cell membrane impermeable and can then interact with intracellular 
charged groups such as Calcium or ROS, generating a fluorescent signal. Images edited from Dojindo website.  
 
 
For measurement of calcium flux using the Clariostar plate reader, 2x105 THP-1 cells or 2x104 
SW 982 synoviocytes were loaded with Fluo-3 by incubation with Fluo-3-AM as described, 
sensitised using COS-1 antiserum , transferred to white, flat bottomed plates in complete 
1) Ester loading and 
cleavage 
2) Calcium binding 
and fluorescence 
 
 
96 
 
medium and loaded in the plate reader set with a focal height of 7.7 mm, gain of 1000 and 
excitation/emission of 505/525 nm respectively. Cells were then stimulated with NHS, HI NHS 
or C5 depleted NHS, and calcium flux measured by increased fluorescence. Fluorescence 
readings were taken at least every 1 minute for at least 10 minutes from each well.  If 
signalling inhibitors, such as BAPTA-AM or Xestospongin C were used, these were pre-
incubated with the cells prior to COS-1 sensitisation at the stated doses for 45 minutes.  Data 
was subsequently analysed using the MARS analysis software and curves generated using 
GraphPad Prism representing the changes in fluorescence over time in each replicate. 
Changes in Calcium concentrations were measured using the following formula: 
[Ca2+] = Kd (325 nM  for Fluo-3-AM) x ((Fluorescence of signal – Minimal Fluorescence (unstimulated 
cells)) / ((Maximal Fluorescence (Triton X control) – Minimal Fluorescence)).   
 
2.23- Measuring mitochondrial potential 
 
To determine whether sublytic MAC induced mitochondrial depolarisation, the mitochondrial 
selective dye tetramethyl rhodamine ethyl ester (TMRE) was used. TMRE is retained in 
polarised mitochondria where the mitochondrial membrane H+ gradient is intact, yielding a 
fluorescent signal, and is lost upon membrane depolarisation. 2x105 THP-1 cells were seeded 
in a 96 well, U bottomed plate at a density of 1x106 cells/ml. In experiments where cell 
signalling inhibitors were used, cells were initially incubated with cell signalling inhibitors for 
45 minutes at the relevant working concentrations. Cells were then incubated with TMRE at 
a concentration of 200 nM for 20 minutes at 37°C to load cells with TMRE. Cells were then 
washed with 1x PBS and sensitised to complement using the COS-1 antiserum as previously 
described. Cells were subsequently washed with 1x PBS prior to resuspension in complete 
medium and sublytic MAC deposition for 30 minutes. C5 depleted serum, antiserum only, 
unstimulated and unstained controls were also included.  FCCP (carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone), an ionophore that causes mitochondrial 
depolarisation, was used as positive control. Fluorescence was measured by either flow 
cytometry or fluorescent plate reader; loss of fluorescence was indicative of a reduction in 
mitochondrial potential an indicator of mitochondrial dysfunction. Data were analysed using 
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Flowingsoftware 2.0 or MARS data analysis platform, dependent on the platform used, and 
outputs created in GraphPad PRISM 5. 
 
2.24 - Generating NLRP3 KO SW 982 synoviocytes via CRISPR Cas9 system 
 
CRISPR/Cas9 genome manipulation allows, specific, targeted gene editing using the Cas9 
endonuclease. To target the Cas9 endonuclease to a DNA region, a short transcript 
containing a scaffold region (also known as Tracr RNA) and a complementary sequence 
(collectively called gRNA) to the target DNA must bind the Cas9 complex and orientate it 
adjacent to the Cas9 cleavage motif, known as a protospacer adjacent motif (PAM) site.  The 
cleavage of target DNA is dependent on the homology of the gRNA with the complementary 
sequence to anchor the endonuclease in place. Upon effective Cas9 binding, the two 
endonuclease domains undergo conformational change, and each mediates a single DNA 
strand cleavage event, cumulatively creating a double strand break (DSB). The repair of the 
induced DSB can then be dictated in the experiment. The provision of a suitable DNA 
template to integrate into the blunt ended DSB allows precise genome editing with 
homology directed repair. If knocking out of gene expression is desired, no template DNA is 
provided; there is a propensity for inaccurate repair of blunt-ended DSB’s, resulting in frame 
shifts in the target gene, introducing premature stop codons and/or missense mutations. A 
schematic for CRISPR Cas9 utilisation for both homology-directed repair and non-
homologous end joining, mediating DSB’s for missense mutations, is shown in Figure 2.6. 
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Figure 2.6. Schematic of CRISPR Cas9 mediated DNA manipulation, with the used workflow of NHEJ for gene knockout 
highlighted. Image adapted  from https://www.addgene.org/crispr/guide/.  
 
The CRISPR experiment was performed at GSK in the Catalyst/C3 DPU labs in Stevenage. The 
resources for the experiment were all sourced from Thermofisher, with 4 gRNAs against 
NLRP3 selected from predefined libraries. SW 982 cells were seeded at a density of 1x106 cells 
well-1 in a 6 well plate and allowed to adhere overnight at 37°C in a 5% CO2 incubator. On the 
day of transfection, Cas9 mRNA (0.5 µg), NLRP3 gRNA (325 ng/ml) and Lipofectamine 3000 
(5.2 µl) were aliquoted separately into 250 µl of OPTIMEM medium and liposomes allowed to 
form for 5 minutes at room temperature. The composition of each tube is shown below in 
Table 4. Two gRNAs were used per sample to maximise the probability of frame shift 
mutations. The tubes containing the RNA mix were then combined with the liposomes for 15 
minutes at room temperature to allow RNA: Lipid complexes to form prior to addition to SW 
982 cells in OPTIMEM for 6 hours at 37°C. After 6 hours, media was replaced, cell colonies 
selected, allowed to recover from transfection and assayed for NLRP3 expression by Western 
blot / RT PCR.  
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Table 6: Plan of CRISPR/CAS9 transfection for WT SW 982 cells. gRNA’s against NLRP3 were acquired from Thermofisher 
TRUE guide range and used in pairs to ensure effective targeting of all NLRP3 isoforms. Untransfected and mock transfected 
(Cas9 mRNA + lipofectamine – gRNA control) were used to compare to the targeted transfections.  
 
2.25– Pouring Agar plates and clone selection 
 
To generate further CRISPR/Cas9 based knockouts a different system was utilised. Firstly, cells 
were transfected with an inducible Cas9 expression plasmid, pCW-Cas9 supplied by Addgene 
which allowed for positive selection through Puromycin resistance, with a subsequent second 
transfection of gRNA and screening for loss of gene expression of the protein of interest. A 
map of the plasmid is shown below in Figure 2.7.  The total plasmid consists of 11,885 bp and 
contains the Cas9 gene under a TET-on inducible promoter and a Puromycin selection marker.  
 
 
 
 
 
 
Tube Condition
Untransfected gRNA pair 1 gRNA pair 2 Mock transfected control
1 250µl OPTIMEM 250µl OPTIMEM 250µl OPTIMEM 250µl OPTIMEM 
gRNA 1 
(325ng/ml)  
CRISPR1098152
_CR
gRNA 3 
(325ng/ml) 
CRISPR1098159_
CR 
gRNA 2 
(325ng/ml) 
CRISPR1098154
_CR
gRNA 4 
(325ng/ml) 
CRISPR1098157_
CR
0.5µg CAS9 
mRNA
0.5µg CAS9 
mRNA 0.5µg CAS9 mRNA
2 250µl OPTIMEM 250µl OPTIMEM 250µl OPTIMEM 250µl OPTIMEM 
5.2µl 
Lipofectamine
5.2µl 
Lipofectamine 5.2µl Lipofectamine
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Figure 2.7. pCW-Cas9 gene map. The total plasmid construct consists of 11,885bp and contains the Cas9 gene under an 
inducible TET ON promoter allowing expression to be transient and potentially limit off target gene editing effects. The 
puromycin resistance gene allows positive survival selection of transfected cells. The plasmid contains restriction enzyme sites 
for XBA1 and NHEL1 at 6001 and 537 respectively, allowing a restriction digest of the plasmid with these enzymes to generate 
two fragments of roughly 5.5 kb and 6.5 kb. Image adapted  from Addgene website  (https://www.addgene.org/50661/).  
 
The initial step of this workflow was the purification of the pCW-cas9 vector from Addgene, 
deposited by Eric Lander and David Sabbiatani and first described by Wang et al 2014. The 
vector was supplied in bacterial stabs set in agar, which were stored at 4˚C prior to use Agar 
stock was generated by adding 15 g of agar powder per litre of Luria Broth (LB) medium and 
microwaved until the agar was dissolved. The solution was then allowed to cool to room 
temperature prior to the addition of 10 µg/ml Puromycin to the solution. Agar solution (10 
ml) was poured into each of 8 plates and allowed to set at room temperature.  To generate 
bacterial colonies, cells from the bacterial stab were streaked on the selective agar plates 
using a sterile pipette tip. 
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The streaked plates were then inverted to prevent condensation dripping onto the cells and 
sealed with parafilm prior to overnight incubation at 37˚C to allow colony growth.  
After the overnight incubation, plates were checked visually, and individual colonies carefully 
selected using a sterile pipette tip and transferred to 30 ml of prewarmed LB broth containing 
10 µg/ml Puromycin. These cultures were then incubated at 37˚C with constant agitation 
overnight to allow liquid culture growth, apparent by the increased turbidity of the culture. 
 
2.26 – Purification of pCW-Cas9 plasmid DNA 
 
To purify plasmid DNA from the clonal liquid cultures the Invitrogen PureLink Maxiprep kit 
was used. The overnight liquid colonies were firstly centrifuged at 600 x g for 10 minutes to 
pellet bacteria. The Maxiprep column was equilibrated in 30 ml of buffer EQ1  (0.1 M sodium 
acetate, 0.6 M NaCl, 0.15 % v/v Triton X) using gravity flow. The resuspension buffer R3 (50 
mM TRIS-HCl, 10 mM EDTA, pH 8.0) was prepared through the addition of RNase A to a final 
concentration of 100 µg/ml in 100 ml prior to use to eliminate RNA contamination. Pelleted 
bacteria were resuspended in buffer R3 in a sterile hood, with gentle inversion and shaking 
until the suspension was homogenous. 10 ml of Lysis buffer L7 (0.2 M NaOH, 1% w/v SDS) was 
then added to the suspension, mixed by inversion and incubated for five minutes at room 
temperature to allow bacterial lysis. The DNA from the lysed bacterial cells was then 
precipitated to remove debris through the addition of 10 ml precipitation buffer N3 (3.1 M 
Potassium acetate, pH 5.5) and inverted until the mixture was homogenous, with the 
precipitated  DNA subsequently loaded on to the Maxiprep column and allowed to gravity 
flow through the column. The flow through from the precipitated lysate was discarded 
alongside the inner filtration cartridge, before washing the column with 50 ml of wash buffer 
W8 (0.1 M Sodium acetate, 825 mM NaCl, pH 5.0). The flow through from the wash step was 
discarded and a fresh sterile 50 ml tube was placed under the column for  elution. Bound 
plasmid DNA was eluted from the column with 15 ml of elution buffer E4 (100 mM TRIS-HCl, 
1.25 M NaCl, pH 8.5) through gravity flow. The eluted DNA was then precipitated by adding 
10.5 ml of isopropanol, mixing and centrifugation at 12,000 x g for 30 minutes at 4˚C. The 
supernatant was discarded, the pellet was resuspended in 5 ml 70% ethanol and centrifuged 
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at 12,000 x g for 5 minutes. The supernatant was removed and the pellet air dried for 10 
minutes then resuspended in 500 µl of TE buffer. DNA concentration was measured by 
nanodrop, aliquoted and stored frozen at -20˚C until use.  
 
2.27- Restriction enzyme digestion and agarose gel electrophoresis of pCW-CAS9 plasmid 
 
To verify that the purified plasmid DNA was intact, pure and encoding the correct sequence, 
the purified DNA was run on an agarose gel, with and without restriction enzyme digestion. 
To perform the restriction digest, 1 µg of plasmid DNA was added to 1 activity unit (the 
amount of enzyme required to digest 1 µg of substrate DNA in a 50 µl volume in 60 minutes)  
of both XBA1 and NHEL in a 30 µL reaction volume containing  0.1 mg/ml BSA in NEB  broad 
spectrum restriction enzyme buffer for 1 hour at 37°C. A 1% agarose gel made from  1% 
agarose solution in 1x TAE buffer containing 50 µg  of  Ethidium Bromide  to allow visualisation 
of DNA was used to resolve the digestion products. The gel was placed in the gel docking 
system with a 10-well comb inserted for sample loading immersed in 1x TAE buffer in the gel 
tank, a DNA samples and broad range molecular weight marker (10 kb-100 bp,) were loaded 
and electrophoresis performed at a constant voltage of 100 V for 1 hour. Resolution was 
checked using UV imaging and the gel run for up to a further hour to increase the high kb 
resolution needed to differentiate the restriction digest products. Images were captured 
using the Thermofisher MyECL system and shown in Figure 2.8.  
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Figure 2.8. Agarose gel electrophoresis of purified pCW-CAS9 vector. Intact pCW-CAS9 vector s 11,800 bp and above the 
heaviest base pair marker, but observable in its linearized, circular and supercoiled structures in Lane 2. The double restriction 
digest of the plasmid using XBA1 and NHEL1 generated the expected 6,500 and 5,500 bp fragments observed in Lane 4. The 
lack of multiple bands indicates little DNA degradation and allows confidence in identity, purity and quality of the plasmid 
DNA for subsequent transfections. 
 
2.28- Transfection of pCW-Cas9 vector in to SW 982 cells 
 
To generate an inducible Cas9 expressing synovial cell line, SW 982 cells were lipofectamine 
transfected with the purified pCW-Cas9 vector and transfected cells selected through 
puromycin resistance. The day before the experiment, 2x105 WT SW 982 cells were seeded 
per well in a 24 well plate in 500 µl of complete medium and left overnight to adhere. On the 
day of the experiment, cells were washed and 1 ml of OPTIMEM added per well. Concurrently, 
DNA: lipid complexes were prepared. A titration of plasmid DNA (2-8 µg) was diluted in 500 
µl of OPTIMEM and lipofectamine dilutions were prepared in separate sterile Eppendorf tubes 
(2-10 µl of lipofectamine in 50 µl of OPTIMEM). The DNA and lipofectamine were then 
combined to allow DNA: Lipid complexes to form and incubated for 20 minutes at room 
temperature, then added to the cells for 6 hours at 37˚C. The medium was changed back to 
complete medium for 24 hours post transfection. Positive selection was then performed by 
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adding 5 µM Puromycin to the medium for 48 hours after transfection. Cell islands were then 
allowed to grow in the absence of Puromycin and expanded to T175 flasks. 
To verify that the T175 cultures retained the plasmid after growth in the absence of  
Puromycin containing selection media, 2x105 WT and pCW-Cas9 treated cells were seeded at 
a density of 4x105 cells /ml  in a sterile 24 well TC plate and allowed to adhere overnight. Cells 
were then subjected to a titration of Puromycin (2.5-0.1 µM) in complete cell medium for 48 
hours and cell viability measured through trypan blue exclusion, relative to unstimulated 
(complete medium – Puromycin) and positive control (complete medium + 1% Triton X)  
shown in Figure 2.9.  
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Figure 2.9. Trypan blue exclusion of WT and PCW-CAS9 transfected SW 982 cells treated with a titration of Puromycin for 48 
hours. PCW-Cas9 transfected SW 982 cells demonstrated statistically significant protection to Puromycin mediated cell death 
relative to WT controls, validating transfection and construct expression. Data presented as mean +/- SEM  from a single 
experiment, representative of two experiments. Data analysed by two-way ANOVA (*** = P<0.001.) 
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2.29 - Purification of total RNA from SW 982 synoviocytes 
 
To verify the loss of expression of NLRP3 from the CRISPR/Cas9 treated cells, RNA was 
collected for analysis with reverse transcriptase PCR (RT-PCR). The mRNA extraction was 
performed using the Sigma GeneElute mammalian total RNA miniprep kit. The buffers 
provided with this kit came supplied, and details of formulation are not available on the 
company website. 2x105 SW 982 WT and CRISPR/Cas9 treated cells were seeded per well at a 
density of 4x105 cells/ml in a 24 well, sterile, flat bottomed sterile plate and allowed to adhere 
overnight at 37°C.  On the day of the experiment, complete media was replaced (500 µl) and 
cells were primed with 100 ng/ml LPS for 4 hours to elevate NLRP3 expression or left 
unstimulated as controls. The cells were washed using 1x sterile PBS and lysed in 250 µl RNA 
extraction buffer + 1:1000 v/v β mercaptoethanol. Cell lysate was then mixed with 250 µl of 
70% ethanol solution, then added to the RNA binding column, centrifuged at 13,000 x g for 
15 seconds, and the flow through discarded. The column was washed with 500 µl of wash 
buffer W3136 and centrifuged at 13,000 x g for 15 seconds, washed again with 500 µl of buffer 
W3261, then eluted using 50 µl of buffer E8024  and centrifugation at 13,000 x g for 1 minute 
through the column. Eluent was collected, concentration and A260/280 nm ratio measured 
on the Nanodrop, and mRNA was stored at -80°C until use.  
 
2.30 - Reverse Transcriptase PCR 
 
To perform the RT-PCR, the Superscript III One-step RT-PCR kit (Thermofisher) was used. The 
procedure was performed as recommended in the generic guide provided with the kit. The 
primer pair used for NLRP3 amplification was purchased from Thermofisher (Primer ID: 
Hs00315580_CE, forward primer sequence: TCTCACTTCAATCCACTGGTTGATA, reverse primer 
sequence: TTAGCCAAATGCTTACCAGAAAGTT, expected amplicon length: 499 bp).  
The PCR reaction mixture was prepared with 21 µl of diluted template RNA added per tube 
giving final concentrations of 200 ng of RNA per tube to ensure template mRNA was within 
optimal range for amplification. The concentration of RNA from samples taken from 
stimulated SW 982 cells was measured by Nanodrop A230 nm to ensure equal loading in to 
 
 
106 
 
the PCR tubes. The remaining  PCR mixture consisted of  25 µl of 2x reaction mixture 
(Superscript One step PCR Kit), 21 µl of sample RNA (diluted in RNA free water with 200 ng of 
total RNA per sample), 1 µl of forward and reverse primers and 2 µl of Superscript III RT / 
Platinum Taq mix added per PCR tube.   
To perform RT-PCR, the thermocycler was preheated to 54°C for 15 minutes prior to 
experiment starting. The thermocycling protocol was as follows: CDNA synthesis and 
denaturation at 54°C for 20 minutes, followed by pre-denaturation at 94°C for 2 minutes. 
Amplification was performed by cDNA denaturation at 94°C for 15 seconds, annealing at 63°C 
(average of calculated optimum annealing temperatures of forward and reverse primers, 
61.2°C and 64.4°C respectively). Extension was performed for 1 minute each cycle for the 499 
bp expected amplification product. Denaturation, annealing and extension was performed  
for 40 cycles and a final extension step added at the end of the final cycle at 68°C for 5 
minutes. 
Following the  RT-PCR process, half (25 µl) of RT-PCR product was then mixed 1:1 with 2x 
agarose gel loading dye and loaded on to a 1% agarose gel containing 50 µg of Ethidium 
Bromide  for DNA visualisation. The agarose gel electrophoresis was performed as previously 
described, until the loading dye front had migrated at least half the length of the gel.  A broad 
range molecular weight marker (10kb-80bp) was used to measure PCR product bp size. The 
gel was subsequently visualised using the Thermofisher MyECL system.  
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Chapter 3: Establishment of protocols for complement attack on nucleated cells 
 
3.1- Introduction 
 
To mimic the effects of complement activation In vivo, systems had to be generated which 
would allow complement activation on target cells, from a serum or purified protein source, 
at a sublytic level (<10% cell death above baseline). The establishment of a reproducible sub-
lethal system is crucial to allow the dissection of lytic and non-lytic effects of MAC on 
inflammatory signalling.  
Previous work on MAC mediated activation of NLRP3 has utilised a variety of methods for this 
process. One method utilised heterologous serum to circumvent the need for sensitisation 
with antibody, subsequently demonstrating a complement mediated induction of IL-1β 
secretion and Caspase-1 release at sublytic levels in LPS primed Dendritic cells (Laudisi et al 
2013). In other studies, the capacity of complement activators which are avidly opsonised was 
investigated in the context of NLRP3 activation. Whilst the focus of the work was on C3 
products and NLRP3 activation, an experiment using reactive lysis generated MAC was 
performed and robust IL-1β production demonstrated; however, percentage cell viability in 
response to attack was not reported (Suresh et al 2016).  
Another paper, published by our group, measured non-lytic MAC in the context of NLRP3 
activation using homologous serum in a CP system (rabbit polyclonal anti-CD59 as a 
complement activator) and demonstrated clear titrations of cell death and C9 deposition on 
the cell surface as well as terminal pathway dependency using complement depleted sera 
(Triantafilou et al 2013). 
Despite the differences in experimental procedure, each of these studies came to the same 
conclusion; the MAC is needed for complement mediated NLRP3 activation. It is therefore 
critical to demonstrate that the systems used in this body of work firstly replicate this 
dependence on MAC, whilst also maintaining the clear separation of lytic and sublytic MAC 
activities. This was investigated using both reactive lysis and CP systems, optimised for the 
subsequent experiments investigating NLRP3 activation.  
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3.2 - Methods of purification and validation of function of complement terminal pathway 
components from normal human serum 
 
Complement terminal pathway components are abundant in NHS, with C5 the most abundant 
at ~80 µg/ml; however, the acute phase nature of the terminal pathway components, with 
the exception of C7, can result in higher concentrations in disease (Noris and Remuzzi 2013). 
To purify these proteins via classical chromatography methods requires large volumes of 
serum and a multistep process requiring salt cuts, ion exchange and size exclusion 
chromatography to yield a pure final product (Van den Berg 2000). However, affinity 
chromatography utilising monoclonal antibodies against terminal pathway proteins allows 
efficient purifications in a single step. Affinity columns comprising monoclonal antibodies 
against C5, C6, C7, C8 and C9 immobilised on Sepharose were generated as described in 
materials and methods Purification was performed on donor plasma from expired platelet 
bags, with 50 – 100 ml of donor plasma applied to the column twice to maximise purification 
yields. An example chromatogram for purification of C9 from 50 ml pooled human plasma is 
shown in Figure 3.1. Purified affinity eluents were collected, and fractions pooled and dialysed 
in to CFD overnight at 4°C. Purified components were then subjected to SDS PAGE with 
Coomassie staining or western blotting to verify protein identity (Figures 3.2 and 3.3 
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Figure 3.1. Representative chromatogram of complement component C9 purification by affinity chromatography using a Hi-
TRAP NHS activated column with 23mg of B7 (in house anti C9 antibody) coupled. 50 ml of pooled NHS was loaded onto the 
column under low salt, natural pH conditions (10 mM TRIS, 150 mM NaCl, pH 7.4) to facilitate protein binding to the column 
coupled antibody. NHS loading on the column generates, a large, saturating UV signal (initial blue peak) due to the high 
protein content. As the pooled NHS is washed off the column, the UV signal drops and the buffer flows to the waste valve. 
The bound protein is then eluted using 5x column volumes of elution buffer(1 M Glycine, 10 mM TRIS pH 4). Protein positive 
fractions were  immediately neutralised with 100 µl of 1 M TRIS pH 10, pooled and dialysed overnight into CFD buffer at 4˚C 
prior to testing for function and purity.  
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Figure 3.2. Coomassie stained SDS PAGE of purified complement terminal pathway components. 1 µg of purified protein from 
affinity purifications was denatured (90 °C for 10 minutes) and loaded on to 4-20% gradient polyacrylamide gels (BioRad) 
under reducing or non-reducing conditions. Pageruler Plus pre-stained protein ladder (Thermofisher) was loaded in to Lane 1 
of both gels. SDS-PAGE was performed under a constant Voltage of 120V for 1 hour. Gels were then stained using Coomassie 
staining solution for at least 1 hour at room temperature. Gels were subsequently destained using destain solution with 5x 
10-minute washes. Gels were then visualised using the Thermofisher MyECL system. C5 molecular weight – 183 kDa, α chain 
110 kDa, β chain 75 kDa. C6 molecular weight – 95 kDa, C7 molecular weight – 110 kDa but runs around 86 kDa under SDS 
PAGE (Stahl et al 2000) C8 – 163 kDa intact, upon reduction α/β chains run at 64 kDa and γ at 24 kDa, C9 molecular weight 
79 kDa. 
 
 
 
 
 
 
Figure 3.3. Western blots of purified C7, C8 and C9 proteins. 1 µg of purified protein from pooled stocks was denatured at 90 
°C for 10 minutes and  loaded under reducing or non-reducing conditions on a BioRad precast 4-20% gradient polyacrylamide 
gel. Samples were then subjected to SDS PAGE for 1 hour at a constant voltage of 120 V. Gels were removed and transferred 
onto nitrocellulose membranes for 1 hour at 100 V  using the wet transfer system. Effective protein transfer was denoted by 
the transfer of the pre-stained Pageruler Plus ladder to the membrane. Membranes were blocked with PBS 5% w/v skimmed 
milk powder for 1 hour at room temperature, washed using PBS 0.1% v/v TWEEN and probed for the respective proteins (C7 
– In house 27D10 anti human C7 polyclonal, C8 – In house J1 mouse anti human C8 monoclonal, C9 – In house rabbit anti 
human C9 polyclonal). Primary antibodies were used at 1/1000 dilution. Membranes were washed using PS 0.1% v/v TWEEN 
3x15 minutes and before respective secondary antibodies were applied at 1/5000 dilution in PBS 5% w/v BSA. Membranes 
were again washed for 3x 15 minutes in PBS 01% w/v TWEEN and before 1 x 30-minute wash in ddH2O. Chemiluminescent 
visualisation was performed using ECL reagents from GE as per manufacturer’s instructions and exposed to Amersham Hyper 
film for 3 minutes for final blots.  
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To generate an active C5b6 complex, two methods were employed. Initially, a freeze thaw 
method was used due to the difficulty in generating C5b6 (Dessauer et al 1985). To form an 
active complex, purified C5 and C6 were mixed in an equimolar ratio and incubated at 4˚C for 
one hour. The mixture was subsequently frozen at -80˚C for 24 hours before rapid defrosting 
in a water bath at 37˚C. The reaction of C5 and C6 in this manner yields no detectable C5a 
biological activity; however, it enables generation of a MAC precursor with lytic function 
similar to the native C5b6 complex. A drawback to this method is that the C56 complex 
generated through freeze thaw is unstable and rapidly decays, requiring the thawed product 
to be used within 3 hours and kept on ice to preserve activity (Cole thesis 2005).  
To determine this activity for future experiments on nucleated cells, the C56 complex was 
incubated on guinea pig erythrocytes (GPE) in a reactive lysis haemolytic assay. GPE’s were 
used for reactive lysis assays due to the lack of expression of CD59 on the cell surface, 
rendering the cells highly sensitive to complement mediated lysis (Boshra et al 2017). A 
titration of initiating C56 complex was applied to a fixed dilution of GPE for 10 minutes at 
room temperature in CFD + 10 mM EGTA before C7 addition in molar excess and a further 15-
minute incubation at 37˚C for 15 minutes. C8 and C9 were then added at a molar excess to 
the C5-7 complex and incubated for a further hour at 37˚C. Intact GPE were pelleted by 
centrifugation at 4˚C at 300 x g for 10 minutes and 100 µl of the haemoglobin containing 
supernatant aspirated and transferred to a 96 well, flat bottomed clear plate. Absorbance at 
405nm was measured, corresponding to released haemoglobin and shown in Figure 3.4 A/B. 
Positive and negative controls (GPE + water, 1% TWEEN 20 positive and GPE + CFD only 
negative) were employed as well as a GPE’s + C56 exposed + 10% NHS with 10 mM EDTA as a 
source of terminal pathway components. This was to ensure any negative results were due 
to a lack of C56 function as opposed to a problem with the preparation of any other terminal 
pathway components. A major caveat of this method is the inability to effectively quantify 
the conversion of C5 and C6 to the functional C56 complex; hence, the stated doses of C56 
complex in Figure 3.4 assume complete conversion of C5 and C6 to C56; however, efficiency 
is likely low and the actual working concentration of complex far lower. 
Percentage haemolysis was quantified by the equation: Percentage haemolysis = ((Positive 
control – Negative control) – (Sample – Negative control)) x 100. 
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In this experiment, the negative controls was GPE’s in 100 µl of CFD only without the addition 
of any complement components. The relatively high rates of background haemolysis (around 
8-10%) of negative control samples (such as C56 only) may be attributable to the multiple 
rounds of pipetting in this method incomplete dialysis of the elution buffers used in 
component purification which may slightly alter absorbance values. 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.A. Titration of haemolytic activity of C56 generated by freeze thaw of purified C5 and C6 proteins. The MAC complex 
was assembled as described above with the C56 initiating complex as the limiting component by concentration. C56 was 
added to guinea pig erythrocytes in 96 well, U bottom plates at the denoted concentrations for 10 minutes at room 
temperature in CFD buffer. C7 was subsequently added in molar excess (80 µg/ml) for 15 minutes at 37 °C. C8 and C9 were 
subsequently added (both at 80 µg/ml ) for 45 minutes at 37 °C. Plates were centrifuged, cells pelleted and haemoglobin 
containing supernatant transferred to flat bottom plates and absorbance at 405nm measured. Percentage haemolysis was 
quantified relative to CFD only negative and water + 0.1% v/v positive controls. Haemolytic activity of the complex was fully 
dependent on the addition of C9 as C56, C567 and C5678 complexes exhibited no significant increases in haemolysis at any 
concentrations of C56 used . The haemolytic capacity was also demonstrated to be independent of C9 addition alone, as the 
C9 only control failed to induce haemolysis. Data was analysed using a one-way ANOVA with a Dunnett post-hoc test to 
compare all groups of the assembling MAC complex to the complete MAC sample. The MAC induced haemolysis was 
statistically significantly higher than initiating complex or components alone (One-way ANOVA with Dunnett post-hoc test, 
all groups compared to C56789 P < 0.001). Data presented as the mean +/- SEM from a single experiment, representative of 
three independent experiments. B. A titration of haemolysis induced by MAC (C56-9) relative to the amount of C56 initially 
deposited on the cells with constant concentrations of C7-C9 used. This demonstrates a C56 dose dependent response. 
Representative data from one of three independent experiments. Data displayed as mean +/- SEM.  
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To circumvent the issues surrounding the C56 system, predominantly the inaccurate 
quantification of the initiating complex, methods of generating a C5b6 complex were 
explored. Initially, C7 depletion of serum utilising affinity chromatography prior to activation 
using zymosan (1 mg/ml) was attempted to arrest complement activation at the C5b6 stage 
and then subsequent purification via SEC / Mono Q cation exchange. However, C7 depletion 
of NHS to an extent sufficient to limit complement activation at the C5b6 stage was not 
achieved with the affinity columns available or generated at that time. Residual haemolytic 
activity was present in NHS despite low volumes of donor normal human serum (10 ml) being 
run over the available anti-C7 affinity columns at the time three times ; therefore, an 
alternative method was required. It should be noted, superior affinity columns were 
generated later and used to effectively deplete C7 from NHS to generate C7 depleted NHS. A 
second way of generating C5b6 is via the activation of purified proteins through the C3/C5 
convertase analogue cobra venom factor (CVF) from Naja Naja Kouathia which activates both 
C5 and C3, making it ideal for this application. 
 
3.3 - Purification of CVF from whole cobra venom and validation of function 
 
CVF is a 146 kDa protease which is the complement activating agent in Cobra venom. Whole 
cobra venom was obtained and lyophilised, reconstituted in 1 ml of 10 mM TRIS buffer pH 7.2 
containing 10 mM EDTA. This solution was loaded onto a Mono Q anion exchange column 
and eluted using a linear gradient of 0-0.5 M NaCl, with a final 1 M NaCl wash to clean the 
column. Protein containing fractions were collected and stored on ice prior to assaying 
complement activating function, with the MONO Q AKTA trace show in Figure 3.5.  
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Figure 3.5. AKTA trace of Mono Q anion exchange column elution of Cobra venom. 10 ml of reconstituted cobra venom was 
concentrated using 100 kDa cut off spin columns through centrifugation at 10,000 x g and was reconstituted in 10 mM TRIS 
buffer. Reconstituted venom was loaded on to the AKTA via a 1 ml loading loop. The AKTA programme was then run and the 
sample loop loaded on to the Mono Q anion exchange column. Large amounts of protein came through the column in the 
void volume, as determined by the large UV peak (Blue) in the early fractions. This is most likely caused by proteins with a 
positive net charge at pH 7.4 and therefore did not interact with the positively charged MONOQ column matrix. The protein 
which bound the matrix was then eluted with a linear gradient of NaCl (0-0.5 M) and protein containing fraction peaks pooled 
and assayed for haemolytic function. The column was flushed through with 1 M NaCl to ensure no protein remained bound. 
Eluted, protein containing fractions were collected and kept separate to test for functionality by haemolytic assays. 
 
To test the haemolytic capacity of the eluted fractions, fractions from each of the protein 
peaks eluted were added to Guinea Pig erythrocytes in CFD + 10 mM EGTA to prevent 
classical pathway activation of NHS. The addition of 10% NHS provided a source of 
complement; however, without a functional CVF protein there would be no complement 
activation due to the EGTA preventing classical pathway activation on GPE cells, with the 
haemolytic titrations of each purification fraction shown in Figure 3.6.  
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Figure 3.6. CVF Mono Q fractions corresponding to elution protein peaks were assayed for haemolytic capacity. GPEs in CFD 
+ 10 mM EGTA were incubated with serial dilutions of the Mono Q fractions as denoted, in the presence of 10%  v/v NHS as 
a source of complement for 1 hour at 37 ˚C in 96 well, U-bottomed plates. Plates were subsequently centrifuged, GPEs 
pelleted and haemoglobin containing supernatant transferred to flat bottom plates for absorbance reading at 405 nm. 
Percentage haemolysis was quantified relative to water + 0.1% TWEEN positive and 10% NHS with no CVF negative 
controls. Run through fractions (A3) and second eluted peak (F10) demonstrated titratable haemolytic activity whilst D10 
(first eluted peak on the NaCl gradient) did not. The haemolytic capacity of A3 may be derived from Cobra venom 
phospholipases which did not bind the Mono Q column at the given pH. Haemolytic capacity of F10 fraction was statistically 
significantly higher than D10 and D7 fractions, with no significant difference observed between F10 and A3 fractions 
(P<0.01, One-way ANOVA with Dunnett post-hoc test, comparing all groups to F10 fraction).  
 
The fractions in the peak including F10 demonstrated haemolytic capacity, but not the peak 
corresponding to the D10 fraction. Therefore, to confirm the identity of the haemolytic agent 
as CVF and to determine the protein purity of the second eluent peak, fractions F6-F12 were 
pooled and SDS PAGE was performed under both reducing and non-reducing conditions with 
2.5 µg of protein loaded per lane on a 4-20% gradient gel (Figure 3.7). The multichain structure 
of CVF consists of a 68.5 kDa α chain, a 48.5 kDa ß chain and a 32 kDa Ƴ chain, disulphide 
linked to generate the functional protein at 144 kDa. Aliquots of CVF were then frozen at -
20˚C until use. From an initial 100 mg of lyophilised total cobra venom, 1.2 mg of purified CVF 
was obtained.  
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Figure 3.7. SDS PAGE of fractions F6 – F12 from Mono Q purification of CVF from whole Cobra venom (Naja Naja Kaouthia). 
2.5 µg of pooled protein from  Mono Q elution fractions F6-F12 was denatured at 90 °C for 10 minutes and  loaded on a 4-
20% gradient polyacrylamide gel under reducing or non-reducing conditions. Gels were subjected to SDS PAGE at a constant 
voltage of 120 V for 1 hour, before gels were stained in Coomassie solution for 1 hour at room temperature. Gels were 
subsequently washed and destained as previously described, and visualised using the Thermofisher MyECL system.Intact CVF, 
which is retained in the non-reduced samples, was observed at around 140 kDa as expected, whereas the α, ß and γ chains 
were generated upon reduction at 68, 48 and 32 kDa respectively.  
 
3.4 – Generation and purification of functional C5b6 complexes 
 
Purified CVF was then utilised to generate C5b6 complexes using a modification of a published 
method (DiScipio et al 1983). CVF (10 µg) was incubated with 10 µg of FB and 1 µg of FD in 
CFD buffer at 37˚C for 15 minutes to form a functional CVFBb convertase.  C5 and C6 (1 mg of 
each component) were added and incubated in the presence of the convertase overnight at 
37˚C. The product was then dialysed at 4˚C into size exclusion chromatography buffer (10 mM 
sodium phosphate, 150 mM NaCl pH 7), concentrated to a 1 ml final volume using Vivaspin 
500 centrifugation column with a 100 kDa MW cut off, and injected into an equilibrated SD200 
size exclusion chromatography column on the AKTA FPLC, with the resulting chromatogram 
shown in Figure 3.8. Protein-containing peaks from the SEC experiment were collected and 
assayed for haemolytic capacity.  
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Figure 3.8. Size exclusion chromatography (SEC) trace of C5b6 preparation using CVFBb to cleave C5; generated C5b then 
binds C6 to form active C5b6 complexes. The reaction mixture of the C5, C6, FB, FD and CVF reaction described above was 
concentrated using 100 kDa cut off spin columns and loaded on to a Superdex 200 size exclusion column on the AKTA FPLC 
system in 10 mM TRIS, 150 mM NaCl via sample loop. The loop was subsequently flushed through with 10 mM TRIS, 150 mM 
NaCl and loaded on to the Superdex column. Protein containing peaks were retained for individual testing for haemolytic 
activity and SDS PAGE analysis. 
 
To determine if any of the protein-containing fractions contained C5b6 as opposed to 
individual complement components or CVF, haemolysis and SDS PAGE were performed. From 
each of the SEC fractions 15 µl was removed, mixed with an equal volume of 2x non-reducing 
SDS loading buffer, separated on a BioRad 4-20% gel and Coomassie stained. Commercially 
available C5b6 was run alongside the fractions to demonstrate the expected banding 
patterns. SEC fractions C10 to C15 displayed a similar banding pattern to commercial C5b6 
with bands tentatively identified as C5α’, C5β and C6 co-eluting in the same fractions, shown 
in Figure 3.9.A, with the subsequent haemolytic testing shown in Figure 3.9.B. 
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Figure 3.9.A. SDS PAGE of SEC fractions for C5b6 generation. 2.5 µl of each size exclusion chromatography fraction was loaded 
under non-reducing conditions on a BioRad 4-20% gel at a constant voltage of 120V for 1 hour. Gels were subsequently 
coomassie-stained and destained as previously described and images captured using the Thermofisher system. Commercially 
sourced C5b6 (Comptech) was also run on the gel to compare with the generated protein. M – molecular weight marker, C4 
– D5 represent SEC fractions collected and compared to Comptech C5b6 protein (LH lane, RH gel). B. Haemolytic Screening of 
SEC fractions. GPE cells were incubated in CFD buffer in a 96 well U bottomed plate with 10 µl of SEC fractions for 10 minutes 
at room temperature, then with C7 (80 µg /ml) for 15 minutes at 37˚C, and finally with C8 and C9 (both 80 µg/ml)  for 1 hour 
at 37˚C. Cells were centrifuged at 300 x g for 5 minutes to pellet intact GPE, supernatant was transferred  to a flat bottomed 
96 well plate and absorbance read at 405 nm. Percentage haemolysis was quantified relative to water + 1% TWEEN positive 
and CFD only negative controls. Data presented as mean +/- SEM from a single experiment, representative of two 
experiments.  
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Fractions C9 to C15 from the SEC elution demonstrated both similar Coomassie staining 
pattern to commercial C5b6 and haemolytic capacity and were therefore pooled, dialysed 
overnight at 4˚C into CFD and aliquoted and stored at -80˚C as a stock solution of C5b6 at 200 
µg/ml until use. A final QC check was performed on the pooled C5b6 stock after dialysis to 
ensure function in the RL system; the stock was haemolytically active in this system (Figure 
3.10). Further validation of the methodology of forming the MAC sequentially in a membrane 
associated manner as opposed to fluid phase assembly and insertion was performed by 
separately adding the MAC components in the fluid phase before exposing GPE cells to the 
soluble MAC complexes (Figure 3.10).  
To perform this experiment, variations of the reactive lysis haemolytic assay protocol were 
used. Guine pig erythrocytes (2% v/v final concentration) were incubated in U-bottomed 96 
well plates in 100 µl of CFD buffer. In a separate plate, C5b6 titrations (0.001 µg/ml – 0.5 
µg/ml) were incubated with C7 + C8 + C9 (all at 1 µg/ml final concentration) in 50 µl of CFD 
for 30 minutes at 37° C. After the 30-minute incubation, C5b6 only (at the stated 
concentrations) was added to one set of triplicate titrations and incubated for 10 minutes at 
room temperature. Subsequently, C7 was added to this titration at 1 µg/ml and incubated at 
37°C for 15 minutes. Finally, C8 and C9 were also added to the cells, both at 1 µg/ml, for 45 
minutes at 37°C. At this point, the pre-incubated C5b6-9 from the second plate was 
transferred to GPEs in CFD to give a corresponding titration of pre-incubated components and 
also incubated on the GPEs for 45 minutes at 37°C. After incubation, U bottomed plates were 
centrifuged, supernatant transferred to a flat-bottomed plate and absorbance at 405nm 
measured as previously described. Concurrent with literature, C5b6-9 incubated in the 
absence of cells demonstrated minimal haemolytic activity, highlighting fluid phase C8 
binding to C5b67 is a potent inhibitor of MAC mediated haemolysis (Nemerow, Yamamoto 
and Lint 1979).  
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Figure 3.10. Pooled C5b6 fractions from SEC purification retain haemolytic capacity in RL system, whereas preincubated C5b6-
9 in the absence of GPEs has minimal haemolytic capacity. GPEs (2% v/v final concentration) were incubated in a U-bottomed 
96 well plate in 100 µl of CFD buffer. In a separate plate, fluid phase C5b6-9 was generated with a titration of C5b6 from 
0.001 µg/ml – 0.5 µg/ml and all other components (C7+C8+C9) at 1 µg/ml together in CFD for 30 minutes at 37°C. A second 
titration was performed with identical concentrations of components sequentially added to GPEs. C5b6 was incubated on 
GPEs for 10 minutes at room temperature, C7 for 15 minutes at 37°C and C8 + C9 for 45 minutes at 37°C. The pre-incubated 
C5b6-9 complexes were added to the GPEs at the same time as the C8+C9 as the sequential component addition protocol.  
C5b6 complexes pre-incubated with C7, C8 and C9 in the absence of GPE at 37˚C for 45 minutes were haemolytically inactive; 
membrane bound MAC statistically significantly increased haemolysis relative to fluid phase MAC (Two-way ANOVA P=0.007). 
Data presented as mean +/- SEM from a single triplicate experiment representative of three independent experiments. 
 
 
3.5 - Generation and validation of  classical pathway system of MAC deposition 
 
Nucleated cells exhibit a much higher resistance to MAC mediated lysis compared to 
erythrocytes due to their ability to mitigate MAC-induced chemiosmotic flux through 
expression of regulators, endocytosis and exocytosis of MAC pores, and active ion pumps to 
offset ion leak through the MAC pore. Due to this, effects of RL-generated MAC on nucleated 
cell death in my hands was limited and difficult to titrate in the manner performed on GPE’s; 
it was therefore not possible to titrate a maximum sublytic dose using the RL system, reducing 
its value for investigating sublytic effects. To overcome this problem, a second system utilising 
classical pathway activation was optimised and titrated to identify maximum sublytic 
condition, with Propidium iodide staining and LDH release from THP-1 cells both used as 
measures of cell death, shown in Figure 3.11. 
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Figure 3.11. A. Classical pathway activation on THP-1 cells sensitised with COS-1 antiserum. 2x105 THP-1 cells seeded at a 
density of 1x106 cells /ml were incubated with titrations of COS-1 antiserum (10% - 0.1% v/v) for 20 minutes at room 
temperature in complete RPMI media. Cells were centrifuged at 300 x g for 5 minutes to pellet cells and remove unbound 
antibody before resuspension in complete RPMI and incubating with NHS / C5 depleted serum (5% v/v) for 1 hour at 37oC. 
Cells were subsequently washed and resuspended into 200 µl FACS buffer and 10 µg/ml  PI added. Cells were protected from 
direct light and analysed on the FACS Calibur flow cytometer. As positive control, cells were lysed with 2% Triton and PI 
positive cells gated relative to this. Negative controls included antiserum only, NHS only, and sensitised cells incubated with 
C5 depleted serum; all demonstrated <10% cell death (Data for negative controls not shown in figure). B.  2x105 THP-1 cells 
seeded at a density of 1x106 cells/ml were incubated with a constant dose of COS-1 sensitising antiserum (5%) in complete 
RPMI media in 96 well U bottom plates for 20 minutes at room temperature. Cells were centrifuged, resuspended and exposed 
to a titration of NHS (0-30% v/v). Cells were washed, resuspended in FACS buffer, PI added and assayed on the FACS Calibur 
as previously described. Data presented from a single triplicate experiment, representative of more than three independent 
experiments.  C.  LDH release assay. 2x105 THP-1 monocytes were seeded at a density of 1x106 cells/ml in a sterile 96 well U 
bottomed plate in complete RPMI media and COS-1 antiserum titrated from 10% to 1.25% v/v as previously described to 
sensitise the cells to complement. NHS or C5 depleted NHS were added at 5% v/v final concentration for 1 hour at 37 °C in 
complete RPMI media. Plates were then centrifuged and 50 µl cell supernatant transferred to  new plate where LDH reagent 
was added 1:1 with supernatant and incubated protected from direct light for 45 minutes at room temperature. The assay 
was stopped using 50 µl of 10% acetic acid and absorbance read at 490 nm on the Magellan plate reader. Percentage LDH 
release was quantified relative to 1x lysis buffer and 5% NHS – antiserum activator positive and negative controls.   
demonstrating a dose dependent increase in LDH release with increased sensitising dose of COS-1 antiserum. Data displayed 
as mean +/- SEM from a single triplicate experiment, representative of three independent experiments. D.  Example PI 
histograms for unstimulated, sublytic MAC attacked and triton-lysed positive control cells with the PI positive gate used for 
quantification displayed from samples stimulated with the methodology described for 3.11.A. 
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The dose of NHS / sensitising antiserum required to generated sublytic attack varied between 
experiments, presumably dependent on the original growth phase and confluence of the cells 
at the time of harvesting for the experiment; therefore, the sublytic dose was titrated prior 
to each experiment. Of note, C5 depleted serum demonstrated no significant cell death, 
allowing confidence the cytotoxicity induced was MAC dependent. The timescale in which the 
cell death was observed (1 hour), suggests an inflammatory and rapid form of death is 
involved in MAC-mediated nucleated cell death, as proposed by others (Elmore 2007).    
 
3.6 - Measuring complement deposition on THP-1 cell surface 
 
To further demonstrate complement activation on the THP-1 cell surface in the classical 
pathway sublytic attack system, flow cytometry staining for C3b and C9 was performed. For 
C9 staining, due to the transient nature of MAC deposition with cells rapidly shedding MAC 
through endocytosis and exocytosis, cells were fixed prior to staining, whereas the more 
stable C3 fragments did not require fixation. Cell stimulation and staining was performed as 
described in the materials and methods.  
Antibody-sensitised THP-1 cells incubated with 5% NHS showed strong staining for C9, 
indicative of MAC formation, whereas all controls were negative (Figure 3.12). C9-staining 
was serum dose dependent and absent when sensitised cells were incubated with C5-
depleted serum, demonstrating that there is complement terminal pathway deposition 
alongside the previously described decreases in cell viability. 
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Figure 3.12.A. C9/MAC staining on THP-1 monocyte cell line. 2x10 5 THP-1 cells were seeded at a concentration of 1x106 
cells/ml in complete RPMI media and were sensitised to complement with 2.5% v/v COS-1 antiserum for 20 minutes at room 
temperature. Cells were washed with sterile PBS and resuspended in 200 µl of RPMI containing NHS or C5 depleted serum at 
the stated concentrations (all described as final % v/v) for 10 minutes at 37˚C. Plates were then centrifuged at 300 x g for 5 
minutes, RPMI supernatant aspirated and cells fixed in 4% v/v PFA at 4˚C for 30 minutes. Cells were washed twice with sterile 
PBS and stained using the mouse monoclonal anti-C9 neoepitope antibody B7 (10 µg/ml in FACS buffer, on ice for 30 minutes) 
and subsequently rabbit anti-mouse IgG Alexa 546 (1/50 v/v dilution in FACS buffer protected from light for 20 minutes). Cells 
were again washed twice with sterile PBS and resuspended in 200 µl of FACS buffer and transferred to FACS tubes before 
fluorescence was measured on the FACS Calibur. Controls of unstained, Mouse IgG and 5% NHS without sensitising antibody 
were also used. B. Quantification of Geometric mean fluorescence of controls, NHS and C5 depleted serum titrations. Data 
presented from single replicates of a single experiment, representative of three independent experiments. 
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To verify complement activation was occurring on the cell surface, staining for C3b 
deposition was also performed. This was also undertaken to address recent observations in 
the literature that CD59/CD46/CD55 triple knockout cells demonstrated C3b deposition 
without a complement activator present, whereas CD55/ CD46 KO cells did not (Thielen et 
al 2017). This led to a proposed hypothesis that CD59 has roles beyond the regulation of the 
terminal pathway and may also regulate at the C3 convertase level. To address this, cells 
were sensitised as described in the materials and methods but also with and without the 
CD59 blocking antibody BRIC 229. It was hypothesised that if CD59 activity influenced C3b 
deposition in this system, cells with CD59 inhibition would have increased C3b staining. To 
verify that CD59 function was effectively inhibited, cell viability was also measured. A 
reduction in cell viability relative to cells with retained CD59 function was taken as an 
indicator that cell surface function was effectively inhibited. 
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B) C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13.A. Histogram overlays of C3b staining relative to unstimulated samples, C5 depleted serum generated a double-
peak pattern of C3b staining not observed with NHS. Histograms presented representative of triplicate samples. C3b 
deposition and cell death in THP-1 monocytes. 2x105 THP-2 monocytes were seeded at a density of 1x106 cells/ml in complete 
RPMI media. Cells were sensitised to complement using 2.5% v/v COS-1 antiserum as previously described +/- 25 µg/ml BRIC 
229 for 20 minutes at room temperature. Cells were subsequently washed and resuspended in complete RPMI prior to 
complement deposition (5% v/v NHS or C5 depleted NHS) for 1 hour at 37 °C. Cells were centrifuged and resuspended in FACS 
buffer, prior to staining with Biolegend anti-C3b FITC antibody at a 1:100 dilution for 20 minutes protected from direct light. 
Cells were washed and resuspended in FACS buffer and transferred to FACS tubes before fluorescence measured on the FL-1 
channel of the FACS Calibur. B. Quantification of mean fluorescence intensity of FITC-C3b staining of THP-1 monocytes from 
A. Significance determined by one-way ANOVA with Dunnett post-hoc test. Statistical significance tested relative to MAC 
without BRIC 229 sample. C. Comparison of PI positive THP-1 cells across control and stimulated samples with unstimulated 
A) 
Unstained (Grey) v 
Unstimulated (Yellow) 
Unstimulated 
(Grey) v COS-1 AS 
without NHS 
(Yellow) 
Unstimulated 
(Grey) v 10% 
NHS - COS-1 AS 
(Yellow) 
Unstimulated (Grey) v 
10% NHS + 25 µg /ml 
BRIC 229 (Yellow) 
Unstimulated 
(Grey) v 10% NHS + 
COS1 AS (Yellow) 
Unstimulated (Grey) v 10% 
C5 depleted serum + COS1 
AS (Yellow) 
Unstimulated (Grey) v 
10% NHS + COS1 AS + 
25µg/ml BRIC 229 
(Yellow) 
Unstimulated (Grey) v 10% 
C5 depleted serum + COS1 
AS + 25µg/ml BRIC 229 
(Yellow) 
C
el
l c
o
u
n
t 
Fluorescence intensity  
U
ns
ta
in
ed
A
nt
is
er
um
 o
nl
y 
(2
.5
%
)
Se
ru
m
 o
nl
y 
(1
0%
 N
H
S)
B
RI
C 
22
9 
+ 
N
H
S 
 M
A
C
A
nt
is
er
um
 +
 C
5 
de
pl
et
ed
 s
er
um
Su
bl
yt
ic
 M
A
C
 +
 B
R
IC
22
9
A
nt
is
er
um
 +
 C
5 
- +
 B
R
IC
22
9
0
50
100
150
200
***
**
**
M
e
d
ia
n
 F
L
1
 (
C
3
b
 F
IT
C
)
** ** **
A
nt
is
er
um
 o
nl
y 
(2
.5
%
)
S
er
um
 o
nl
y 
(1
0%
 N
H
S
)
B
R
IC
 2
29
 +
 5
%
 N
H
S 
 M
A
C
A
nt
is
er
um
 +
  C
5 
de
pl
et
ed
 s
er
um
S
ub
ly
tic
 M
A
C
 +
 B
R
IC
22
9
A
nt
is
er
um
 +
 C
5 
- +
 B
R
IC
22
9
Tr
ito
n 
X
 (2
%
)
-20
0
20
40
60
80 ***
P
e
rc
e
n
ta
g
e
 P
I 
p
o
s
it
iv
e
 c
e
ll
s
 a
b
o
v
e
 b
a
s
e
li
n
e
 
 
126 
 
control baseline subtracted. Experimental conditions were as described in 3.13.A for the stimulation of THP-1 cells. Upon 
stimulation with complement (COS-1 antiserum +/- BRIC 229 and NHS / C5 depleted NHS) cells were resuspended in FACS 
buffer and PI staining performed as previously described.  Above baseline cell death was only observed with NHS + sensitising 
antiserum, which was statistically significantly increased with the addition of BRIC 229 anti-CD59 antibody. Data presented 
as the mean +/- SEM from a single experiment, representative of three independent experiments. Significance determined by 
One-Way ANOVA with Dunnett post-hoc test relative to MAC sample (** = P<0.01. *** = P<0.001). 
 
Whilst the previous experiments demonstrated no role for CD59 inhibition in C3b 
regulation, there was an interesting observation in that C5-depleted NHS, which caused 
neither haemolysis nor nucleated cell death, deposited more C3b on the cell surface than 
the same dose of NHS. To explore whether this was an artefact of the C5 depletion process 
yielding an increased level of C3 activation, or if the lack of terminal pathway has a real 
effect on activation and amplification, follow up experiments were performed. NHS was pre-
incubated (30 minutes at room temperature) with Eculizumab at a dose sufficient to inhibit 
all C5 activity. The inhibitory concentration of Eculizumab was calculated as around 1.5x 
molar ratio of antibody to final C5 concentration. As NHS was used at 5% v/v final 
concentration, with an estimated C5 concentration of 80 µg/ml in NHS, final C5 
concentrations in this system were estimated as 4 µg/ml. As C5 has a molecular mass of 180 
kDa and IgG has a molecular mass of 160 kDa, 6 µg/ ml of Eculizumab was used to 
completely inhibit C5 activity. NHS, C5 depleted NHS or NHS + eculizumab were then 
incubated with complement sensitised THP-1 cells as above and C3b deposition measured. 
NHS with Eculizumab generated a similar C3b staining pattern to that seen in C5-depleted 
serum with a highly C3b positive population not present in NHS-treated samples (Figure 
3.14). Negative controls of NHS without an activating antiserum and heat inactivated NHS + 
antiserum were used to validate the experiment. 
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Figure 3.14. A.  Representative overlay histograms of stimulation conditions, demonstrating the similar staining patterns of 
C5 depleted serum and Eculizumab treated NHS, both generating a population of highly C3b positive cells. 2x105 THP-1 cells 
at a concentration of 1x106 cells /ml in a sterile 96 well U bottomed plate were sensitised to complement using 2.5%  COS-1 
antiserum (v/v) in complete RPMI media as previously described. Cells were subsequently washed with sterile PBS and 
resuspended in complete media, prior to NHS, C5 depleted NHS or NHS pre-incubated with eculizumab addition to the cells 
for 30 minutes at 37°C. Cells were subsequently washed with sterile PBS and resuspended in FACS buffer prior to staining for 
C3b deposition using the Biolegend anti-C3b FITC antibody at a 1:100 dilution. Cells were washed with sterile PBS and 
resuspended in FACS buffer before fluorescence was analysed on the FACS Calibur. B. Quantification of C3b staining on THP-
1 cells incubated with NHS, NHS + Eculizumab or C5 depleted NHS as described in 3.14.A. Both eculizumab pre-treated NHS 
and C5 depleted NHS deposited significantly more C3b than NHS on COS-1 sensitised THP-1 cells in this system (One-way 
ANOVA with Dunnett post-hoc test comparing to NHS + antiserum sample. Data presented as Mean +/- SEM from a single 
experiment, representative of three independent experiments. * = P<0.05).  
 
The finding that either C5 depletion or C5 inhibition markedly increased C3b deposition on 
THP-1 cells was unexpected; this could have real impact if excessive C3b deposition is 
occurring on nucleated cells exposed to plasma in patients on Eculizumab. 
To further investigate whether this observed elevated C3b deposition was specific to C5 
depletion and inhibition or a general phenomenon of terminal pathway inhibition, an in 
house anti-C7 inhibitory antibody (23D10) was used alongside Eculizumab. In contrast to the 
results obtained with C5 blockade or depletion, blocking terminal MAC formation at the C7 
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stage did not statistically significantly affect the levels of C3b deposition on the cells (Figure 
3.15 A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 A. FACS profiles of C3b staining on  THP-1 cells sensitised to complement and stimulated with NHS, C5 depleted 
NHS or NHS + in house anti-C7 antibody incubated with NHS prior to addition to sensitised cells. . 2x105 THP-1 monocytes 
were seeded at a density of 1x106 cells/ml in complete RPMI media. Cells were sensitised to complement using 2.5% v/v COS-
1 antiserum as previously described. Cells were subsequently washed with sterile PBS and resuspended in complete media, 
prior to NHS, C5 depleted NHS or NHS pre-incubated with eculizumab or in house anti-C7 antibody. Sources of complement 
were added to the cells for 30 minutes at 37°C. Cells were subsequently washed with sterile PBS and resuspended in FACS 
buffer prior to staining for C3b deposition using the Biolegend anti-C3b FITC antibody at a 1:100 dilution. Cells were washed 
with sterile PBS and resuspended in FACS buffer before fluorescence was analysed on the FACS Calibur B.  Mean fluorescence 
of THP-1 cells treated with NHS, C5 depleted NHS, NHS + Eculizumab and NHS + anti-C7 blocking antibody, stained for C3b 
deposition. Intact cells were gated on forward and side scatter. B. Quantification of mean C3b staining fluorescence intensity 
from 3.15.A. Statistically significant differences were determined using  One-Way ANOVA with Dunnett Post hoc test 
comparing samples to antiserum + NHS (***=  P<0.001) 
 
The finding that MAC block at the C7 stage, in contrast to block at the C5 stage, did not 
increase C3b staining on NHS-exposed THP-1 cells is intriguing. As both blocking mAbs 
prevent lytic cell death, this is unlikely to be a consequence of differences in cell loss.  One 
possibility is that C5 block, by preventing C5 interaction with the convertase, allows more C3 
to be cleaved by the convertase, whereas C7 block does not alter C5 interactions or impact 
convertase function.  
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3.7 - The induction of Ca2+ flux in response to MAC deposition 
 
One of the crucial mechanisms of MAC induced cell signalling is via the induction of elevated 
cytosolic Ca2+ concentrations. The elevation of cytosolic Ca2+ from the nanomolar range in 
unstimulated cells to several micromolar upon MAC deposition has been implicated as an 
important trigger, not only in MAC induced inflammatory cell signalling, but also in the repair 
processes and resistance of cells to MAC mediated death (Morgan and Campbell 1985). 
Therefore, it was crucial to ensure that the expected Ca2+ flux was observed with the systems 
used in these experiments. Methods were modified from previously published work from our 
group showing that sublytic MAC induced Ca2+ flux using the fluorescent dye Fluo-3-AM by 
flow cytometry (Triantafilou et al 2013). Fluo-3-AM is a cell permeable esterified compound 
which becomes de-esterified by cytosolic esterases, trapping the dye in the cytoplasm. 
Intracellular Fluo-3 fluorescence at 525 nm upon Ca2+ binding can be measured through the 
FL-1 channel on a flow cytometer. Fluo-3-loaded cells were sensitised as before and incubated 
with NHS or C5 depleted serum or NHS + 10 mM EDTA to prevent complement terminal 
pathway activation and alternative pathway amplification respectively. Incubation with a 
sublytic dose of NHS caused an increase in fluorescence signal, indicative of increased 
intracellular Ca2+ , after 10 and 15 minutes at 37oC and persisting for at least 20 minutes 
(Figure 3.16 A/B). EDTA-treated NHS did not cause a change in fluorescence at these times 
and C5-depleted serum caused a small increase in fluorescence, possibly due to C3 cleavage 
product (C3a or C3b) signalling through cognate receptors. To generate time resolved data, a 
plate-based assay was used. Cells were loaded with dye and sensitised as with the flow 
protocol, however sensitised cells were then resuspended in CFD buffer, transferred to 96 
well, opaque plates and stimulated with NHS / C5 depleted NHS and fluorescence at 515 nm 
recorded (Figure 3.16 C). 
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Figure 3.16. Calcium flux in response to sublytic MAC deposition on THP-1 monocytes. 2x105 THP-1 cells were loaded with the 
Calcium sensitive dye Fluo-3-AM at 2.5 µM for 45 minutes at 37˚C in complete RPMI in 96 well, U-bottomed plates. Cells were 
washed and sensitised to complement using COS-1 antiserum as previously described. Cells were then exposed to NHS, NHS 
containing EDTA or C5 depleted serum and fluorescence measured on different platforms. A. Fluorescence was measured 
over time in each condition via FACS analysis and data analysed using Flowing software 2.0.  Data are from a single 
experiment, representative of three independent experiments. B. Bar graph showing mean fluorescence intensities in the 
different conditions at 10 minutes.  C. Quantification of changes in MAC mediated increases in intracellular Ca2+ over time in 
a fluorescence plate reader. 2x105 COS-1 sensitised THP-1 cells were transferred to opaque, black plates for plate reader 
fluorescence reading (505 nm / 525 nm excitation / emission). Baseline fluorescence was obtained from unstimulated cells, 
and maximal fluorescence was obtained at the end of the experiment through adding 2% Triton X to control wells. Change in 
fluorescence at 515 nm was converted to Ca2+ concentration through the equation [Ca2+] = Kd (325 nM  for Fluo-3-AM) x 
((Fluorescence of signal – Minimal Fluorescence (unstimulated cells)) / (Maximal Fluorescence (Triton X control) – Minimal 
Fluorescence).  Data presented as mean +/- SEM from one experimental set of triplicate values, representative of three 
independent experiments. 
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3.8 - Sublytic complement deposition affects the intracellular oxidative state 
 
A second important consequence of sublytic MAC deposition on nucleated cells is the 
production and release of ROS/ RNS. Whilst sublytic MAC deposition has been demonstrated 
to induce ROS secretion from monocytes, the intracellular generation of ROS and the nature 
of the ROS generated has largely been unexplored. Sublytic MAC deposition on rat mesangial 
cells was demonstrated to induce the release of O2- and H2O2: driving tissue damage, but the 
intracellular signalling responsible was not explored (Couser et al 1986). The importance of 
these observations, and further delineating MAC mediated ROS/RNS production is the 
pleiotropic roles ROS performs as a secondary messenger within the cell, activating a host of 
inflammatory and cell death associated mechanisms; including the NLRP3 inflammasome.   
Cellular ROS / Superoxide production was tested using a detection kit (Abcam) that allows 
analysis of two subsets of intracellular ROS through flow cytometry. The two dyes are 
dihydrofluorescin esters which are cell permeable; however, upon cell entry the compounds 
are deacetylated by intracellular esterases to trap the non-fluorescent precursor compounds 
in the cell where they can be oxidised by ROS / Superoxide and generate fluorescent products. 
The exact probe molecular identities are not disclosed by the manufacturer. The green probe 
(FL-1 channel) allows measurement of hydrogen peroxide, peroxynitrite, hydroxyl radicals, 
nitric oxide and peroxy radicals; the orange probe (FL2 channel) allows the measurement of 
Superoxide and hypochlorous acid radicals, cumulatively allowing a thorough investigation 
into ROS/RNS production within the cell in response to MAC stimulation. THP-1 monocytes 
(2x105) were loaded with a 1:2000 dilution of the respective ROS/RNS probes reconstituted 
in dimethylformamide (DMF) for 30 minutes; DMF was used as solvent as DMSO can 
modulate ROS signalling and may generate spurious results. Cells loaded with the respective 
dyes were subsequently antibody using COS-1 antiserum sensitised as previously described 
(2.5% v/v final concentration), washed and resuspended in NHS / C5 depleted serum for 20 
minutes prior to further centrifugation and resuspension in FACS buffer. Cells were then 
analysed on the Becton Dickenson FACS Calibur and plots generated using Flowing software 
2. Due to the overlapping fluorescence spectra of the dyes and difficulties encountered in 
compensation, cells were stained separately with the individual dyes, shown in Figure 3.17. 
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Figure 3.17. Deposition of sublytic MAC on THP-1 cells alters the cell redox potential through generation of superoxide. A. 
2x105 THP-1 cells were loaded with the ROS sensitive dyes (Abcam) at the recommended 1:2000 dilution in DMF for 45 minutes 
at 37˚C in complete RPMI in 96 well, U-bottomed plates. Cells were washed and sensitised to complement using COS-1 
antiserum as previously described. Cells were then exposed to NHS, NHS containing EDTA or C5 depleted serum and 
fluorescence measured on different platforms. A. Fluorescence was measured at 30 minutes each condition via FACS analysis 
and data analysed using Flowing software 2.0.  Data are from a single experiment, representative of three independent 
experiments Sublytic MAC causes an elevation of superoxide derived ROS/RNS in a dose dependent manner relative to 
unstimulated controls, which is not observed when C5 depleted serum is used.  B. C5 depleted serum does not alter the 
oxidative stress / hydroxyl radical staining of the cells; however, sublytic MAC causes a shift with a decrease of FL-1 
fluorescence. C. Quantification of FL2 mean fluorescence from A. D. Quantification of mean FL1 fluorescence from B. Data 
presented from an individual, single replicate experiment, representative of three independent experiments.  
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The observation that sublytic MAC generates an elevation of intracellular superoxide (A and 
C) and a decrease in hydroxyl radical states (B and D) was unexpected, however the literature 
of MAC driven ROS production is relatively scarce, with a single paper highlighting an 
elevation of superoxide production on rat mesangial cells, but not addressing other oxygen 
or nitrile species (Adler et al 1986).  A possible explanation for the reduction in fluorescence 
signal in regard to the hydroxyl radical stain might be that the dye leaked from the cells upon 
MAC deposition and membrane disruption; however, decrease in signal was only seen for the 
green (FL1) channel, not the orange (FL2), making non-specific dye release from damaged 
cells an unlikely explanation. Therefore, the observed dichotomy of elevated superoxide and 
reduction of hydroxyl staining suggests a real phenomenon with marked changes in Oxygen 
and Nitrile species.  
 
3.9 - Conclusions of Chapter three 
 
In this section of work, I have demonstrated that sublytic MAC may be generated from the 
reactive lysis and serum / antibody systems. The purification and validation of individual 
terminal pathway components, C5b6, CVF and the CVFBb complex, which together were 
subsequently utilised to generate functional reactive lysis systems, was shown. Both early 
complement (C3b) and terminal pathway (C9) deposition could be demonstrated on THP-1 
cells subjected to sublytic MAC using a classical pathway system.  
In contrast to recent reports from other groups, blockade of CD59 caused no significant 
differences in C3b deposition in complement attacked cells with the functional blocking of 
CD59 using BRIC229; large changes in C9/MAC staining and cell death were observed, 
validating that CD59 function was impaired (Thielen et al 2017). The literature suggesting 
CD59 was implicated in C3 regulation was derived from the observation that only cells 
deficient in CD46/CD55/CD59 were susceptible to spontaneous C3 deposition when exposed 
to NHS, whereas CD46/CD55 deficient cells did not undergo spontaneous C3 deposition as 
determined by FACS. Due to the contrasting methods used, the differences are hard to verify.  
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Most likely, this difference is attributable to MAC mediated damage driving further C3b 
deposition on these cells, which is then not regulated by CD55 / CD46 (Thielen et al 2017). 
From this set of experiments, a further interesting observation was made that C5 depleted 
NHS, used as a control to demonstrate that cell death or sublytic effects were terminal 
pathway dependent, caused increased C3b deposition on the cell surface relative to the same 
dilution of NHS alone. To verify this, NHS was incubated with a C5 blocking concentration of 
Eculizumab prior to addition to sensitised cells and compared to NHS – Eculizumab and C5 
depleted NHS samples. The C3b staining pattern and intensity was comparable between C5 
depleted NHS and NHS + Eculizumab, and significantly increased relative to NHS alone. 
Interestingly, the strongly C3 fragment positive populations observed with C5 depleted and 
Eculizumab treated NHS samples has also been observed in PNH patients, where CD59 
negative RBC’s had two distinct C3 fragment positive and negative populations (Sica et al 
2018). Comparative FACS dot plots are shown in Figure 3.18.  
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Figure 3.18 – Comparative C3b staining dot plots between classical pathway stimulated THP-1 cells (histogram data 
described in Figure 3.14) and C3d staining on PNH patient erythrocytes (Y axis CD59, dot plots sourced from Sica et al 2018).  
PNH patients on stable eculizumab treatment (e.g. 11 weeks of treatment) demonstrate CD59 negative, C3b positive cells 
distinct from the C3 negative main population, similar to the subpopulations observed in these experiments, suggesting that 
the observed effects of C5 inhibition in this system may be replicated in vivo. 
 
To further investigate whether this was a C5 specific effect or a general observation with 
terminal pathway inhibition, an anti-C7 antibody was also tested in the same experimental 
system. Surprisingly, the effects of C7 inhibition differed from that of C5 inhibition or 
depletion. C7 inhibited NHS had comparable levels of C3b deposition on the THP-1 cell surface 
to NHS without terminal pathway inhibition, as opposed to C5 depleted NHS which 
demonstrated significantly increased C3b deposition. This suggests that there may be a 
mechanism by which C5 inhibition or depletion impacts the activity of the C3 convertase. One 
possible explanation for this could be that the C5 convertase still retains a low affinity for C3, 
therefore, in the absence of C5 interaction, more C3 is cleaved and deposited on the cell 
Highly C3b positive cells 
COS-1 antiserum +C5 depleted 
NHS  
COS-1 antiserum + NHS + 
Eculizumab  
COS-1 antiserum + NHS  
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surface whereas in C7 inhibited serum the C5 convertase can still preferentially bind the C5 
ligand. This has direct impact, if further explored, on patients treated with Eculizumab. If C5 
inhibition elevates C3b deposition in response to complement activation, but C7 inhibition 
results in comparable C3b surface levels to NHS, some effects of Eculizumab on processes 
such as extravascular haemolysis may be attenuated, which would be beneficial for the 
patient (Hill et al 2010; Gottleib et al 2012; Sica et al 2018).   
 The fundamental hallmarks of MAC deposition which pertain to NLRP3 activation, including 
Calcium flux and ROS generation have been observed in systems with MAC being formed, but 
not in C5 depleted controls, demonstrating specificity to MAC mediated effects in the systems 
used.  The sharp, rapid increase in intracellular Calcium in response to sublytic MAC, but not 
C5 depleted serum or serum inhibited with 10 mM EDTA validates that Calcium flux is MAC 
dependent and is not induced by antibody deposition on the cell surface.  
The observation of a differential ROS/RNS profile, with MAC mediating an increase in a 
superoxide detecting agent whilst cocommitantly decreasing staining for oxidative stress was 
surprising. The distinction of ROS species generated in response to sublytic MAC in THP-1 cells 
is poorly defined and understanding these differences may have important connotations in 
cell signalling, survival and recovery.    
The generation of the sublytic MAC system utilising COS-1 antiserum and NHS allowed the 
investigation of both sublytic and lytic MAC on nucleated cells in subsequent chapters. Other 
sensitising antibodies including monoclonal anti-HLA  and anti-CD15 (TG1) and polyclonal 
anti-CD59 failed to effectively activate complement and allow titratable cell death (data not 
shown). The sublytic threshold demonstrated in the COS-1 system on THP-1 monocytes was 
2.5% (v/v) COS-1 antiserum to sensitise the cells to complement attack, with 5% (v/v) NHS to 
yield cell death <10% above baseline levels. This is comparable to the system used by our 
group previously to investigate the role of sublytic MAC in the activation of NLRP3 in A549 
lung epithelial cells, in which 5% NHS was used, however the dose and duration of 
complement sensitisation using anti-CD59 polyclonal antiserum was not defined (Triantafilou 
et al 2013). 
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This work therefore lays the foundation to apply the protocols established here to observe 
the effects of sublytic MAC in the context of NLRP3 activation and manipulate some of the 
described responses, such as Calcium and ROS/RNS and observe the effects on NLRP3 activity.  
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Chapter 4: Investigating sublytic MAC induced inflammasome activation and IL-1β secretion 
in monocytic cells 
 
4.1 - Introduction 
 
In the previous chapter, the classical pathway and reactive lysis methods were established 
and demonstrated to deposit MAC on the cell surface. In this chapter, both systems were 
used to investigate the mechanisms by which sublytic MAC induced inflammasome activation 
and IL-1β secretion in monocytic cells. The activation of complement and MAC formation on 
nucleated cells has previously been demonstrated to induce NLRP3 activation and IL-1β 
secretion by our group in A549 lung epithelial cells, with others demonstrating similar effects 
in LPS primed human dendritic cells and mouse BMDM’s; however, the current understanding 
of conserved and cell type specific inflammasome activation pathways in response to MAC 
remains unclear (Laudisi et al 2013; Triantafilou et al 2013; Suresh et al 2016). The absence 
of a general mechanism explaining how MAC induces NLRP3 activation is apparent from the 
lack of consensus of previous studies, with cellular perturbations such as Ca2+ influx, K+ efflux, 
ROS production and mitochondrial dysfunction all implicated by different studies. The range 
of different potential mechanisms explored in the current literature is summarised in Table 7. 
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Paper 
Proposed mechanism(s) 
of sublytic MAC induced 
NLRP3 activation 
Mechanism(s) of MAC 
mediated NLRP3 
shown to have no 
effect in this system 
Triantafilou et al 
2013 
Ca2+ influx, secondary 
calcium release from 
intracellular stores, 
mitochondrial 
dysfunction,  N/A 
Laudisi et al 2013 
(supplemental 
information) Ca2+ influx, K+ efflux N/A 
Suresh et al 2016 ROS production, K+ efflux 
P2XR7 -/- (ATP 
receptor) cells did not 
have significantly 
reduced MAC 
mediated IL-1β release 
compared to WT 
Kumar et al 2018 N/A N/A 
 
Table 7: Summary of mechanisms of MAC mediated NLRP3 activation explored in existing literature. 
 
Due to the range of mechanisms of MAC induced NLRP3 activation proposed in these papers, 
and the lack of any contraindicating evidence between papers, all these established NLRP3 
activation pathways (Ca2+ influx and release from stores, K+ efflux and ROS production) were 
investigated in this system. The objective of this was to demonstrate which cellular processes 
had effects on sublytic MAC mediated NLRP3 activation in this system, as well as attempt to 
establish any interaction between mechanisms, such as Ca2+ mediated mitochondrial 
dysfunction or ROS production.  Alongside these broad cellular mechanisms, the effects of 
inhibiting sublytic MAC activated signalling pathways, such as AKT, PI3K, JNK1 and ERK in the 
context of NLRP3 activation and IL-1β secretion were explored to attempt to elucidate 
conserved signalling pathways linking MAC and NLRP3 
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4.2 - Investigating the mechanisms of sublytic MAC activation of NLRP3 
 
THP-1 cells were stimulated using LPS priming with subsequent COS-1 antiserum sensitisation 
and NHS treatment to induce sublytic complement activation on the cell surface. 2x105 THP-
1 cells were seeded at a density of 1x106 cells / ml in complete RPMI media in 96-well, U-
bottomed sterile plates and primed with 100 ng/ml LPS for 4 hours. Cells were subsequently 
sensitised to complement using 2.5% (v/v) COS-1 antiserum and subject to sublytic attack 
using 5% (v/v) NHS or C5 depleted NHS as described in the materials and methods (Chapter 
2, Section 2.14)  for 1 hour prior to harvesting of supernatant for assay of IL-1β secretion 
(Figure 4.1.A). Sublytic MAC treatment statistically significantly increased IL-1β secretion 
relative to unstimulated controls and cells treated with C5 depleted NHS, the latter 
demonstrating MAC dependence. Stimulation of cells with sublytic MAC without a priming 
stimulus did not elicit an IL-1β response (data not shown).  
 
 
 
 
 
 
 
 
Figure 4.1.A. 2x105THP-1 monocytes were seeded at a density of 1x106 cells /ml in complete RPMI media. Cells were then 
primed with 100 ng/ml LPS  for 4 hours. Primed cells were subsequently exposed to a sublytic dose of COS-1 antiserum (2.5% 
v/v) + NHS or C5 depleted serum (5% v/v) as previously described. After one hour of sublytic MAC stimulation, cell supernatant 
was collected  and IL-1β measured by ELISA. LPS primed THP-1 cells exposed to sublytic MAC generated statistically 
significantly more IL-1β than LPS primed alone, LPS + 2.5% v/v COS-1 antiserum without NHS, LPS + 5% v/v NHS without 
sensitising antiserum  or LPS primed, COS-1 sensitised (2.5% v/v)  and exposed to C5 depleted serum (5% v/v). Data presented 
as the mean +/- SEM from a single experiment, representative of three independent experiments. Statistical significance 
determined by one-way ANOVA with Dunnett post-hoc test, comparing all columns with Sublytic MAC + LPS. (*** = P<0.001, 
**= P<0.01).  
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4.3 - Sublytic MAC induced IL-1β secretion is NLRP3 dependent 
 
The mechanism by which sublytic MAC induces the observed IL-1β secretion is not defined 
in THP-1 cells, although the literature from other cell types would suggest it would be 
through canonical NLRP3 and Caspase-1 activation as Caspase-1 P10 / P20 generation has 
been demonstrated to accompany MAC mediated IL-1β secretion (Triantafilou et al 2013, 
Laudisi et al 2013, Suresh et al 2016). Therefore, 2x105 THP-1 cells at a density of 1x106 cells 
/ ml in complete RPMI media were primed with 100 ng/ml LPS and stimulated with sublytic 
MAC (2.5% v/v sensitising COS-1 antiserum and 5% v/v NHS) as described in the previous 
section, but with the addition of pre-treatment with pharmacological modulators of NLRP3. 
Three inhibitors were selected: MCC950, a small molecule inhibitor of NLRP3; AC-YVAD-
FMK, an inhibitor of Caspase-1; ZVAD-FMK, a pan-caspase inhibitor. These were selected to 
target different processes related to canonical or non-canonical inflammasome activation. If 
the induction of IL-1β synthesis and secretion was through canonical NLRP3 and Caspase-1 
activation then MCC950, AC-YVAD-FMK and Z-VAD-FMK would all be expected to decrease 
the levels of cytokine released, whereas if secretion was via a non-canonical inflammasome 
forming with Caspases 4/5/11  Z-VAD-FMK would inhibit cytokine secretion, but AC-YVAD-
FMK would be ineffective (Ding and Shao 2017). Each inhibitor was titrated across literature 
derived doses on LPS primed THP-1 cells and incubated for 45 minutes prior to  sublytic 
MAC deposition; IL-1β secretion into the supernatant after MAC exposure was assayed by 
ELISA (Figure 4.2. A-C). The measured IL-1β levels were then compared to the LPS + MAC 
controls to determine significant changes in secretion. It was demonstrated that the NLRP3 
and Caspase-1 specific inhibitors MCC950 and AC-YVAD-FMK caused dose dependent 
reductions in IL-1β secretion in response to sublytic MAC. NLRP3 inhibition through MCC950 
also elicited a reduction of Caspase-1 activation in THP-1 cells in response to sublytic MAC, 
suggesting canonical NLRP3 activation was occurring (Figure 4.2.D).  
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A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. 2x105THP-1 monocytes were seeded at a density of 1x106 cells /ml in complete RPMI media. Cells were then primed 
with 100 ng/ml LPS  for 4 hours. After LPS priming, cells were incubated with the denoted inflammasome inhibitors for 45 
minutes at 37 °C. Primed cells were subsequently exposed to a sublytic dose of COS-1 antiserum (2.5% v/v) + NHS (5% v/v) as 
previously described. After one hour of sublytic MAC stimulation, cell supernatant was collected  and IL-1β measured by ELISA. 
A. IL-1β secretion from LPS primed THP-1 cells pre-treated with MCC950 – the specific NLRP3 pharmacological inhibitor.  B. 
IL-1β secretion from LPS primed THP-1 cells pre-treated with Z -VAD- FMK, a pan-caspase inhibitor. C.  IL-1β secretion from 
LPS primed THP-1 cells pre-treated with AC-YVAD-FMK, a specific caspase 1 inhibitor. Data A-C presented as Mean +/- SEM 
from a single experiment, representative of three independent experiments. Statistical significance determined by one-way 
ANOVA with Dunnett post-hoc test (* = P<0.05, ** = P<0.01, ***= P<0.001). D. Caspase-1 Glo luminescence readings. 
2x105THP-1 monocytes were seeded at a density of 1x106 cells /ml in complete RPMI media. MCC950 treated samples were 
treated for 45 minutes prior to sublytic MAC deposition. Cells were sensitised to complement using COS-1 antiserum (2.5% 
v/v) and NHS / C5 depleted NHS (5% v/v) incubated with Caspase-1 glo reagent for 90 minutes prior to luminescence reading 
on the Clariostar plate reader. Data presented as mean +/- SEM from a single experiment, representative of three independent 
experiments. Statistical significance determined by one-way ANOVA with Dunnett post-hoc test, comparing all groups relative 
to sublytic MAC. (*=P<0.05, **=P<0.01).  
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There was a clear, dose dependent inhibition of complement-driven IL-1β secretion upon 
incubation with MCC950 and AC-YVAD-FMK (Figure 4.2.A and C)  and significant inhibition of 
Caspase-1 activation upon incubation with MCC950 (Figure 4.2.D). These data suggest that 
NLRP3 activity is crucial for Caspase-1 activation in response to sublytic MAC, that both 
NLRP3 and Caspase-1 function are crucial for MAC-induced IL-1β secretion. To ensure that 
NLRP3 and Caspase-1 specific inhibitors had no unexpected effects in modulating 
complement activation, thus decreasing MAC deposition and subsequent IL-1β release, a 
haemolytic assay was performed with sensitised Sheep erythrocytes incubated with NLRP3 
and Caspase-1 inhibitors prior to NHS addition as a source of complement. Pre-treatment of 
Sheep erythrocytes with either inhibitors did not statistically significantly inhibit haemolysis; 
therefore, the repression of IL-1β secretion was assumed to be through modulation of 
intracellular signalling (Figure 4.3). From this I conclude that NLRP3 is the central mediator 
of sublytic MAC mediated IL-1β production and the resultant inflammatory effects in LPS-
primed THP-1 cells. 
 
 
 
 
 
 
 
 
 
Figure 4.3.Haemolytic assay; sensitised sheep erythrocytes were pre-incubated with MCC950 or AC-YVAD-FMK for 30 
minutes prior to complement deposition with NHS. 2% v/v sheep erythrocytes were sensitised to complement using 
ambocepter (1:2000 dilution in CFD) as previously described in 96 well, U bottomed plates. Sensitised erythrocytes were 
then plated in 96 well, U bottomed plates and MCC950 / AC-YVAD-FMK added at the denoted concentrations for 45 minutes 
at 37 °C. Sensitised, inhibitor treated cells were then exposed to a titration of NHS in CFD (1-0.01% v/v) for 45 minutes. 
Sheep erythrocytes were then centrifuged at 300 x g and cell supernatant transferred to a flat bottomed plate for 
absorbance readings at 405nm. Percentage haemolysis was quantified relative to CFD only and water + 0.1% v/v TWEEN 
positive and negative controls. The addition of either pharmacological agent had no statistically significant effects on 
erythrocyte lysis, therefore excluding the possibility the inhibitory effects demonstrated are through mitigation of 
complement activation in the context of sheep erythrocyte haemolysis. Data analysed by One-way ANOVA with Dunnett 
post-hoc test comparing AC-YVAD-FMK and MCC950 to control with no pharmacological inhibitors used. Data presented as 
mean +/- SEM from a single experiment, representative of three independent experiments.  
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4.4 - Molecular mechanisms of sublytic MAC activation of NLRP3 – Potassium Efflux 
 
Potassium (K+) efflux from the cell is one of the strongest current hypotheses for underlying 
activation mechanism of NLRP3, despite K+ itself not being an established secondary 
messenger, in contrast to ROS and Ca2+. A recent publication however points to a loss of 
membrane potential, for which K+ and Ca2+ are both critical regulators, as the key factor in 
NLRP3 activation (Zhang et al 2018). To address the role of K+ efflux in NLRP3 activation in 
THP-1 cells, increasing concentrations of K+ were titrated into the stimulation medium. THP-
1 cells were primed with 100 ng/ml LPS for 4 hours and sensitised as previously described 
using COS-1 antiserum. However, before cells were exposed to sublytic MAC, the 
stimulation medium was supplemented with titrated doses of sterile KCl (50-5 mM) and 
compared to control stimulus (RPMI without added KCl). 
In concordance with published literature, elevated extracellular K+ concentrations resulted 
in a repression of IL-1β secretion and Caspase-1 activity (Figures 4.4.1 A and C). However, 
whether this was due to a change in tonicity of the media with a resultant reduced osmotic 
potential, or due to the changes in free K+ were unclear. Therefore, a second experiment 
was performed where the titrated KCl concentrations were reciprocated with an inverse 
titration of NaCl, giving a constant total added salt content to the media of 50 mM. The 
addition of NaCl, even in the absence of KCl, also abrogated IL-1β secretion, suggesting that 
the inhibitory effects of elevated KCl, in this instance at least, may be mediated by the 
altered osmotic potential or membrane potential rather than directly through K+ gradients 
(Figures 4.4 B and C). The changes in salt concentration had no significant effects on the 
ELISA assay used to measure secreted IL-1β, as a 500 pg/ml standard used across the salt 
concentrations demonstrated non-significant differences in Abs 450 nm, allowing 
confidence in the data (Figure 4.4.D). Finally, to exclude the possibility that the Cl – 
counterion was having effects on NLRP3 activation, KHCO3  was used as an alternative salt, 
which also demonstrated capacity to inhibit sublytic MAC mediated IL-1β secretion (Figure 
4.4.E). To ensure there were no large repressive effects on complement activation through 
adding hyperosmotic concentrations of salt to the stimulation media, a haemolysis assays 
was used. The addition of 50 mM of all salts had repressive effects in a classical haemolytic 
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assay, with KHCO3 and KCl significantly reducing haemolysis. This was probably through 
reducing the chemiosmotic gradient across the cell membrane, subsequently reducing 
haemolysis; however, it was demonstrated that complement activation was still occurring 
under the high salt conditions (Figure 4.4.F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.A. Complement-induced IL-1β secretion from LPS primed THP-1 monocytes with a titration of KCl added to 
stimulation media. 2x105THP-1 monocytes were seeded at a density of 1x106 cells /ml in complete RPMI media. Cells were 
then primed with 100 ng/ml LPS  for 4 hours. Primed cells were subsequently exposed to a sublytic dose of COS-1 antiserum 
(2.5% v/v) + NHS or C5 depleted serum (5% v/v) as previously described + the denoted concentration of sterile KCl added to 
the stimulation media. Supernatants were then analysed by Il-1β ELISA for inflammasome activation. Data presented as mean 
+/- SEM from a single experiment, representative of three independent experiments.  B. Samples were stimulated as in 4.4.A, 
however with changes in K+ across the titration were matched with reciprocal changes in NaCl, to keep osmolarity and charge 
constant across the titration. All samples demonstrated statistically significant inhibition relative to RPMI with no added salt. 
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Data presented as mean +/- SEM from a single experiment, representative of three independent experiments. C. Changes in 
salt concentration had no effect on signal of IL-1β standard run at 500 pg/ml on the duo set ELISA, eliminating the possibility 
that changes in signal were due to salt interfering with the assay. D. CaspaseGlo assay determining the effects of the addition 
of monovalent cations to RPMI.  Caspase-1 Glo luminescence readings. 2x105THP-1 monocytes were seeded at a density of 
1x106 cells /ml in complete RPMI media.  Cells were sensitised to complement using COS-1 antiserum (2.5% v/v) and NHS / 
C5 depleted NHS (5% v/v) with or without the addition of 50 mM sterile KCl/ NaCl and incubated with Caspase-1 glo reagent 
for 90 minutes prior to luminescence reading on the Clariostar plate reader. The addition of 50 mM NaCl or KCl to RPMI media 
significantly inhibited the activity of Caspase 1, however there was no significant difference between NaCl and KCl treated 
samples. Data presented as mean +/- SEM from a single experiment, representative of three independent experiments. E.  
Potassium hydrogen Carbonate (KHCO3) was titrated as described for KCl in 4.4.A. The inhibitory effects of the addition of 
Potassium with a different counterion were measured by IL-1β ELISA as previously described. KHCO3 demonstrated significant 
inhibition of IL-1β secretion, suggesting no role for Cl – in the observed inhibition of MAC mediated NLRP3 activation. F.  
Haemolysis assay on complement sensitised sheep erythrocytes comparing the effects of additional KCl, NaCl and KHCO3 on 
classical complement activation. Ambocepter sensitised erythrocytes were plated in 96 well, U bottomed plates and each salt 
was added at the denoted concentrations alongside NHS for 45 minutes at 37 °C. Sheep erythrocytes were then centrifuged 
at 300 x g and cell supernatant transferred to a flat bottomed plate for absorbance readings at 405nm. Percentage haemolysis 
was quantified relative to CFD only and water + 0.1% v/v TWEEN positive and negative controls. KHCO3 and KCl caused 
significant (P<0.05) inhibition of MAC mediated lysis of Sheep erythrocytes, however the difference for NaCl was non-
significant. For all titration experiments, statistical analysis was performed by one-way ANOVA with Dunnett post-hoc test to 
compare test groups to buffer control (***=P<0.001; * = P<0.05). 
 
4.5 - Molecular mechanisms of sublytic MAC activation of NLRP3 – Calcium influx  
 
The central role for Ca2+ flux in MAC mediated NLRP3 activation has been previously 
demonstrated by our group in A549 lung epithelial cells. In this cell type, chelation of 
intracellular Ca2+ by pre-incubation of the cells with cell permeable BAPTA-AM significantly 
inhibited IL-1β secretion, but this effect was also demonstrated with Xestospongin C, 
Dantrolene and 2-ABP, which inhibit secondary release of Ca2+ from ER stores through RYR 
and IP3R regulated channels (Triantafilou et al 2013). To determine if similar effects were 
seen in THP-1 cells, cells were primed with 100 ng/ml LPS for 4 hours as previously 
described. Subsequently, titrations of BAPTA-AM and Xestospongin C were added to the 
cells for 45 minutes. Cells were then washed, sensitised to complement and attacked with 
sublytic MAC and supernatants collected after 1 hour. Pre-incubation with either 100 µM 
BAPTA-AM or 10 µM Xestospongin C statistically significantly inhibited both IL-1β secretion 
and Caspase-1 activity (Figures 4.5. A-C). 
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Figure 4.5.A.  IL-1β secretion from LPS primed THP-1 cells in response to sublytic MAC with BAPTA-AM. 2x105THP-1 
monocytes were seeded at a density of 1x106 cells /ml in complete RPMI media. Cells were then primed with 100 ng/ml LPS  
for 4 hours. After LPS priming, cells were incubated with the denoted concentration of BAPTA-AM for 45 minutes at 37 °C. 
Primed cells were subsequently exposed to a sublytic dose of COS-1 antiserum (2.5% v/v) + NHS (5% v/v) as previously 
described. After one hour of sublytic MAC stimulation, cell supernatant was collected  and IL-1β measured by ELISA.  
Statistically significant inhibition of IL-1β secretion was observed with > 25 µM BAPTA-AM treatment relative to MAC 
treated control by One-Way ANOVA with Dunnet post-hoc test (*=P<0.05, *** = P<0.001). Data displayed as the mean +/- 
SEM from a single experiment, representative of three independent experiments. B.  IL-1β secretion from LPS primed THP-1 
cells in response to sublytic MAC with pre-treatment using IP3R antagonist Xestospongin C. Cell stimulation protocol was 
performed as in 4.5.A, however Xestospongin C was titrated at the denoted concentrations in place of BAPTA-AM. Data 
presented mean +/- SEM from a single experiment, representative of three independent experiments. Statistical analysis 
was performed relative to MAC stimulated control by one-way ANOVA with Dunnett post-hoc test (*=P<0.05, *** = 
P<0.001). C. Caspase-1 glo assay comparing levels of Caspase-1 activity in sublytic MAC attacked cells, controls and cells 
pre-treated with the highest doses of Calcium signalling inhibitors prior to sublytic MAC deposition. 2x105THP-1 monocytes 
were seeded at a density of 1x106 cells /ml in complete RPMI media. BAPTA-AM / Xestospongin C treated samples were 
treated for 45 minutes prior to sublytic MAC deposition. Cells were sensitised to complement using COS-1 antiserum (2.5% 
v/v) and NHS / C5 depleted NHS (5% v/v) and incubated with Caspase-1 glo reagent for 90 minutes prior to luminescence 
reading on the Clariostar plate reader. A statistically significant decrease in Caspase-1 activity was observed with BAPTA-
AM and  Xestospongin C treatment relative to sublytic MAC control. Data presented as mean +/- SEM from a single 
experiment, representative of three independent experiments. Statistical analysis was performed by one-way ANOVA with 
Dunnett post-hoc test (*=P<0.05, *** = P<0.001).  
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To  observe the effects of BAPTA-AM or Xestospongin C treatment on MAC induced Ca2+ 
flux, Fluo-3-AM loaded THP-1 cells were pre-treated with 100 µM of BAPTA-AM or 10 µM of 
Xestospongin C prior to sensitisation with COS-1 antiserum. Cells were then attacked with 
sublytic doses of MAC and Ca2+ influx measured through fluorescence at 525 nm on the 
Clariostar plate reader. As previously shown, sublytic MAC induced a large Ca2+influx 
compared to C5 depleted and HI NHS controls. The dose of BAPTA-AM previously 
demonstrating inhibition of IL-1β secretion also caused complete ablation of MAC mediated 
elevations of Ca2+  concentrations through chelation of Ca2+ and preventing binding to Fluo-
3, whilst Xestospongin C treatment caused a slightly slower kinetic profile of Ca2+ influx to 
sublytic MAC treated cells that was not statistically significant, and similar levels of total 
Ca2+influx. This, alongside the demonstrated inhibition of IL-1β release and Caspase-1 
activation suggests not only that Ca2+influx is an important mediator of sublytic MAC 
mediated NLRP3 activation, but that secondary release from ER stores is also an important 
signalling event mediating NLRP3 activation and IL-1β secretion, but IP3 receptor inhibition 
has no effect on the early Ca2+ flux events mediated by MAC (Figure 4.6). 
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Figure 4.6. Kinetic profile of Ca2+ influx into Fluo-3 loaded THP-1 monocytes through sublytic MAC deposition. 2x105 THP -1 
monocytes were seeded at a density of 1x106 cells / ml in complete RPMI media in sterile U-bottomed plates. Cells were 
incubated with the denoted concentrations of BAPTA-AM and Xestospongin C for 45 minutes in complete RPMI media. Cells 
were subsequently loaded with 2.5 µM Fluo-3 as previously described. Cells were then washed and sensitised to 
complement using 2.5% v/v COS-1 antiserum as previously described. Sensitised THP-1 cells were transferred to opaque, 
black plates for plate reader fluorescence reading (505 nm / 525 nm excitation / emission) in complete RPMI media. 
Baseline fluorescence was obtained from unstimulated cells, and maximal fluorescence was obtained at the end of the 
experiment through adding 2% Triton X to control wells. Immediately prior to plate loading, sensitised cells were exposed to 
sublytic NHS (5% v/v) or C5 depleted NHS and changes in Fluo-3 fluorescence measured over time. Data presented as the 
mean +/- SEM from a single experiment, representative of three independent experiments.  
 
 
 
4.6 - Molecular mechanisms of sublytic MAC NLRP3 activation – ROS production and 
mitochondrial dysfunction 
 
In the previous chapter, it was demonstrated that sublytic MAC deposition on THP-1 cells 
alters the ROS / RNS profile of the cells relative to C5 depleted controls. Elevations in cellular 
ROS have also been implicated in NLRP3 activation in response to sublytic MAC  and can also 
be a downstream product of mitochondrial depolarisation which in turn, can be induced 
through elevated intracellular Ca2+concentrations (Suresh et al 2016; Bertero and Maack 
2018) . To determine if ROS production was an important mediator of NLRP3 activation in this 
system and test the interplay between ROS production and Ca2+ influx or mitochondrial 
depolarisation, sublytic MAC stimulations in the presence of the ROS scavenger N-Acetyl-
Cysteine (NAC) were performed. Previous studies have demonstrated that NAC is an effective 
modulator of NLRP3 in various cell types undergoing challenge with an array of stimuli, 
 
 
150 
 
including inhibition of MAC induced IL-1β secretion, but not Caspase-1 activation (Suresh et 
al 2016; Cui et al 2017; Chimin et al 2017) 
A titration was performed of literature derived doses of NAC on LPS primed THP-1 monocytes 
prior to sublytic MAC deposition; ≥ 2mM NAC statistically significantly inhibited sublytic MAC 
IL-1β secretion (Figure 4.7.A), however Caspase-1 activity was not statistically significantly 
changed  relative to MAC only controls (Figure 4.7.B). 
 
 
 
 
 
 
 
 
 
Figure 4.7.A. IL-1β secretion in from LPS primed THP-1 cells pre-treated with the ROS scavenger NAC. . 2x105THP-1 monocytes 
were seeded at a density of 1x106 cells /ml in complete RPMI media. Cells were then primed with 100 ng/ml LPS  for 4 hours. 
After LPS priming, cells were incubated with the denoted concentration of NAC for 45 minutes at 37 °C. Primed cells were 
subsequently exposed to a sublytic dose of COS-1 antiserum (2.5% v/v) + NHS (5% v/v) as previously described. After one hour 
of sublytic MAC stimulation, cell supernatant was collected  and IL-1β measured by ELISA. Treatment with ≥ 2 mM NAC 
significantly decreased IL-1β secretion relative to the LPS + MAC positive control. Data presented as the mean +/- SEM from 
a single experiment, representative of three independent experiments. Statistical significance was determined by one-way 
ANOVA with Dunnett post-hoc test comparing all groups to LPS + MAC control (* = P,0.05, **= P<0.01). B. CaspaseGlo assay 
titrating NAC on THP-1 monocytes prior to sublytic MAC deposition. 2x105THP-1 monocytes were seeded at a density of 1x106 
cells /ml in complete RPMI media. BAPTA-AM / Xestospongin C treated samples were treated for 45 minutes prior to sublytic 
MAC deposition. Cells were sensitised to complement using COS-1 antiserum (2.5% v/v) and NHS / C5 depleted NHS (5% v/v) 
and incubated with Caspase-1 glo reagent for 90 minutes prior to luminescence reading on the Clariostar plate reader. No 
statistically significant differences were observable between the sublytic MAC and sublytic MAC + NAC groups, however there 
was a trend towards inhibition with increasing NAC doses. Data presented as mean +/- SEM from a single experiment, 
representative of three independent experiments. Statistical significance was determined by one-way ANOVA with Dunnett 
post-hoc test comparing all groups to LPS + MAC control (* = P,0.05, **= P<0.01). 
 
Whilst NAC treatment significantly decreased IL-1β secretion, it failed to inhibit Caspase-1 
activity , suggesting differences in cellular processes involved in the different events. To 
investigate this,  BAPTA-AM and NAC were titrated on THP-1 monocytes prior to sublytic 
MAC deposition and superoxide production measured. It was hypothesised that if BAPTA-
AM treatment affected superoxide production in response to sublytic MAC, it could provide 
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a link between Ca2+ and ROS mediated NLRP3 activation. However, the generation of 
superoxide in response to MAC was unaffected by BAPTA-AM across the titration of doses, 
whilst titration of NAC generated significant decreases in sublytic MAC induced superoxide 
(Figure 4.8).  
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Figure 4.8. Chelation of intracellular Calcium with BAPTA-AM has no effect on sublytic MAC mediated superoxide production, 
suggesting that the production of ROS is not Calcium dependent. In contrast, N-acetyl-cysteine reduced superoxide production 
in response to sublytic MAC. 2x105 THP-1 cells were loaded with the superoxide sensitive dye (Abcam) at the recommended 
1:2000 dilution in DMF for 45 minutes at 37˚C in complete RPMI in 96 well, U-bottomed plates. Cells were washed and treated 
with NAC / BAPTA-AM at the denoted doses for 45 minutes at 37 °C. Cells were subsequently sensitised to complement using 
COS-1 antiserum (2.5% v/v) as previously described. Cells were then exposed to sublytic NHS or C5 depleted NHS (5% v/v) for 
30 minutes, washed, resuspended in FACS buffer and run on the FACS Calibur as previously described. Data presented as the 
mean fluorescence +/- SEM from a single experiment, representative of three independent experiments. Data analysed by 
one-way ANOVA with Dunnett post-hoc test (*** = P < 0.001; **=  P<0.01).  
 
These data suggest that there is no clear role for Ca2+influx in superoxide production in 
response to sublytic MAC, again suggesting that the observed effects of the inhibitors of 
ROS and Ca2+in terms of IL-1β secretion and Caspase-1 activity are independent. To further 
explore the potential of Ca2+ to induce other NLRP3 activating stimuli, the role of Calcium in 
the induction of mitochondrial depolarisation in response to sublytic MAC was investigated 
(Zhou et al 2018). One mechanism by which Calcium could induce secondary NLRP3 
activators was through causing mitochondrial dysfunction. Mitochondria act as a nexus for 
NLRP3 activation through being a source of ROS, Cardiolipin and mitochondrial DNA, all of 
which have been demonstrated to function as NLRP3 activators (Cassell et al 2018). Firstly, 
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to  verify that sublytic MAC causes mitochondrial dysfunction, a specific fluorescent dye for 
mitochondrial membrane polarisation, tetramethyl rhodamine ethyl ester (TMRE) was used. 
TMRE is a net positively charged molecule and becomes sequestered to the mitochondria; 
however, if the mitochondrial membrane potential becomes abrogated, a common feature 
of dysfunction, the dye is no longer retained, resulting in a decrease of fluorescent signal. 
The mitochondrial uncoupling ionophore Carbonyl Cyanide 4-Trifluoromethoxy 
phenylhydrazone (FCCP) was used as a chemical agent mediating uncoupling as a positive 
control. 
Sublytic MAC deposition on THP-1 monocytes triggered a dose dependent and significant 
decrease in TMRE fluorescence at 549/575 nm on the Clariostar plate reader, indicating that 
MAC deposition caused mitochondrial depolarisation, an indicator of dysfunction (Figure 
4.9.A).  
To investigate the role of Calcium in sublytic MAC mediated mitochondrial damage, the 
chelator BAPTA-AM and the IP3R antagonist Xestospongin C were used and mitochondrial 
potential measured. Treatment with BAPTA-AM induced a lower TMRE stain in response to 
sublytic MAC but did not alter TMRE staining in the absence of MAC. Together with the data 
shown previously that BAPTA-AM treatment inhibits IL-1β secretion, Caspase-1 activation 
and elevation of intracellular Calcium concentrations, this suggests that ROS and 
mitochondrial dysfunction are distinctly different NLRP3 activating events from Calcium 
influx in this system (Figure 4.9.B).  
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Figure 4.9.A. TMRE staining of mitochondria in THP-1 cells measured using the Clariostar plate reader. 2x105 THP-1 cells 
seeded at density of 1x106 cells / ml in complete RPMI media were preloaded with 500 nM TMRE for 30 minutes at 37°C. 
Cells were subsequently sensitised to complement using COS-1 antiserum (2.5% v/v) and exposed to a titration of sublytic – 
lytic complement with (1.25% - 10% v/v)  NHS or C5 depleted NHS as a negative control for 1 hour. A 20 µM FCCP positive 
control was used as to generate a high level of mitochondrial dysfunction, resulting in a low TMRE stain. Data presented as 
the mean +/- SEM from a single experiment, representative of three independent experiments. Statistical significance was 
determined by one-way ANOVA with Dunnett post-hoc test comparing all groups to unstimulated control (* = P,0.05, **= 
P<0.01) B. The same experiment was performed by flow cytometry to ensure the signal was from intact cells through 
FSC/SSC gating. 2x105 THP-1 cells were loaded with TMRE as described in A. Samples exposed to cell signalling modulators 
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were incubated with BAPTA-AM / Xestospongin C were incubated with the denoted concentrations at 37 °C for 45 minutes. 
Cells were then sensitised to complement using 2.5% v/v COS-1 antiserum and stimulated with sublytic MAC (5% v/v) NHS  
or C5 depleted NHS for 1 hour. Intact cells stimulated with sublytic MAC generated a negative TMRE peak, which was not 
present in C5 depleted controls or antiserum only controls. BAPTA-AM treatment of cells caused decreased TMRE staining, 
suggesting that chelation of intracellular calcium was increasing mitochondrial dysfunction. Data presented from a single 
experiment, representative of three independent experiments. 
 
4.7 - Inhibition of sublytic MAC activated kinases and their roles in NLRP3 activation 
 
The induction of sublytic MAC signalling can occur through a variety of intracellular 
signalling pathways, the roles of which in inducing inflammation are unclear. As both 
Calcium and ROS induced by sublytic MAC were demonstrated to activate NLRP3 in the 
previous set of experiments, both triggering stimuli derived signalling pathways may be the 
secondary mediators of the signalling effects. Many downstream kinases and signalling 
pathways have been linked to sublytic MAC deposition on the cell, with some of these 
potentially influencing cell viability and cytokine production. As described in the 
introduction, sublytic MAC deposition elicits a range of cytoplasmic kinase responses 
(Section 1.6). From the established literature, the targeting of relevant kinases to sublytic 
MAC signalling may yield suggestions as to how the previously described diverse stimuli for 
NLRP3 activation coalesce, as well as provide potential targets for therapeutic inhibition. 
Therefore, pharmacological agents against known sublytic MAC mediated signalling 
pathways were used in a similar manner to the inhibitors of NLRP3 activation used 
previously. The signalling pathways inhibited were selected based on previous association 
with sublytic MAC mediated signalling (Towner et al 2016). A schematic of the signalling 
pathways targeted in this experiment and the inhibitors used to do so is shown in Figure 
4.10.  A wide range of Calcium induced kinases were targeted including PI3K (LY294002)/ 
AKT signalling (Perifosine), mTOR (Everolimus), ERK (PD98059) and JAK (AG490), and the 
effect of inhibition of these pathways on IL-1β secretion examined (Figure 4.11).  
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Figure 4.10 – Schematic of sublytic MAC activated cell signalling pathways and the inhibitors used to modulate their 
activation. Cryo-EM image of the MAC edited from Menny et al 2018.  
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Figure 4.11. 2x105THP-1 monocytes were seeded at a density of 1x106 cells /ml in complete RPMI media. Cells were then 
primed with 100 ng/ml LPS  for 4 hours. Primed cells were subsequently incubated with the denoted concentrations of each 
cell signalling inhibitor for 45 minutes. Cells were then washed and exposed to a sublytic dose of COS-1 antiserum (2.5% v/v) 
+ NHS or C5 depleted serum (5% v/v) as previously described. Supernatants were then analysed by Il-1β ELISA for 
inflammasome activation. Data presented as mean +/- SEM from a single experiment, representative of three independent 
experiments Data represents mean +/- SEM from a single triplicate experiment, representative of three independent 
experiments. Statistical significance determined by one-way ANOVA with Dunnett post-hoc test comparing all groups to 
MAC + LPS control. Only Perifosine and MCC950 treatment caused statistically significant changes in IL-1β secretion 
(***=P<0.001).  
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Across the range of pharmacological inhibitors sublytic MAC mediated activated kinases 
used, only Perifosine caused statistically significant changes in IL-1β secretion, alongside the 
MCC950 negative control (Figure 4.11). Due to the large effect of AKT inhibition through 
Perifosine on IL-1β secretion and the relatively small changes caused by inhibitors of other 
pathways, the mechanism by which Perifosine mediates changes in NLRP3 activity were 
investigated. Perifosine is an Alkyl phospholipid which acts as a novel AKT inhibitor by 
restricting AKT translocation to the cell membrane and interactions of the Pleckstrin 
homology domain with binding partners (Richardson et al 2012). To determine whether 
Perifosine acts independently of MAC, a second experiment was performed titrating 
Perifosine to see if the effects were dose dependent, whilst investigating if the effects were 
MAC mediated or simply caused by administration of Perifosine to primed cells or 
unstimulated cells and exploring the effects of Perifosine in Caspase-1 activation in response 
to sublytic MAC (Figure 4.12 A /B). 
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Figure 4.12.A. The effects of Perifosine titration on IL-1β release in THP-1 monocytes. 2x105THP-1 monocytes were seeded at 
a density of 1x106 cells /ml in complete RPMI media. Cells were then primed with 100 ng/ml LPS  for 4 hours. Primed cells 
were subsequently incubated with the denoted concentrations of each Perifosine for 45 minutes. Cells were then washed and 
resuspended in complete RPMI and exposed to a sublytic dose of COS-1 antiserum (2.5% v/v) + NHS or C5 depleted serum (5% 
v/v) as previously described. Supernatants were then analysed by Il-1β ELISA for inflammasome activation. The effects of 
perifosine on LPS primed cells or previously unstimulated cells was significantly less than sublytic MAC stimulated cells, 
suggesting that Perifosine’s effect is through synergism with MAC rather than an independent mechanism. Data presented 
as the mean  +/- SEM from a single experiment, representative of three independent experiments. Data analysed by one-way 
ANOVA with Dunnett post-hoc test  relative to sublytic MAC treated samples(*** = P < 0.001; **=  P<0.01). B. Pre-treatment 
of cells with 50 µM Perifosine caused a non-statistically significant trend towards an increase in sublytic MAC mediated 
activation of Caspase-1 (P=0.07, students T-test), measured using the Caspase-1 Glo system. 2x105THP-1 monocytes were 
seeded at a density of 1x106 cells /ml in complete RPMI media. Perifosine treated samples were treated for 45 minutes prior 
to sublytic MAC deposition. Cells were sensitised to complement using COS-1 antiserum (2.5% v/v) and NHS / C5 depleted 
NHS (5% v/v) and incubated with Caspase-1 glo reagent for 90 minutes prior to luminescence reading on the Clariostar plate 
reader. Data presented as Mean +/- SEM from a single experiment, representative of three independent experiments. 
 
The data demonstrate that Perifosine increased sublytic MAC-induced IL1β secretion in a 
dose dependent manner but did not alter secretion from LPS primed or non-primed THP-1 
cells. The effects of modulating other portions of the AKT signalling pathway with sublytic 
MAC were investigated. Perifosine, LY294002 (PI3K inhibitor, upstream of AKT in canonical 
signalling (Figure 4.12), LB100 (specific PP2A inhibitor, prevents dephosphorylation of AKT 
and increases activity), AKT 1/2 (alternative AKT inhibitor) and everolimus (mTOR inhibitor) 
were all utilised to determine if the effects of Perifosine were AKT signalling specific or due 
to off target effects of the drug, shown in Figure 4.13.   
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Of all the compounds used, only Perifosine induced significant changes in sublytic MAC 
mediated inflammasome activation, suggesting that the effects were non-specifically linked 
to the compound (Figure 4.13). This may be through the induction of TNFα-R signalling and 
activation of the RIPK1/3 necroptosome complex which has been described previously 
(Conos et al 2017). This was supported by the dose dependent increases in cell death with 
Perifosine after 4 hours, suggesting the induction of cell death pathways and with a 
chronology supporting a necroptotic pathway and in line with literature suggesting 20 µM 
and higher doses of Perifosine are capable of inducing necroptotic death in THP-1 cells 
(Papa et al 2007). 
 
 
 
 
 
 
 
 
 
Figure 4.13.A. Perifosine potentiates sublytic MAC activation of NLRP3 in an AKT independent manner. 2x105THP-1 monocytes 
were seeded at a density of 1x106 cells /ml in complete RPMI media in 96 well, U-bottomed plates. Cells were then primed 
with 100 ng/ml LPS  for 4 hours. Primed cells were subsequently incubated with the denoted concentrations of Perifosine, AKT 
1/2  and LB-100 in complete media for 45 minutes. Cells were then washed and resuspended in complete media and exposed 
to a sublytic dose of COS-1 antiserum (2.5% v/v) + NHS or C5 depleted serum (5% v/v) as previously described for 1 hour. 
Supernatants were then analysed by Il-1β ELISA for inflammasome activation. Only Perifosine statistically significantly 
increased IL-1β release relative to sublytic MAC treated cells, suggesting the other AKT pathway targeting compounds do not 
exert the same effects. Data presented as the mean +/- SEM from a single experiment, representative of three independent 
experiments. Data analysed by one-way ANOVA with Dunnett post-hoc test relative to sublytic MAC sample (*** = P < 0.001; 
**=  P<0.01).  B. Doses of Perifosine which were utilised in experiments induced large amounts of cell death within 4 hours of 
administration as determined by PI staining of cells on FACS. 2x105 THP-1 monocytes were seeded per well at a density of 
1x106 cells / ml  in 96 well plates and stimulated with the denoted concentrations of Perifosine for 2 or 4 hours at 37 °C. Cells 
were subsequently centrifuged, washed and resuspended in FACS buffer and 10 µg/ml PI added as previously described and 
cell death measured by PI fluorescence on the FACS Calibur.  
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Although the effects of Perifosine were not specific to AKT and caused elevated IL-1β 
release as opposed to the targeted decrease, it provided useful insights into the 
mechanisms underlying the activation process. MAC has been previously demonstrated to 
induce cell necroptosis, therefore if a pro-necrotic stimulus such as Perifosine caused an 
elevation in NLRP3 activation, it suggests an anti-necroptotic stimulus may provide the 
desired inhibitory effects (Lusthaus et al 2018). Furthermore, the incorporation of Perifosine 
into the cell membrane disrupts lipid raft structure due to the preferential incorporation of 
the phospholipid into cholesterol rich regions, suggesting that there may be links to lipid raft 
mediated signalling pathways and NLRP3 activation, with both mechanisms warranting 
further investigation.  
To investigate whether necroptotic signalling was involved in MAC mediated NLRP3 
activation and MAC mediated cell death, one of the inhibitors utilised in the published work 
(Lusthaus et al 2018), Necrostatin-1 (NEC) was utilised. NEC is widely utilised as an allosteric 
inhibitor of RIPK1; however, it may also influence cell fate through inhibition of the IDO 
pathway, which modulates immune tolerance as well as inflammatory responses. NEC was 
titrated on THP-1 cells at literature derived doses (50-10 µM) prior to attacking cells with a 
lytic dose of MAC (5% COS-1 antiserum, 10% NHS) and PI uptake measured. In contrast to 
the literature in other monocytic cell lines, in THP-1 cells there was no effect of NEC on 
rapid, lytic MAC mediated death (Lusthaus et al 2018) (Figure 4.14. A and B). However, 
whilst NEC pre-treatment did not cause protection from MAC mediated cell death, it may 
influence the activation of NLRP3 and IL-1β secretion, which had previously been 
demonstrated in BMDM’s with other NLRP3 activators (Lawlor et al 2015). NEC was again 
titrated on primed cells prior to sublytic MAC deposition, and IL-1β secretion measured by 
ELISA. NEC pre-treatment did not cause statistically significant changes in IL-1β secretion at 
any of the experimental concentrations (Figure 4.14.C) 
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Figure 4.14.A/B. Kinetic assays for rates of PI uptake in  THP-1  cells pre-treated with NEC for 45 minutes. 2x105 THP-1 cells 
were seeded / well in complete RPMI media. Cells were pre-treated with literature derived doses of Necrostatin-1 or DMSO 
vehicle control for 45 minutes. Cells were subsequently washed and resuspended in complete media prior to sensitisation to 
complement with 2.5% v/v COS-1 antiserum as previously described. Cells were subsequently transferred to black, opaque 
plates with 10 µg/ml Propidium Iodide. Cells were stimulated with 10% NHS as a lytic source of complement prior to loading 
on the Clariostar plate reader and fluorescence measured at 480 / 630 nm over half an hour. Treatment of THP-1 cells with 
Necrostatin-1 or the DMSO vehicle control generated no significant protection from MAC mediated cell death. Data 
presented as Mean +/- SEM from a single experiment, representative of three independent experiments. C. IL-1β ELISA of 
supernatant from LPS primed, NEC-1 pre-treated cells (0-50 µM) exposed to sublytic MAC / C5 depleted serum. 2x105THP-1 
monocytes were seeded at a density of 1x106 cells /ml in complete RPMI media in 96 well, U-bottomed plates. Cells were 
then primed with 100 ng/ml LPS  for 4 hours. Primed cells were subsequently incubated with the denoted concentrations of 
Necrostatin-1 in complete media for 45 minutes. Cells were then washed and resuspended in complete media and exposed 
to a sublytic dose of COS-1 antiserum (2.5% v/v) + NHS or C5 depleted serum (5% v/v) as previously described for 1 hour. 
Supernatants were then analysed by Il-1β ELISA for inflammasome activation. Whilst Necrostatin-1  treatment did generate 
a titratable effect on IL-1β secretion, the changes in IL-1β secretion were non-significant (one-way ANOVA with Dunnett 
post-hoc test comparing all samples to LPS + MAC control). Data presented as Mean +/- SEM from a single experiment, 
representative of three independent experiments. 
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NEC pre-treatment of THP-1 cells did not statistically effect IL-1β secretion (Figure 4.14.C.) 
or cell death (Figure 4.14.B.). Due to the lack of affect for NEC inhibition on IL-1β secretion, 
other targets were chosen from the previously mentioned work in the field of MAC 
mediated death signalling pathways which would align with the observation of Perifosine 
induced elevation of IL-1β secretion in this system. One of the  pathways which may link 
Perifosine treatment and other MAC mediated affects is JNK signalling (Lusthaus et al 2018). 
Therefore, the effects of inhibiting JNK were explored in LPS primed THP-1 cells. Inhibition 
of JNK signalling alone generated a trend towards inhibition of IL-1β secretion inhibition in a 
dose dependent manner; however, this did not reach statistical significance (Figure 4.15.A) . 
In models of Histoplasma capsilatum activation of NLRP3 in dendritic cells, JNK signalling 
was augmented by ERK1/2, suggesting a more general role for MAPK in NLRP3 activation 
(Chang et al 2017). From this, a broader blockade of MAPK with both JNK and ERK1/2 
inhibition was performed; this combination generated a statistically significant decrease in 
IL-1β and Caspase-1 activation relative to sublytic MAC alone controls (Figure 4.15. B/C).   
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Figure 4.15. A. 2x105 THP-1 monocytes were seeded at a density of 1x106 cells/ ml in complete RPMI media in 96 well, U 
bottomed plates. Cells were subsequently primed with 100 ng/ml of LPS for 4 hours. Cells were washed and pre-treated 
with the denoted concentrations of the JNK inhibitor SP600125 for 45 minutes at 37 °C. Cells were washed and resuspended 
in complete media and exposed to 2.5% v/v COS-1 antiserum and 5% v/v NHS as previously described. Cell supernatant was 
collected and IL-1β measured by ELISA. Pre-treatment with the JNK inhibitor SP600125 did not statistically significantly 
affect IL-1β secretion, however demonstrated a dose dependent response (one-way ANOVA with Dunnet post-hoc test 
comparing samples to LPS + sublytic MAC). Data presented as mean +/- SEM. Data from a single experiment, representative 
of three independent experiments. B.  2x105 THP-1 monocytes were stimulated with the same method as A, however, cells 
were incubated with both SP600125 and the ERK inhibitor PD98059 at the denoted concentrations for 45 minutes at 37 °C 
prior to sublytic MAC deposition. IL-1β secretion was statistically significantly lower with pre-treatment with both JNK and 
ERK inhibitors (One-way ANOVA with Dunnett post-hoc test comparing pre-treatments with LPS + sublytic MAC control. 
Data presented as mean +/- SEM from one experiment, representative of three independent experiments. C. 2x105 THP-1 
monocytes were seeded at a density of 1x106 cells / ml in complete RPMI media in 96 well, U bottom plates. Cells were pre-
treated with ERK and JNK inhibitors (PD98059 - 50 µM) and (SP600125 – 50 µM) for 45 minutes. Cells were washed and 
resuspended in complete media prior to stimulation with sublytic MAC (sensitisation with 2.5% v/v COS-1 antiserum for 20 
minutes at room temperature and NHS 5% v/v). Caspase-1 activity was measured after 90 minutes using the Caspase-1 glo 
system on the Clariostar plate reader. Treatment of the cells with the combination of JNK and ERK inhibitors, both at 50 µM, 
yielded a statistically significant decrease in Caspase-1 luminescence (one-way ANOVA with Dunnett post-hoc test 
comparing all samples with sublytic MAC control). Data presented as mean +/- SEM from a single experiment, 
representative of three independent experiments.   
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4.8 - Sublytic MAC in the reactive lysis system induces IL-1β secretion from THP-1 cells and 
primary macrophages 
 
To demonstrate the effects of sublytic MAC deposition on THP-1 and SW982 cells a reactive 
lysis (RL) system was also utilised. THP-1 monocytes were  C5a primed (25 ng/ml) and C56 
generated from the freeze thaw method as a source of complement terminal pathway 
activation. Cells were primed with 25 ng/ml C5a for 4 hours at 37˚C prior to deposition of C56. 
Cells were incubated with varying concentrations of C56 at room temperature for 10 minutes 
to allow interaction with the cell membranes prior to C7 addition in molar excess to the C56 
with a further incubation for 15 minutes at 37˚C. Cells were then washed via centrifugation 
at 300 x g for 5 minutes and resuspension prior to C8 and C9 addition. Cells were then 
stimulated overnight with the C56-9 and the supernatant collected. The aspirated 
supernatant was then assayed for IL-1β content by ELISA (Figure 4.16 A/B).  
 
 
 
 
 
 
 
Figure 4.16.A. C56 mediated reactive lysis MAC formation on THP-1 monocytes induces IL-1β secretion. 2x105 THP-1 
monocytes were seeded at a density of 1x106 cells/ ml in complete RPMI media in 96 well, U bottomed plates. Cells were 
subsequently primed with 100 ng/ml of LPS for 4 hours. C56 was added to the cells for 10 minutes at room temperature in 
complete RPMI media  at the denoted concentrations (0-10 µg /ml).  C7  was then added to the cells at 10 µg/ml for 15 
minutes at 37 °C. Cells were subsequently washed and resuspended in complete media, before C8 and  C9 were applied (10 
µg/ml each) for 1 hour. IL-1β release was then measured by ELISA. The generation of maximal IL-1β was dependent on mature 
MAC (C56-9) and was titratable with the amount of C56 initially deposited on the cells. C7 / C8 / C9 alone had negligible 
effects in terms of IL-1β secretion. B. Titration of the C56 initiating complex with constant dose of C7 – C9 demonstrating a 
dose dependent IL-1β response. Data presented as mean +/ SEM from a single experiment, representative of three 
independent experiments. 
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To confirm the efficacy of the RL system, as well as investigate the capacity of complement to 
both prime and activate NLRP3 in myeloid lineage cells, primary macrophages were also 
stimulated with sublytic doses of MAC. CD14+ cells were purified from donor blood utilising 
the MACS purification system (Miltenyi Biotech), seeded 2x105 cells / well at a density of 1x106 
cells/ml in RPMI media in 24 well plates and differentiated in to macrophages using 100 ng/ml 
GM-CSF in complete RPMI for 4 days at 37˚C as described in the materials and methods 
(Section 2.5).  
On the day of the experiment, differentiated primary macrophages media was replaced and 
cells were primed with 25 ng/ml or 10 ng/ml C5a for 4 hours. Primed cells were then 
stimulated with reactive lysis MAC, generated sequentially as previously described, with 3 
µg/ml or 0.75 µg/ml C5b6 + 3 µg/ml C7 C8 and C9 for 1 hour. Cells were then lysed in RIPA 
buffer containing complete protease inhibitor cocktail (Roche) and lysate probed for IL-1β on 
the ODYSSEY western blot platform (Section 2.19). Briefly, samples and chameleon pre-
stained ladder were loaded on to 4-12% gradient BIS-TRIS gels and run at a constant voltage 
of 120 V for 1 hour. Protein content was then transferred to PVDF membrane using the 
Invitrogen power blotter system. Membranes were blocked for 1 hour in PBS 5% w/v BSA and 
membranes probed for IL-1β (mouse anti-human, CST) and β-actin (rabbit anti-human, CST) 
at 1:1000 dilutions respectively for 1 hour in PBS + 5% w/v BSA. Membranes were washed in 
PBS 0.1% TWEEN and probed with the respective secondary antibodies anti mouse 680nm 
and  anti rabbit 800nm for 1 hour in PBS 5% w/v BSA protected from light. Membranes were 
then washed with PBS 0.1% v/v TWEEN and deionized H2O. Membranes were then visualised 
using the ODDYSEY system, allow  detection at 800nm (gel A – IL-1β) and 680nm (gel B – β-
actin).  Mature IL-1β was only detectable via western blot in cells stimulated with complete 
MAC (C5b-9) at the higher concentration (3 µg/ml C5b6 initiator) with a 25 ng/ml C5a priming 
stimulus, which was ablated by the treatment of cells with 10 µM MCC950 for 30 minutes 
before MAC deposition, demonstrating IL-1β maturation being dependent on NLRP3 
activation (Figure 4.17 A.) 
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Figure 4.17.A. Sublytic MAC deposition on C5a primed primary macrophages induces IL-1β cleavage.2x105 myeloid derived 
macrophages were primed with 25 ng/ml or 10 ng/ml of C5a for 4 hours in complete RPMI media. Cells were washed and 
stimulated with reactive lysis MAC, with 0.75 µg/ml or 3 µg/ml initiating C5b6 complex. Cells incubated with MCC950 were 
incubated for 45 minutes at 37 °C prior to reactive lysis MAC assembly. Cells were stimulated with the denoted concentrations 
of C5b6 for 10 minutes at room temperature, before the addition of C7 at 5 µg/ml for 15 minutes at 37°C. Cells were washed 
and complete RPMI media replaced, prior to C8 and C9 addition at 5 µg/ml for 1 hour at 37 °C. Cells were subsequently lysed 
in 200 µl of RIPA buffer with protease inhibitors and cell lysates subjected to SDS PAGE on 4-12% gradient BIS-TRIS gels for 1 
hour at a constant voltage of 120 V. Protein was transferred to PVDF membranes with the Invitrogen fastblot system and 
membranes blocked in PBS 5% w/v BSA. Membranes were probed with CST mouse anti-human IL-1β and rabbit anti human 
β-actin antibodies at 1:1000 dilutions. Membranes were washed and probed with the respective secondary antibodies 
coupled to 680 nm and 800 nm emitting fluorophores, and fluorescence captured on the ODYSSEY Western blot system. 
Production of IL-1β is dependent on full MAC C5b-9 deposition (Lane 10) and is inhibited by pre-treatment of the cells with 10 
µM MCC950 for 30 minutes (Lane 11). Lane 1 – Molecular weight marker, 2 – Unstimulated cells, 3 – C5b6 only, Lane 4 – C7 
only, Lane 5 – C8 only, Lane 6 – C9 only, Lane 7 – C5a only, Lane 8 – C5b67 + C5a, Lane 9 C5b678 + C5a, Lane 10 – C5a + MAC, 
Lane 11 – C5a + MAC + 10 µM MCC950. B. β-actin western blot of 4.16.A.  
 
To obtain a more global view of effects induced by sublytic MAC on cells, RNA-Seq was 
performed on cells stimulated with sublytic, reactive lysis MAC and compared to C7 + C8 + C9 
only controls. 2x105 THP-1 cells were seeded at a density of 1x106  cells/ml in 96 well U bottom 
plates in complete RPMI media. Cells were stimulated with reactive lysis MAC as previously 
described with 3 µg/ml C5b6 initiating complex + C7 to C9 in molar excess at 10 µg/ml and 
RNA extracted at 1 and 8 hours respectively. Stimulated samples were compared to a C7 + C8 
+ C9 control with no C5b6 initiating complex. After stimulation, mRNA  was extracted and 
data analysis were performed by Dr You Zhou and David Lee, whilst the RNA SEQ was 
undertaken by Cardiff gene park. 
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 In total, 307 genes from 61 pathways demonstrated significant differences between the 
control and stimulated samples. Interestingly, at 8 hours some of the highest Z scored 
pathways (those with the most significant changes in gene expression of pathway 
constituents) have connotations for NLRP3 activation and IL-1β signalling.  Firstly, IL-1 
signalling itself was highlighted as significantly altered at 8 hours relative to controls, 
reinforcing the data acquired the protein level. Further associated pathways with MAC 
deposition include Calcium induced signalling alongside pathways with implications in NLRP3 
activity, for example, PKA signalling, which was highlighted as the most upregulated pathway 
after 8 hours is an established negative regulator of NLRP3 activation and may provide a 
negative feedback loop between sublytic MAC and NLRP3 (Gros and Gros 2016).   
 
 
Table 8. Table of highest Z-score, significantly changed ENSEMBL pathways from RNA-Seq analysis of reactive lysis 
stimulated THP-1 monocytes after 8 hours relative to unstimulated (C7+C8+C9) controls. 2x105 monocytes were seeded at a 
density of 1x106 cells/ml in complete RPMI media in sterile 96 well, U bottomed plates. Cells were stimulated with RL MAC 
as previously described. Briefly, cells were stimulated with 3 µg/ml C5b6 for 10 minutes at room temperature, followed by 
C7 at 5µg/ml for 15 minutes at 37 °C. Cells were subsequently stimulated with 5µg C8 and C9 for 1 or 8 hours. Stimulated 
cells were washed in sterile PBS and lysed in RNA extraction buffer before mRNA extraction and RNA SEQ were performed 
by Dr You Zhou, David Lee and Cardiff gene park. Changes in mRNA expression were categorised by ENSEMBL pathways, 
with the largest changes in mRNA expression at 8 hours having multiple pathways to the activation of NLRP3 include PKA 
signalling, Calcium induced signalling and IL-1 signalling, reinforcing the data generated through other methods. 
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Guided by the highly significant changes in PKA pathway component expression in the RNA-
Seq analysis, and the known role of PKA in prostaglandin synthesis and NLRP3 regulation, 
inhibition of PKA in the context of MAC activation of NLRP3 was explored. PKA is a cAMP 
activated kinase which exerts a range of cellular effects, including in the context of NLRP3 
activation the induction of prostaglandin biosynthesis through activation of PKC and 
induction of COX-2 expression, which results in PGE2 production from membrane lipids 
(Klein et al 2007). The induction of PGE2 production is important due to the established 
roles of prostaglandins as potent negative regulators of NLRP3 activation (Sokolowska et al 
2015). Therefore, the MAC, by inducing the activation of PKA signalling, may be a negative 
feedback mechanism to limit the levels of NLRP3 activation either directly or through the 
cAMP-PKA-COX2-PGE2 pathway and prevent excessive cytokine production. To investigate 
this, the classical activation method was used with the specific PKA antagonist H-89 at 
literature derived doses to investigate whether PKA inhibition in cells exposed to sublytic 
MAC altered NLRP3 activity and the subsequent Caspase-1 activation and IL-1β release. H89 
administration did not significantly affect IL-1β secretion and Caspase -1 activation; despite 
a slight trend towards an increase at higher doses (Figure 4.18). 
 
 
 
 
 
 
 
 
 
Figure 4.18. The PKA antagonist H89 did not statistically significant affect  IL-1β secretion from LPS primed THP-1 cells 
exposed to sublytic MAC. 2x105 THP-1 cells were seeded at a density of 1x106 cells /m in complete RPMI media in 96 well, U 
bottomed plates. Cells were subsequently  pre-treated with a titration of H89 hydrochloride (50 – 5 µM) , a potent PKA 
inhibitor, for 45 minutes prior to sublytic MAC deposition through sensitisation with 2.% v/v COS-1 antiserum and 5% v/v 
NHS. Cells were stimulated with sublytic MAC for 1 hour and supernatants assayed for IL-1β secretion by ELISA. H89 
administration had no statistically significant effects on IL-1β release from LPS primed THP-1 cells (One-way ANOVA with 
Dunnett post-hoc test). 
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Whilst H89 pre-treatment had no statistically significant effects in these experiments, the 
timescale and conditions for inflammasome activation and the previous RNA-Seq 
experiments are markedly different, 1-hour MAC exposure versus 8 hours and reactive lysis 
versus classical activation. Therefore, the data do not rule out a role for PKA in cellular 
responses to sublytic MAC.  
 
4.9 – Conclusions of Chapter 4 
 
In this chapter I have demonstrated that sublytic MAC deposition on primed monocytic cells 
through both reactive lysis and classical activation methods results in IL-1β secretion and 
Caspase-1 activation in a NLRP3 dependent manner. 
Upon investigating the mechanisms underlying NLRP3 activation in response to sublytic 
MAC, it was first shown that elevation of extracellular monovalent cations (K+ and Na+) 
through supplementation of the stimulation medium resulted in abrogation of NLRP3 
activation, irrespective of the nature of the cation. Although K+ ions have previously been 
implicated , my data show that either Na+ or K+ ions mediate the effect, provoking questions 
as to whether the retention of membrane and osmotic potential play roles in the activation 
process (Brough and Rivers-Aughty 2015).  
The role of Ca2+ flux in sublytic MAC induced NLRP3 activation has previously been 
demonstrated by our group in A549 lung epithelial cells and was further investigated in 
these experiments (Triantafilou et al 2013) . In concordance with the literature, pre-
treatment of LPS primed THP-1 cells with either BAPTA-AM or the IP3R antagonist 
Xestospongin C inhibited MAC-induced IL-1β secretion and Caspase-1 activation in a dose 
dependent manner (Figure 4.5. A-C). The involvement of IP3R-regulated calcium channels in 
NLRP3 activation links the ER network and ER stress with NLRP3 activation in response to 
sublytic MAC, with ER stress mediated NLRP3 activation previously reported in response to 
other stimuli (Li et al 2010). Understanding whether ER stress was a critical factor in sublytic 
MAC mediated NLRP3 was not directly investigated due to the time limitations of the 
project but may offer an interesting avenue for future research. However, the role of Ca2+ in 
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mediating ROS production, mitochondrial dysfunction and the role of ROS / RNS in NLRP3 
activation were all explored to try and unify the hypotheses. Whilst ROS ablation through 
the ROS scavenger NAC dose dependently inhibited IL-1β secretion in response to MAC 
(Figure 4.7.A), it failed to inhibit Caspase-1 activity (Figure 4.7.B). This observed dichotomy is 
unexpected and not easily explained. It is possible that the inhibition of ROS signalling alters 
the inflammasome response to sublytic MAC by driving the cell signalling down a non-
canonical inflammasome route through Caspase 4/5/11 activation, separating IL-1β 
secretion and Caspase-1, however, this has not been previously documented. The further 
observation that Superoxide production, the predominant ROS response to sublytic MAC in 
THP-1 cells demonstrated in Chapter 3 section 8, was unaffected by BAPTA-AM treatment 
(Figure 4.8), indicates that Calcium flux and ROS production are not tightly linked events. 
Loss of mitochondrial membrane potential, a marker for mitochondrial dysfunction, was 
dose dependently induced through complement MAC deposition. However, treatment with 
the Calcium chelator BAPTA-AM did not reduce mitochondrial depolarisation; indeed, Ca2+ 
chelation caused increased loss of membrane potential in MAC-attacked cells (Figure 4.9). 
Taken together the data show that Ca2+  flux, essential for MAC-mediated NLRP3 activation, 
is not acting through either ROS production or mitochondrial dysfunction in this system. 
To observe any effects of the inhibition of  kinases activated by sublytic MAC, a panel of 
pharmacological inhibitors were used (Figure 4.11). Only MCC950, which directly inhibits 
NLRP3, and the AKT inhibitor Perifosine had statistically significant effects on MAC-induced 
IL-1β secretion from the panel of molecules selected. The stark effects of Perifosine in 
upregulating IL-1β secretion were further explored. Firstly, it was demonstrated that 
Perifosine exerted a dose dependent effect on IL-1β secretion that was dependent on 
sublytic MAC deposition, as Perifosine alone or with an LPS prime did not induce IL-1β 
release (Figure 4.12.A).  Other AKT inhibiting compounds such as the AKT 1/2 inhibitor, PP2A 
inhibitor, PI3K inhibitor and mTORC1 inhibitor all failed to induce the same increase in IL-1β 
release observed with Perifosine (Figures 4.11, 4.12 and 4.13). This then suggests that 
Perifosine mediated elevation of IL-1β release in response to sublytic MAC is not through 
AKT signalling. Whilst Perifosine is marketed as an AKT inhibitor, it has a range of effects on 
the cell, including the induction of cell death pathways and the activation of cell stress 
responses shown in Figure 4.19. 
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Figure 4.19. Schematic of the pleiotropic effects of Perifosine. Although Perifosine is marketed as an inhibitor of AKT 
translocation to the cell membrane and subsequent activation through PHD interactions, Perifosine also elicits an array of 
other effects. These include increasing cell stress through ER dysfunction and the induction of CD95 signalling which can 
invoke necrotic cell death pathways through RIPK1/3 activation. This in turn can induce cell death, cellular stress and 
activation of inflammatory MAPK’s such as JNK. Image sourced from Fenestrele et al 2014. 
 
Because the role of Perifosine in the induction of IL-1β could not be attributed to its 
function as an AKT inhibitor, I explored whether off-target effects of the molecule were 
responsible for the observed elevations of IL-1β secretion. One of these off-target effects is 
the activation of JNK signalling. JNK has previously been implicated in NLRP3 activation and 
linked to MAC mediated cell death as demonstrated in Figure 4.20 (Okada et al 2014; 
Lusthaus et al 2018). The specific JNK inhibitor, SP6100, caused a non-significant reduction 
in IL-1β secretion (Figure 4.15.A); however, the ERK pathway has also been implicated in 
NLRP3 activation but inhibition had no significant effects on IL-1β release alone (Figure 4.11) 
(Chang et al 2017). 
 
Pathways / processes 
implicated in NLRP3 
activation 
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Figure 4.20– The role of MAPK’s in the activation of NLRP3 in response to Dectin 1/2 activation. Both  JNK and ERK  were 
implicated in the induction of lysosomal destabilisation in the proposed model. Image based on Chang et al 2017.  
 
The dual inhibition of both ERK and JNK in MAC-attacked cells demonstrated dose 
dependent inhibition of both IL-1β secretion and Caspase-1 activity (Figure 4.14. B /C). This 
provides evidence that some of the established intracellular signalling pathways in response 
to sublytic MAC have active roles in NLRP3 activation (Towner et al 2016). A possible 
mechanistic hypothesis, encompassing the multi-source data suggesting that IP3R mediated 
Ca2+ flux plays an important role in NLRP3 activation, is that ER stress is a central mediator 
of NLRP3 activation in response to MAC, as both ERK and JNK activation are inducible 
through ER stress responses (Figure 4.20), and IP3R localise on the ER, which also mediates 
ROS production; ER stress can thus potentially link the array of pathways proposed.  
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Figure 4.21. ER stress can mediate both JNK and ERK activation, as well as being the central organelle containing IP3R and 
being an important mediator of ROS/RNS production. Image based on diagram from Wasserman-Dozorets and Rubinstein 
2017.  
 
Direct testing of the effects of sublytic MAC on the ER was not performed due to time 
constraints, so whilst offering a potential hub for the observed mechanisms, further work is 
needed to verify the ER as the central organelle responsible for NLRP3 activation in this 
system, however, ER stress in response to sublytic MAC has been demonstrated in other 
studies (Cybulsky et al 2002) .  
A second method of forming MAC on the cell surface was performed to verify the classical 
pathway results. MAC formation through reactive lysis on C5a primed THP-1 monocytes 
induced dose dependent IL-1β secretion (Figure 4.16.B.) that was dependent on the 
formation of complete MAC pores, with C56-8 intermediates or individual components not 
inducing cytokine secretion (Figure 4.16.A). This was also subsequently demonstrated on 
PBMC derived primary macrophages, with none of the individual components or 
intermediate complexes generating mature IL-1β detectable by Western blot (Figure 4.17 
A/B). The IL-1β signal was also abrogated through the pre-treatment of the cells with 
MCC950, demonstrating the NLRP3 dependence of MAC-induced IL1β secretion.  
 
 
173 
 
Beyond the activation of NLRP3, reactive lysis derived MAC was also used to stimulate THP-1 
monocytes and RNA-Seq performed by collaborators Dr You Zhou and David Lee, with the 
largest Z-Scoring ENSEMBL pathways shown in Table 8. The highlighted pathways have some 
biologically expected results such as Calcium and apoptotic pathways being highly 
upregulated, whilst others such as PKA signalling were of interest in terms of relaying 
inflammatory cell signalling. In preliminary experiments, PKA inhibition was explored in the 
context of NLRP3 activation; however, there was no statistically significant effect of PKA 
signalling inhibition on sublytic MAC mediated IL-1β secretion (Figure 4.18).  
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Chapter 5 - Investigating the roles of NLRP3 in MAC mediated nucleated cell death 
 
5.1- Generation of SW 982 NLRP3-/- cells 
 
As previously demonstrated by our group and others, MAC deposition on cells can instigate 
NLRP3 activation and subsequently Caspase-1 activity and IL-1β release (Triantafilou et al 
2013; Laudisi et al 2013; Suresh et al 2016). Whilst MAC deposition on nucleated cells is 
generally non-lytic, large numbers of MAC complexes can result in a lytic form of cell death. 
As NLRP3 activation can also result in a lytic, necrotic form of cell death through Gasdermin 
D pore formation this raises the question of whether MAC mediated nucleated cell death 
functions, at least in part, through NLRP3 (Fink and Cookson 2006). There has been previous 
work demonstrating that MAC mediated cell death is partially transduced through 
intracellular signalling pathways; Caspase inhibition or blocking of necroptotic pathways 
partially ameliorated MAC mediated cell death, but no work has been published specifically 
focussing on the role of NLRP3 (Lusthaus et al 2018).  
To investigate the role of NLRP3 in MAC signalling in a different cell type, SW 982 
synoviocytes were used. These cells were edited using the  CRISPR/Cas9 system with 
commercially sourced gRNA against Exon 1 of NLRP3 to induce frameshift mutations in the 
gene, resulting in a loss of expression as described in materials and methods (methods 
described in section 2.24). To verify the loss of NLRP3 expression, WT and CRISPR/CAS9 
treated cells were tested for successful knockout by Reverse Transcriptase Polymerase chain 
reaction (RT-PCR) and Western blot for mRNA and protein expression respectively, with 
methods described in sections 2.19 and 2.30 respectively. Briefly, 2x105 SW 982 
synoviocytes were seeded / well in 24 well sterile plates in complete RPMI media and 
allowed to adhere overnight. Cells were then stimulated  with LPS (100 ng/ml) for 4 hours to 
induce elevated NLRP3 expression. Cells were washed with sterile PBS before lysis in RIPA 
buffer (Western blot) or RNA extraction buffer + β-mercaptoethanol (RT PCR) and stored at -
20°C until use. For RT-PCR, RNA purification and extraction was performed as described in 
section 2.29, prior to RNA quantification using  absorbance at 260/230 nm on the Nanodrop 
system. 200 ng of sample mRNA was then added per PCR tube, and RT PCR performed as 
described in section 2.30. The resultant PCR product was then loaded on to agarose gel and 
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electrophoresis performed as previously described. As the mRNA loading in to the original 
RT-PCR reaction was equal, that was taken as a loading control for this experiment. 
NLRP3 mRNA expression was detected in LPS primed SW 982 synoviocytes using RT-PCR 
followed by electrophoresis (Fig 5.1.1A); specific bands were present at the expected PCR 
product size in WT cells (expected amplification product size – 498 bp) and was absent in 
knockout cells. A rabbit monoclonal anti-NLRP3 antibody (CST) was used in Western blots to 
detect NLRP3 protein; although a non-specific band marginally heavier than NLRP3 was 
present in all cell lysates,  the specific band representing the protein (circa 120 kDa) was 
present in WT LPS-primed cells but absent in KO cells (Fig 5.1.1B).  
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Figure 5.1.1. A. RT-PCR of NLRP3 expression from WT or NLRP3 KO cells. 2x105WT or KO SW 982 synoviocytes were seeded 
in 12 well plates in complete RPMI media and allowed to adhere overnight. On the day of the experiment, cell media was 
replaced, and relevant samples primed with LPS  (100 ng/ml) for 4 hours. Cells were washed with sterile PBS and lysed in 
100 µl of RNA extraction buffer + β-mercaptoethanol. Extracted RNA was quantified on the Nanodrop and equal amounts of 
template RNA (200 ng/ sample) added to the RT PCR mixture as described in section 2.30. The resultant RT-PCR product was 
run on a 1% agarose gel and visualised using ethidium bromide on the Thermofisher MyECL system. The expected PCR 
amplicon length was 497 bp and was visualised in the WT cells primed with LPS, but not the NLRP3 KO cells or unprimed WT 
cells. 5.1.1.B. Western blot of NLRP3 expression in WT and NLRP3 KO SW 982 cells. Cells were seeded and stimulated with 
LPS as in A. After stimulation, cells were lysed using  100 µl of RIPA buffer + protease inhibitors. 15 µl of sample lysate was 
denatured at 90 °C for 10 minutes under reducing conditions and subjected to reducing SDS PAGE and Western blot analysis 
(CST mouse anti-human NLRP3 antibody and . NLRP3 WT cells demonstrated NLRP3 expression, which was absent in 
CRISPR/Cas9 treated cells. The membrane was then stripped and re-probed for β-actin.  
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5.2 - Investigating the roles of NLRP3 in the cell response to MAC in SW 982 synoviocytes 
 
After validating the absence of NLRP3 expression in the CRISPR/Cas9 treated cells, sublytic 
titrations of NHS were set up to observe differences in response to complement deposition 
in the presence and absence of NLRP3 expression. WT or NLRP3 KO SW 982 were seeded at 
2x104 cells per well in a 96 well plate and assay performed as described in the materials and 
methods. Briefly, seeded cells were allowed to adhere overnight in complete RPMI media. 
Cell media was then replaced on the day of the experiment and cells sensitised to 
complement using 2.5% v/v COS-1 antiserum as previously described, for 20 minutes at 
room temperature. Cell media was then replaced, and the cells exposed to titrations of NHS 
as a source of complement (5-0.25% v/v). Under the conditions used, WT cells were 
sensitive to killing in the LDH assay, with up to 50% cell death being observed at 2.5% NHS 
prior to a slight plateau at 5% NHS; in contrast, NLRP3 KO cells were highly resistant to lytic 
killing, with statistical significance across all titrated doses of NHS. Representative data 
shown below in Figure 5.2. 
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Dose of NHS Difference t P value Summary 
5.000 45.63 22.35 P<0.001 *** 
2.500 44.23 21.66 P<0.001 *** 
1.250 29.54 14.47 P<0.001 *** 
0.5000 26.43 12.94 P<0.001 *** 
0.2500 7.651 3.747 P < 0.05 * 
 
Figure 5.2. LDH release assay between WT and NLRP3 -/- SW 982 synoviocyte cells. 2x104 SW 982 WT and NLRP3 KO cells 
were seeded in 96 well sterile plates in complete RPMI media and allowed to adhere to the plate overnight. On the day of the 
experiment, and cell media replaced. Cells were sensitised with 2.5% v/v COS-1 antiserum at room temperature as previously 
described, prior to media being replaced and a titration of NHS (0.25 – 5% v/v) for 1 hour, alongside NHS without sensitising 
antibody negative and 1x final concentration lysis buffer positive control. 50 µl of cell supernatant was aspirated and mixed 
1:1 with LDH buffer protected from direct light for 45 minutes. The LDH reaction was subsequently stopped with the addition 
of 50 µl of 10% v/v acetic acid and absorbance measured at 492 nm. The loss of NLRP3 resulted in a significant reduction in 
cell death and subsequent LDH release from the cells. This experiment was repeated >5 times. Data from a single 
representative experiment presented as the mean +/- SEM and analysed using a two-way ANOVA with a Bonferroni Post-hoc 
test in GraphPad Prism. 
 
Due to the stark contrast in cell death readouts by LDH release, a second death assay was 
performed to confirm the results. This was performed by PI staining in both flow cytometry 
and 96 well plate-based formats.  
To perform flow cytometry, adherent SW 982 cells were removed from the TC plastic 
surface using Trypsin EDTA solution and resuspended in sterile Eppendorf’s in complete 
RPMI media prior to complement attack. Cells were then stimulated using COS-1 antiserum 
/ NHS as previously described for the LDH assay. In flow cytometric assays, WT cells were 
lysed on exposure to complement (with the generation of a PI positive population, whereas 
while NLRP3 KO cells were resistant to killing, replicating the LDH assay findings (Figure 5.3). 
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Figure 5.3.A. Flow cytometry analysis of SW 982 WT cells stained with Propidium iodide and attacked with complement or 
exposed to antiserum or serum only controls. 2x105 WT cells were trypsinised and sensitised to complement with 2.5% v/v 
COS-1 antiserum for 20 minutes at room temperature as previously described. Cells were then stimulated with a titration of 
NHS (2.5-10% v/v NHS) for 1 hour. Positive (1% v/v Triton X) and negative (unstimulated) cells were also included. Cells were 
subsequently stained using 10 µg/ml propidium iodide and fluorescence measured by flow cytometry on the FACS Calibur. 
WT SW 982 cells  demonstrated an NHS dose dependent increase in PI positive staining B. NLRP3 -/- cells were sensitised to 
complement and stimulated with NHS as described for the WT cells. NLPR3 -/- cells  demonstrated positive PI staining with 
the Triton X positive control, validating the assay, but were not lysed when exposed to complement attack. C. Direct 
comparison of PI staining histograms of  WT cells (Blue) and NLRP3 -/- SW 982 cells (Pink)  from A. and B.  (Pink) across a 
titration of NHS doses for PI positive staining. D. Quantification of the PI positive gated populations from Figure C. 
 
 
To ensure the that no PI positive NLRP3 -/- SW 982 cells were lost on the flow gating 
strategy, the change in PI mediated fluorescence over 1 hour of complement attack was also 
measured using the Clariostar fluorescent plate reader (Fig 5.4). Again, sensitised WT SW 
982 cells exposed to NHS demonstrated an increase in PI fluorescence, beginning at around 
8 minutes after  initiation of complement attack, whereas the NLRP3 -/- SW 982 cells 
demonstrated comparable fluorescence to WT C5 depleted NHS controls confirming that 
the cells were not lysed in the absence of MAC. 
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Figure 5.4.A. WT SW 982 cells demonstrated a dose dependent increase in PI fluorescence upon classical pathway 
activation.  2x104 WT SW 982 were seeded per well in 96 well opaque white plates. Cells were sensitised to complement 
using 2.5% v/v COS-1 antiserum for 20 minutes. Cell media was replaced, and 10 µg/ml of PI added to the cell media. Cells 
were subsequently stimulated with NHS or C5 depleted as described and changes in PI fluorescence measured over 45 
minutes.  A Statistically significant difference in fluorescence (P < 0.001) was observed between 10% NHS + COS-1 antibody 
and  unstimulated and C5 depleted NHS controls, analysed by one-way ANOVA with Dunnett post-hoc test. Data presented 
as mean +/- SEM from a single experiment, representative of three independent experiments. B. Comparison of sensitised 
WT and NLRP3 -/- SW982 cells PI uptake in response to exposure to two doses of NHS as a source of complement. NLRP3 -/- 
in SW982 cells statistically significantly (P<0.001) reduced PI uptake compared to WT (one-way ANOVA with Bonferroni 
post-hoc test comparing serum doses between cell types). No statistically significant difference was observed dependent on 
NHS dose in NLRP3 -/- SW 982 cells. Data presented as mean +/- SEM from a single experiment, representative of three 
independent experiments. 
 
Across both PI and LDH assays WT cells were consistently susceptible to MAC mediated cell 
death, whilst NLRP3 -/- cells were protected. To explore whether pharmacological 
inflammasome inhibition replicated this finding, MCC950, the specific NLRP3 inhibitor, was 
added to the cells at 10 µM as previously described in other studies (Coll et al 2015). Cells 
were then sensitised, exposed to NHS and lytic susceptibility assessed by PI uptake 
compared to cells without MCC950 treatment (Figure 5.5). Cells pre-treated with MCC950 
demonstrated statistically significant protection from MAC mediated lytic death, albeit not 
to the same extent as the genetic knockout, further supporting a role for NLRP3 in 
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mediating cell death. The reasons for the less marked effect of pharmacological inhibition 
are unclear but may relate to longer term ablation of NLRP3 function, drug dose or efficacy 
in the system. 
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Figure 5.5. PI uptake in of WT SW 982 synoviocytes in response to MAC in cells treated with 10 µM MCC950 v untreated over 
time. 2x104 WT SW 982 cells were seeded per well in opaque white plates in 200 µl of complete RPMI media and allowed to 
adhere to the plate overnight. On the day of the experiment, cell media was  replaced with fresh complete RPMI. Samples 
pre-treated with 10 µM MCC950 were incubated at 37 °C for 45 minutes. After incubation, cell media was replaced, and cells 
sensitised to complement with 2.5% v/v COS-1 antiserum for 20 minutes at room temperature. Cell media was again replaced 
with complete RPMI and PI added at a final concentration of 10 µg/ml. Plates were then transported to the clariostar plate 
reader and PI fluorescence measured at  an excitation / emission profile of 480 / 630 nm respectively and a gain of 800. 
MCC950 pre-treated samples exposed to MAC were compared with untreated cells and with C5 depleted NHS as a MAC-
negative control. MCC950-treated cells showed statistically significantly reduced PI uptake relative to untreated cells on 
exposure to 10% NHS. Data presented as mean +/- SEM and analysed by One-way ANOVA with Bonferroni Post-Hoc test 
comparing all pairs of columns (P<0.001).   
 
 The role of necroptosis in MAC mediated cell death was also investigated. SW 982 cells 
were pre-incubated with a titration of Necrostatin-1, a RIP kinase inhibitor that blocks 
necroptotic killing, prior to complement sensitisation and attack with NHS / C5 depleted 
NHS. Cell viability was subsequently measured using the LDH release assay. SW 982 cells 
demonstrated dose-dependent protection from MAC mediated cell death with the addition 
of Necrostatin-1 (Figure 5.6).  
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Figure 5.6. LDH release assay with a pre-treatment titration of Necrostatin-1 on SW 982 synoviocytes prior to MAC deposition. 
2x104 WT SW 982 cells were seeded per well in sterile 96 well plates in complete RPMI media and allowed to adhere to the 
plate overnight. On the day of the experiment, media was replaced, and cells treated with a titration of Necrostatin-1 (50-10 
µM) for 45 minutes at 37 °C. Cells media was subsequently replaced cells sensitised to complement with 2.5% v/v COS-1 
antiserum for 20 minutes at room temperature. Sensitised cells media was replaced and 5% v/v NHS / C5 depleted serum 
added to the cells for 1 hour at 37 °C, alongside NHS without sensitising antibody negative and 1x final concentration lysis 
buffer positive control. 50 µl of cell supernatant was aspirated and mixed 1:1 with LDH buffer, protected from direct light, for 
45 minutes. The LDH reaction was subsequently stopped with the addition of 50 µl of 10% v/v acetic acid and absorbance 
measured at 492 nm.  Pre-treatment with 50 µM Necrostatin-1 statistically significantly inhibited LDH release from the cells 
relative to untreated controls. Data presented as mean +/- SEM from a single experiment, representative of three independent 
experiments. Statistics performed with One-way ANOVA with Dunnett post-hoc test, comparing all samples with MAC treated 
controls (** = P ≤ 0.01) .   
 
 
To determine whether NLRP3 expression influenced Caspase-1 activity in response to MAC 
in SW 982 cells the Caspase-1 Glo assay was used as previously described in materials and 
methods and Chapter 4. WT and NLRP3 -/- SW 982 cells were LPS primed, sensitised and 
stimulated with complement and Caspase-1 glo  reagent added for 1 hour. Luminescence 
was subsequently read on the Clariostar plate reader. Caspase-1 activity in NLRP3-/- cells 
was significantly lower that WT at both serum doses used for MAC challenge and was 
significantly inhibited through pre-treatment of the cells with the NLRP3 inhibitor MCC950 
(Fig 5.7). LPS priming of WT SW 982 cells also caused non-significant increases in Caspase-1 
activity relative to unstimulated WT controls, suggesting that levels of Caspase-1 activation 
may be occurring in response to the priming stimulus. No significant difference in Caspase-1 
activity was observed between lytic (10% NHS) and sublytic (2.5% NHS) MAC on WT SW982 
cells. These data suggest that MAC is activating  Caspase-1 via NLRP3 in these cells as the 
response is lost in NLRP3 -/- cells; however, IL-1β secretion was not detectable in ELISA of 
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cell supernatants. This concurs with other reports which demonstrated undetectable levels 
of IL-1β release from SW 982 cells stimulated with canonical NLRP3 activators (Sugiyama et 
al 2014). 
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Figure 5.7. Caspase-1 activity assay of NLRP3 -/- and WT SW 982 cells.  WT and NLRP3 KO cells were seeded at 2x104 cells / 
well in opaque white plates in complete RPMI media and allowed to adhere overnight. On the day of the experiment, cells 
were  primed with 100 ng/ml LPS for 4 hours at 37 °C. Cell media was subsequently replaced and 10 µM MCC950 control 
samples treated at 37 °C for 45 minutes. Cells were subsequently sensitised to complement with 2.5% v/v COS-1 antiserum 
for 20 minutes at room temperature. Cell media was replaced and cells stimulated with MAC at lytic (10% v/v) and non-lytic 
(2.5 % v/v) doses and incubated with Caspase-1 glo reagent for 90 minutes prior to luminescence reading on the Clariostar 
plate reader. Only WT cells demonstrated a statistically significant elevation of Caspase 1 activity in response to MAC.  Data 
presented as mean +/- SEM from a single experiment, representative of three independent experiments. Data analysed 
using a one-way ANOVA with Dunnett post-hoc test to compare all columns to MAC 10% NHS WT sample(** = P ≤ 0.01, *** 
= P≤ 0.001). 
 
The data show, across multiple different platforms and assay techniques, that NLRP3 -/- and 
NLRP3 inhibitor treated SW 982 cells are significantly protected from complement mediated 
cell death compared to  WT and untreated counterparts. Levels of Caspase-1 activation in 
response to MAC were significantly increased in the WT cells but not in NLRP3-/- cells 
relative to controls. The mechanism by which NLRP3 knockout or inhibition induces 
protection from lysis requires further investigation as is likely of importance in 
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understanding the effects of MAC on nucleated cell death pathways, including necroptosis 
as shown here. 
As a first step in understanding mechanism, I tested whether complement was being 
activated to similar degrees on the surfaces of both cell types. While loss of NLRP3 has not 
been previously reported to alter cell surface protein expression, the observed lack of cell 
death could be due to an altered cell surface epitope profile, resulting in inefficient antibody 
binding from COS-1 antiserum and consequent lack of complement activation and MAC 
mediated death. WT and NLRP3 -/- SW 982 cells were stimulated with COS-1 antiserum and 
NHS as previously described, then stained for complement activation marker C3b as a 
marker of complement activation (Figure 5.8). 
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Figure 5.8.A. C3b staining of WT and NLRP3 -/- SW 982 synoviocytes. 2x105 WT and NLRP3 KO cells were trypsinised per 
sample and sensitised to complement with 2.5% v/v COS-1 antiserum in complete RPMI media for 20 minutes at room  
temperature in sterile Eppendorf’s. After sensitisation, cells were centrifuged, media replaced, and 2.5% v/v NHS or HI NHS 
added for 1 hour at 37 °C  as previously described. Cells were subsequently washed, fixed with 4% PFA for 20 minutes at 4 °C 
and then stained with a monoclonal anti-C3b FITC antibody (Biolegend) at a 1:50 dilution for 30 minutes protected from direct 
light. Cells were washed with sterile PBS and resuspended in 200 µl of FACS buffer and transferred to FACS to tubes prior to 
analysis by flow cytometry on the FACS Calibur and histograms generated using FlowingSoftware 2. The FL-1 fluorescence 
corresponding to C3b deposition was comparable between WT and NLRP3 -/- SW 982 cells at the NHS doses used in sublytic 
attack experiments (5%, 2.5%), indicating a similar capacity to fix complement on the surface using COS-1 antiserum at lower 
serum doses WT cells stained more strongly for C3b.B. Quantification of mean fluorescence from 5.8.A. 
 
 
 
 
A) 
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5.3 - Investigating whether NLRP3 modulates complement regulator expression on the SW 
982 cell surface 
 
 
The data above show that NLRPs-/- cells are protected from complement lysis when exposed to NHS, 
however, demonstrate C3 fragment deposition similar to WT. To further understand how NLRP3 
expression and complement mediated cell death were linked, a key question was whether inhibition 
or deletion of NLRP3 altered the cell surface expression of complement regulators such as CD55 and 
CD59, which in turn might explain how NLRP3-/- cells are protected from complement lysis. Firstly, 
CD55 and CD59 expression was compared between the two cell types under unstimulated 
conditions by flow cytometry as described in the materials and methods. WT SW 982 cells showed 
specific staining for CD55 compared to various antibody controls and there was no significant 
difference in CD55 expression between WT and NLRP3-/- cells (Fig 5.9A); in contrast, WT SW 982 
cells showed no specific staining for CD59 (except for a small positive sub-population apparent in the 
histograms) while NLRP3-/- cells expressed CD59 abundantly on the cell surface (Figure 5.9.B) 
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B)     
 
 
 
 
 
Figure 5.9. Analysis of CD55 and CD59 expression on WT and NLRP3 -/- SW 982 synoviocytes. A. Comparison of expression 
of CD55 between WT and NLRP3 KO cells. 2x105 WT and NLRP3 KO cells were trypsinised from the flask and transferred to 
sterile Eppendorf’s. Cells were stained for CD55 with 10 µg/ml BRIC 215 in FACS buffer for 30 minutes at room temperature 
protected from direct light. Cells were washed twice with sterile PBS and were subsequently stained with 1:50 dilution of 
anti-mouse IgG Alexa 546 for 30 minutes in FACS buffer, protected from direct light. Cells were washed, resuspended in 
FACS buffer and transferred to FACS tubes before fluorescence was measured on the FACS Calibur.  Both WT and NLRP3 -/- 
SW 982 cells stained positively for CD55, but with no significant differences between the two cell types. B. WT and NLRP3 
KO cells were prepared as in A. Cells were subsequently stained for CD59 expression using 10 µg / ml MEM43  mAb in FACS 
buffer for 30 minutes at room temperature. Cells were washed twice with sterile PBS and resuspended in FACS buffer, 
before staining using a 1:50 dilution of anti-mouse IgG Alexa 546 for 30 minutes protected from direct light. Cells were 
washed, resuspended in FACS buffer and transferred in to FACS tubes. Fluorescence was subsequently recorded on the FACS 
Calibur. WT cells were negative for CD59 expression, except for a small positive subpopulation. NLRP3 -/- cells stained 
strongly and universally positive for CD59 expression, to the same level as the small CD59 positive subpopulation of the WT 
cells.  
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To further investigate the elevation of cell surface CD59 expression in NLRP3 -/- cells, both 
WT and NLRP3 -/- cells were treated with MCC950, the specific NLRP3 inhibitor, to 
determine if pharmacological inhibition could partially replicate the effects seen at the 
genetic level. Cells were pre-treated with a titration of MCC950 doses (10-1 µM) for 1 hour 
prior to staining for CD59 as previously described. Exposure of WT SW 982 cells to MCC950 
caused a dose-dependent increase in CD59 expression; as anticipated, the NLRP3 inhibitor 
had no effect on CD59 expression in NLRP3-/- cells (Figure 5.10). Exposure to the higher 
doses of MCC950 increased CD59 expression in WT to levels similar to those in NLRP3-/- 
cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Changes in CD59 cell surface expression in response to treatment with MCC950. 2x105 WT and NLRP3 -/- SW 
982 synoviocytes were trypsinised from flasks and resuspended in complete RPMI in sterile Eppendorf tubes. Cells were 
subsequently treated with a titration of MCC950 (10-1 µM) for 1 hour at 37°C prior in complete RPMI. Cells were then fixed 
in 4% v/v PFA at 4°C for 20 minutes. Cells were washed and stained for CD59 using 10 µg/ml MEM 43 in FACS buffer for 30 
minutes. Cells were washed, resuspended in FACS buffer and stained using anti-mouse IgG FITC (1:50 dilution) as previously 
described. Cells were subsequently washed with sterile PBS, resuspended in FACS buffer and transferred to FACS tubes prior 
to fluorescence measurement using the FACS Calibur. Treatment of WT cells with MCC950 induced a dose dependent 
increase in CD59 staining on the cell surface, whereas the NLRP3 -/- cells exhibit no changes with drug administration.  
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The rapid changes in CD59 expression observed in the above experiments (within an hour of 
exposure to inhibitor) suggested a non-transcriptional / translational mechanism was 
responsible for the changes observed. This is supported by established literature 
demonstrating CD59 translocation from intracellular to cell surface localisations upon cell 
activation in neutrophils and as part of insulin secretion in β-cells of the Pancreas (Okada et 
al 1994;Renstrom et al 2016). Therefore, it was hypothesised that the differences in CD59 
staining between WT and NLRP3-/- cells could be reduced or eliminated by permeabilising 
the cells with 0.1% Triton X after fixing to allow antibody staining of any intracellular CD59 
stores. After permeabilization, apparent CD59 expression in WT cells was markedly increased 
and the differences in expression between WT and NLRP3-/- cells effectively lost (Figure 5.11) 
 
 
 
 
 
 
 
 
 
Figure 5.11. CD59 staining in permeabilised and non-permeabilised WT and NLRP3-/- SW 982 synoviocytes. 2x105 WT and 
NLRP3 KO cells were trypsinised and transferred to sterile Eppendorf tubes in complete RPMI media. Cells were 
subsequently fixed using 4% v/v PFA for 20 minutes at 4 °C. Cells were washed with sterile PBS, resuspended in FACS buffer 
and stained using 10 µg/ml BRIC 229 +/- 0.1% v/v Triton X (dependent on permeabilisation state) for 30 minutes. Cells were 
subsequently washed and resuspended in FACS buffer before the addition of anti-mouse Alexa 546 (1:50 dilution) in FACS 
buffer +/- 0.1% v/v Triton X 100 protected from direct light for 30 minutes. Cells were subsequently washed , resuspended in 
FACS buffer and fluorescence analysed on the FACS Calibur. WT SW 982 cells fluorescence increased upon permeabilization, 
whereas staining of KO cells was reduced. The overlay demonstrated that staining of the two permeabilised cell types was 
comparable, suggesting WT cells but not NLRP3-/- cells had stores of CD59 within the cell exposed on permeabilisation. 
Data analysed using Flowing software 2. 
 
To verify the complement regulator data collected by flow cytometry, confocal microscopy 
was used. WT and NLRP3 -/- cells were seeded and stained for CD59 using MEM43 and 
Alexa 546-labelled secondary anti-mouse IgG, and a lipid raft marker, Cholera toxin subunit 
B labelled with Alexa 488, to determine cell surface localisation and visualised on the Zeiss 
KO Unpermeabilised (Pink) 
v KO Permeabilised (Blue) 
WT Unpermeabilised (Pink) 
v WT Permeabilised (Blue) 
KO Permeabilised 
(Blue) v WT 
Permeabilised (Pink)  
KO Unpermeabilised (Pink)v 
WT Unpermeabilised (Blue) 
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confocal microscope, as described in the materials and methods. Co-localisation of CD59 
and Cholera toxin subunit B was determined using Zen black software, with a Pearson’s 
coefficient > 0.5 taken as significant co-localisation. Whereas unpermeabilised WT cells 
were negative for CD59 staining, permeabilization revealed intracellular CD59 in a granular 
distribution; unpermeabilised NLRP3-/- cells stained strongly for CD59, partly co-localised 
with the lipid raft marker, and permeabilization reduced CD59 signal (Figure 5.12 and Table 
7). The lack of CD59 positive staining for permeabilised NLP3 -/- cells may be explained by 
the lack of intracellular CD59 due to the high cell surface expression, and that 
permeabilising conditions may not be optimal for cell surface antigen staining. 
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Figure 5.12. Confocal microscopy of WT and NLRP3 -/- SW 982 cells probing for CD59 expression and lipid rafts. 4x104  WT 
and NLRP3 KO cells were seeded per well on sterile glass chamber slides and allowed to adhere to the surface overnight in 
complete RPMI media. On the day of the experiment, cells were fixed using 4% v/v PFA for 20 minutes at 4°C. Cells were 
subsequently washed with sterile PBS and stained with 10 µg/ml BRIC 229 +/- 0.1% v/v Triton X (dependent on 
permeabilisation state) for 30 minutes in sterile PBS + 0.2% w/v BSA. Cells were washed twice with sterile PBS before 
staining with anti-mouse Alexa 546 (1:50 dilution) in  sterile PBS, 0.2% w/v BSA +/- 0.1% v/v Triton X 100 protected from 
direct light for 30 minutes. Samples stained for lipid rafts also had Cholera Toxin B- Alexa 488 conjugate added at 1 µg/ml 
at this stage. Cells were washed twice with sterile PBS, and nuclear visualisation was performed with a 1:2,000 dilution of 
ToPRO in sterile PBS protected from direct light for 10 minutes. The casket removed, and cover slips applied as per the 
materials and method (section 2.18). Cells were imaged using the  ZEISS confocal microscope using a 1.4 NA 63x Zeiss 
objective lens SW 982 cells were demonstrated to have far lower cell surface CD59 staining when unpermeabilised, and 
poor colocalization between Alexa 488 and Alexa 546. NLRP3 -/- cells demonstrated strong cell surface expression of CD59  
and co-localisation with lipid raft marker. Upon permeabilization, a large amount of signal is lost from the NLRP3 -/- cells, 
whereas the WT cells had strong staining of CD59 on- intracellular granules. Table 8. Quantification of Pearson’s 
colocalisation co-efficient between Cholera toxin B Alexa 488 and MEM43 + anti mouse IgG 546. Only NLRP3 -/- SW 982 
cells, non-permeabilised demonstrated significant colocalisation. Scale bars shown om images in the top left corner of 
images at 10 µm.  
 
 
 
 
 
 
 
 
 
 
Sample
Pearson's co-
efficient Significant colocalisation
Anti-mouse Alexa-546 
control
-0.003 No
Cholera Toxin B subunit 
Alexa 488 control
0.12 No
NLRP3 -/- SW982, non-
permeabilised
0.73 Yes
NLRP3 -/- SW982, 
permeabilised
0.24 No
WT SW982 Non-
permeabilised
0.35 No
WT SW982 
permeabilised
0.31 No
Table 8 
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5.4 – Investigating the effect of inhibition of complement regulator function on susceptibility 
to MAC mediated cell death 
 
NLRP3 -/- SW 982 cells were resistant to MAC mediated cell death, and, as shown above, 
had increased cell surface expression of CD59; this may regulate the levels of MAC 
deposited on the cell surface and effect the observed resistance. To test this, CD59 function 
was inhibited using the blocking mAb MEM43 on both WT and NLRP3 -/- cells.  
Adherent WT and NLRP3 -/- SW 982 cells were sensitised using 2.5% COS-1 antiserum alone 
or with MEM43 and incubated with 10% NHS in the presence of 1 µM PI. Readings were 
taken on the Clariostar plate reader with  excitation of 480 nm, a dichroic setting of 568nm 
and an emission of 615nm respectively. A positive control of 100% lysis was obtained 
through the addition of 1% Triton X to triplicate wells of WT and KO cells for 10 minutes at 
the end of the experiment 
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Figure 5.13.A-E.Percentage cell death of WT v NLRP3 KO SW 982 synoviocytes stimulated with lytic MAC over time. 2x104 
WT and NLRP3 KO cells were seeded / well in white, opaque plates in complete RPMI media and allowed to adhere to the 
plate overnight. On the day of the experiment, media was replaced, and cells sensitised to complement with 2.5% v/v COS-1 
antiserum +/-  MEM43 anti-CD59 antibody at doses between 0 and 37.5 µg/ml for 20 minutes at room temperature. Cell 
media was replaced, and PI added at 10 µg/ml. Plates were transported to the Clariostar plate reader and subsequently  
attacked with 10% NHS as a source of complement. PI fluorescence was measured over time with excitation at 480 nm, a 
dichroic setting of 568 nm and an emission of 615 nm respectively. Data was analysed in the MARS analysis software and 
plotted in GraphPad PRISM 5. In the absence of MEM43 or presence of the lowest dose (5 µg/ml), NLRP3-/- cells were 
resistant to lysis. At higher doses of MEM43, lysis of NLRP3-/- cells increased approaching that of WT cells.  Lysis of WT cells 
was not affected by the presence of MEM43.  F,G. Dose responses to MEM43 for WT and NLRP3-/- SW 982 synoviocytes 
respectively.    
A) B) 
C) D) 
E)
) 
G)
) 
F)
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Although the data above demonstrate that the observed differences in cell death between 
WT and NLRP3-/- cells was predominantly CD59 dependent, there remains the possibility 
that downstream effects of MAC deposition, are also affected. To test this, Ca2+ influx, was 
investigated. It was hypothesised that the WT SW 982 cells would experience a MAC 
mediated spike in Ca2+ whereas the NLRP3 -/- cells would experience little or no change due 
to the increased CD59 expression. Cells were loaded with Fluo-3-AM as previously described 
for THP-1 cells (Chapter 3, section 7) and in materials and methods. Time 0 readings were 
taken, sensitised cells were stimulated with a titration of NHS or C5 depleted NHS and the 
changes in fluorescence from baseline measured. A positive control of maximal exposure of 
the dye to Ca2+ was performed with 1% Triton X and the change in intracellular Ca2+ 
concentration calculated. NLRP3 -/- SW 982 cells did not exhibit Ca2+ flux above baseline, 
whereas MAC treated WT cells demonstrated a rapid influx as previously described (Fig 
5.14.A). To confirm that this was due to the higher expression of CD59 inhibiting MAC 
formation on the NLRP3-/- cell surface, cells were incubated with MEM 43 at a previously 
demonstrated inhibitory dose and Ca2+ flux measured. With CD59 function impaired, NLRP3 
-/- SW 982 cells demonstrated a similar Ca2+ flux profile to WT cells (Fig 5.14.B).  
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Figure 5.14.A. Calcium flux assay comparing WT and NLRP3 -/- (KO) SW 982 cells. 2x104 WT and NLRP3 KO cells were 
seeded at 2x104 cells per well in opaque white plates in complete RPMI media and allowed to adhere overnight. On the day 
of the experiment, media was replaced and both cell types were loaded with 2.5 µM Fluo-3-AM for 45 minutes at 37 °C in 
complete medium as previously described. Cells were subsequently washed twice with sterile PBS and sensitised to 
complement with 2.5 % v/v COS-1 antiserum for 20 minutes at room temperature. Cells media was then replaced, and cells 
transported to the Clariostar plate reader. The plate reader was configured with 505 nm / 525 nm excitation / emission 
respectively cells and exposed to 10 or 5% NHS or C5 depleted NHS as a source of complement and fluorescence measured. 
WT SW 982 cells exhibited a rapid influx of Ca2+, whereas NLRP3 -/- cells did not exhibit a Ca2+ signal in the same manner, 
suggesting that MAC formation was inhibited on these cells, in agreement with the PI staining data. B. Cells were prepared 
as in A. However, upon sensitisation, WT and NLRP3 KO samples were treated +/- 25 µg/ml Mem43, which was permissive 
of PI uptake on NLRP3 KO cells from figure 5.13. Plate reader configuration and NHS stimulation conditions were performed 
as in A. and Ca2+ flux measured.  After CD59 blockade, NLRP3-/- SW 982 cells showed a similar Ca2+ influx to the  WT cells, 
suggesting the protection from Ca2+ flux and PI uptake is CD59 dependent.  
 
 
 
 
 
A) 
B) 
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5.5 -Conclusions of Chapter 5 
 
In this series of experiments, the effects of NLRP3 deletion or inhibition in SW 982 synovial 
cells was investigated. It was demonstrated that commercially available gRNA’s against 
NLRP3 exon 1 in a CRISPR/Cas9 system were effectively ablated NLRP3 expression at the 
mRNA and protein levels. Unexpectedly, loss of NLRP3 expression in these cells rendered 
them highly resistant to MAC mediated cell death, demonstrated using both LDH release 
and PI uptake assays, with cell death under the selected conditions less than 10% greater 
than controls, whereas WT cells demonstrated 50% cell death. This surprising finding is not 
without precedent;  SiRNA knockdown of RIPK1, a central mediator of necroptosis, in a 
range of cell types was recently demonstrated to influence MAC mediated death, reducing 
killing measured by PI and Trypan blue uptake by 40-50% through RIPK1, RIPK3 and 
phospho-MLKL mediated necroptotic cell death (Lusthaus et al 2018).  
 To determine the mechanism by which NLRP3 deletion or inhibition protected SW 982 cells 
from MAC killing, complement deposition and regulator expression were measured; one 
purpose of these experiments was to ensure there were no off-target effects of the CRISPR 
process used to target NLRP3 on complement resistance mechanisms. CD55 expression and 
C3b deposition upon complement activation were comparable between the two cell types, 
indicating that there was no difference in capacity to activate the early stages of 
complement; however, CD59 expression on the cell surface was essentially absent in WT 
cells and markedly upregulated on the NLRP3 -/- cells, measured by both flow cytometry 
and confocal microscopy.  Permeabilisation experiments showed that WT SW 982 cells 
retained a large proportion of CD59 within the cell, likely in granule stores. Remarkably, WT 
cells exposed to the specific NLRP3 inhibitor MCC950 showed a rapid, dose-dependent 
increase in surface expression of CD59 and increased resistance to MAC lysis. Cell surface 
expression of CD59 was demonstrated to be the major cause of MAC resistance in NLRP3-/- 
cells by blocking CD59 function with the monoclonal antibody MEM43; this treatment 
rendered the NLRP3 -/- cells sensitive to complement mediated death to a comparable 
degree to WT SW 982 cells. MAC-induced Ca2+ flux was also absent in NLRP3 -/- cells, 
confirming failure of MAC pore formation; MEM43 blocking restored MAC-induced Ca2+ flux 
to levels equivalent to WT cells.  
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The mechanism by which CD59 localisation is affected by NLRP3 expression is unclear. 
However, CD59 translocation to the membrane has been previously demonstrated following 
cell activation by FMLP, and CD59 has been implicated in the secretion pathways of insulin 
from β pancreatic cells, demonstrating that CD59 cellular localisation can undergo rapid 
alterations, impacting functional roles in cellular processes (Okada et al 1994; Krus et al 
2014). Further, both CD59 translocation and NLRP3 activity have links to the trafficking and 
distribution of cholesterol within the cell. Previous studies have highlighted that CD59 
translocation from the ER to the Golgi is cholesterol dependent, with cholesterol depletion 
using methyl-β-cyclodextrin inhibiting CD59 ER to Golgi transport (Bonnon et al 2010). This 
relates to NLRP3 activation because NLRP3 activation can be mediated not only by ER stress, 
but also by altered cholesterol homeostasis within the organelle (de la Roche et al 2018). It 
was shown that inhibition of effective trafficking of cholesterol to the ER, via both 
pharmacological and genetic deficiency, dampened inflammasome responses, whereas 
inhibition or modulation of sterol transport to the plasma membrane had no effect on 
NLRP3 activation.  Yet more suggestions of an association between NLRP3 and CD59 come 
from a study linking MAC deposition, NLRP3 activation and IL-1β secretion in a Uveitis 
model, where MAC induced IL-1β production was demonstrated to be pathogenic (Kumar et 
al 2018). Interestingly, a disparity was observed between C9 -/- mice and WT mice treated 
with a soluble CD59 expression vector. C9 -/- mice lacking MAC still demonstrated 
histological retina damage which was consistent with the WT Uveitis mice, despite a 
reduction in inflammasome associated activation markers. In contrast to C9 -/- mice, WT 
mice which were treated with a soluble CD59 expression vector  had statistically significantly 
reduced histological damage as well as NLRP3, IL-1β and Caspase activation levels which 
were further decreased relative to controls than in C9 -/- mice, suggesting an inflammasome 
related role for CD59 beyond MAC regulation (Kumar et al 2018).  
 Taken together, these data, alongside the observations made in this thesis, suggest a link 
between endosomal transport systems, CD59 cellular localisation and NLRP3 activity; 
however, further investigation is necessary to delineate specific mechanisms linking the two 
proteins. 
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Chapter 6 – Final discussion and conclusions 
 
6.1 – Research aims 
 
The complement system and NLRP3 inflammasome are both individually potent drivers of 
inflammation; however, they may act in synergy to drive inflammation in chronic and acute 
conditions. In this thesis, I have explored the molecular mechanisms linking sublytic MAC 
deposition and NLRP3 activation. By furthering the current understanding of the interplay 
between the two systems, the work may guide strategies for modulation of the signalling 
pathways involved, thus potentially mitigating complement induced inflammation in disease 
models in the future.  
 
6.2 – Outline of study 
 
The complement system is an evolutionarily conserved innate immune pathway which 
mediates inflammatory, opsonic and lytic responses upon activation by pathogens or altered 
cell surface epitope expressing cells (reviewed in Sarma and Ward 2011). The lytic and a 
portion of the inflammatory effects of complement activation are attributable to the MAC, 
with pore formation resulting in chemiosmotic lytic effects on bacterial and non-nucleated 
cells. MAC formation on nucleated cells, however, is generally tolerated due to cell surface 
regulation, active removal of MAC lesions from the membrane via endo- and exo-cytosis and 
active transport of ions to rectify the dysregulated ion balance (Morgan et al 2016).  
Despite the reduced susceptibility of nucleated cells to MAC mediated lysis, sublytic MAC 
deposition is not without consequence. The induced signalling events have been 
demonstrated to mediate proliferation, adhesion, apoptosis and cytokine secretion (Morgan 
2016), the last of which is the focus of this work. One of the inflammatory cytokines which 
has previously been demonstrated by our group to be induced by sublytic MAC is IL-1β, which 
was secreted in an NLRP3 inflammasome dependent manner (Triantafilou et al 2013). The 
activation of NLRP3 by sublytic MAC was demonstrated to require the complete complement 
terminal pathway and was Ca2+ flux dependent; further studies implicated ROS as a secondary 
messenger in macrophages, but more detail has not been resolved (Suresh et al 2016). 
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Furthermore, as MAC activates NLRP3 in a range of cell types and NLRP3 and Caspase-1 
activation can mediate pyroptotic cell death, the ability of MAC to induce pyroptosis and the 
relevance of NLRP3 activation as a driver of MAC mediated cell death were also explored.  
 
6.3 – Summary of main findings  
 
In the first results chapter, methods of instigating complement activation to allow 
investigation of the effects of sublytic MAC were explored, with both early (C3b) and terminal 
pathway (C9) complement deposition on sensitised THP-1 cells demonstrated to verify 
activation and MAC formation. Interestingly, recent literature has suggested a role for CD59 
in the modulation of C3 deposition (Thielen et al 2018). To investigate this, the levels of C3b 
deposition were measured by flow cytometry on MAC-attacked THP-1 monocytes +/- BRIC 
229, a CD59 inhibiting antibody. Whilst BRIC 229 significantly modulated CD59 function and 
enhanced MAC mediated cell death, it failed to elicit any changes in C3b deposition (Figure 
3.13 A/B). Whilst the method used to inhibit CD59 function (CRISPR/CAS9 deletion v antibody 
inhibition) and the cell types differed in the published study, my data did not support the 
surprising contention that CD59 regulated C3b deposition.  
Following on from these experiments, it was observed that C5 depleted serum controls, which 
were permissive of C3b deposition but had no complement mediated cell death, deposited 
statistically significantly more C3b on the cell surface than the same dose of NHS (Figure 3.14 
B). This finding was replicated by inhibiting C5 in NHS with Eculizumab, yielding a similar effect 
to C5 depletion and demonstrating that the observation was not an artefact of the protein 
purification process; however, inhibition of the terminal pathway at the C7 stage using 23D10, 
an in house inhibitory monoclonal antibody, did not generate higher levels of C3b deposition 
compared to NHS (Figure 3.15 and 3.16). A possible explanation for this may be that in the 
absence of available C5 ligand, the C5 convertase can continue to cleave C3, resulting in 
increased levels of C3b deposition on the cell surface. Whilst the literature on C5 convertase 
affinity for C3 is scarce, generation of the C5 convertase is dependent on C3b concentration; 
it is therefore possible that in the absence of C5 the convertase may bind and cleave more C3 
(Rawal and Pangburn 2001).  
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After establishing mechanisms of sublytic MAC deposition, the capacity of sublytic MAC to 
induce NLRP3 activation was explored. Sublytic MAC induced IL-1β release and Caspase-1 
activation in an NLRP3 dependent manner in LPS primed THP-1 cells, with C5 depleted 
controls failing to induce responses, demonstrating a dependence on MAC (Figures 4.1 and 
4.2.D). Inhibitors of NLRP3, Caspase-1 and all Caspases dose-dependently inhibited sublytic 
MAC mediated IL-1β secretion without significantly affecting complement activity (Figure 
4.2.A-C). 
The mechanisms underlying MAC-induced NLRP3 activation where then investigated. K+ efflux 
is a leading hypothesis for NLRP3 activation in inhibiting MAC mediated NLRP3 activation 
(Suresh et al 2016).  In accordance with the literature, the addition of KCl to the extracellular 
medium inhibited IL-1β secretion in response to sublytic MAC; however, this inhibitory effect 
was also noted for NaCl titrations performed alongside KCl (Figure 4.4.A/B),  suggesting that 
there was no specific role for K+ in the activation mechanism but rather the effect was simply 
due to salt concentration (Figure 4.4.D). High extracellular salt concentrations were also 
protective in haemolytic assays, suggesting that the buffering of osmotic potential, 
independent of cell signalling pathways, has the potential to reduce MAC mediated damage, 
and therefore may indirectly influence NLRP3 activation. A possible explanation is that cell 
swelling, which is dependent on the osmotic potential across the cell membrane, is an 
important mediator of MAC mediated NLRP3 activation. Other studies in the absence of pore 
forming activators have highlighted that hypotonic solutions can induce NLRP3 activation in 
LPS primed cells; therefore, hypertonic extracellular conditions may prevent cell swelling in 
response to membrane damage, consequently reducing inflammasome activation.  
The role for Ca2+ influx was then addressed and more clearly demonstrated in the current 
work. Both BAPTA-AM and Xestospongin C dose-dependently altered the Ca2+ flux profiles 
and inhibited IL-1β secretion from THP-1 monocytes (Figures 4.5 and 4.6). The direct 
modulation of Ca2+ concentrations, through chelation or the addition of excess extracellular 
calcium is problematic in the context of complement activation because Ca2+ has a direct role 
in classical pathway activation; chelation or addition of Ca2+ could ablate or enhance 
complement activation. It was hypothesised that inhibition of intracellular Ca2+ flux through 
BAPTA-AM treatment might affect secondary pathways such as ROS production and 
mitochondrial damage / depolarisation, which may align with published data that suggest a 
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Ca2+ flux / ROS / Mitochondrial dysfunction axis as a causative mechanism for NLRP3 
activation in response to MAC (Keep, Galluzzi and Kroemer 2011). However, whilst pre-
treatment of THP-1 cells with BAPTA-AM abrogated both IL-1β secretion and Ca2+ flux, it failed 
to inhibit MAC-induced Superoxide production and marginally decreased TMRE staining, 
indicative of elevated mitochondrial dysfunction. Subsequently BAPTA-AM chelation of 
intracellular Ca2+ was shown not to inhibit NLRP3 activation through ROS inhibition or 
mitochondrial protection (Figures 4.8 and 4.9). Interestingly, the ROS scavenger NAC inhibited 
IL-1β secretion and had marginal effects on Caspase-1 activity, suggesting a role for ROS in 
MAC induced NLRP3 activation that was not directly linked to Ca2+ influx (Figure 4.7).  
To determine whether inhibition of any downstream, Ca2+ and MAC activated kinases 
impacted NLRP3 activation, several previously established sublytic MAC activated pathways 
were targeted using specific cell signalling inhibitors (Figure 4.10). Across an initial screen of 
MAC induced kinases, the inhibition of AKT using Perifosine, an alkylphospholipid which 
inhibits membrane associated AKT signalling, caused a significant increase in MAC induced IL-
1β secretion and an increase in the Caspase-1 activity, albeit to a non-significant level via the 
Caspase-1 glo luminescence assay (Figure 4.11 A/B ) . However, other AKT pathway inhibitors 
failed to induce the same effects (Figure 4.12.) This suggested that Perifosine may be inducing 
off-target effects on other pathways which mediate this effect. Some of the previously 
described effects of Perifosine include activation of FAS-L signalling and JNK activation, both 
associated with non-canonical IL-1β and IL-18 secretion in an NLRP3 independent manner 
(Latz et al 2012). The impact of these off-target effects were then investigated.  Blockade of 
signalling through JNK and ERK 1/2, previously described as modulators of NLRP3 activation, 
MAC induced kinases, caused statistically significant decreases in both IL-1β secretion and 
Caspase-1 activity, suggesting that a broad MAPK inhibitory strategy was necessary to impact 
NLRP3 activation in response to MAC (Figure 4.14 A-C).  
The reactive lysis system for the generation of MAC avoids some of the potential confounding 
factors often encountered in using NHS to study MAC mediated signalling events, including 
potential pleiotropic effects of using heterologous serum as a complement source and 
signalling induced by antibody binding on the cell surface. Sublytic MAC generated using 
reactive lysis mediated inflammasome activation and IL-1β secretion in THP-1 monocytes 
(Figure 4.15) and primary macrophages (Figure 4.16). The transcriptomic changes in response 
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to reactive lysis generated sublytic MAC were recorded using RNA-Seq; which has identified 
several target pathways although these have not yet been validated. Preliminary analysis of 
the integrated pathways correlates well with RNA profiles in a recently published study in 
experimental autoimmune encephalomyelitis (EAE) where disease progression is MAC 
mediated (Michailaidou et al 2018). Whilst the RNA-Seq performed in the published paper 
was from mouse spinal cord, the RNA-Seq Z-score pathway hits correlate with our reactive 
lysis data from THP-1 monocytes, suggesting that highly conserved pathways are activated in 
response to MAC. The pathways highlighted by the RNA-Seq analysis in the published study 
are shown in Figure 6.1. This work is currently being replicated and built upon by others in 
the lab, to attempt to generate a consensus as to underlying transcriptional changes in 
response to sublytic MAC. Many of the highlighted pathways from our reactive lysis model 
and that of the mouse EAE model have implications for this work. As investigated, PKA 
signalling may be a negative regulator of NLRP3 activation, whilst IL-1 signalling validates 
inflammasome activation occurring are of importance from our RNA-Seq experiment. Further 
pathways from the EAE model which have implications for inflammatory signalling, NLR 
activation or links to pathways investigated in this thesis include ROS/RNS production in 
macrophages, NF-κB signalling, p38 MAPK signalling, TLR signalling, Inflammasome pathway 
and IRF activation by cytosolic PRR’s (Michailaidou et al 2018).   
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Figure 6.1. Comparison of RNA SEQ pathway analysis of reactive lysis stimulated THP-1 monocytes with Rat spinal cord RNA 
from an EAE model. Arrows highlight the same or similar pathways implicated in both experiments, suggesting even in 
diverse models of MAC mediated signalling conserved pathways are activated. Image adapted  from Michailaidou et al 
2018.  
 
Finally, as PKA signalling was implicated as the most changed signalling pathway from the 
RNA-Seq data and has implications as a negative regulator of NLRP3, a PKA antagonist H89 
dichloride was utilised. However, H89 had no significant effects on IL-1β secretion, suggesting 
that the upregulation of PKA-related mRNA in response to sub-lytic MAC, at least when 
observed 8 hours after MAC deposition, is not clear evidence of a role of PKA in inhibiting 
NLRP3 activity. 
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Figure 6.2. Schematic of working hypothesis of MAC mediated NLRP3 activation in THP-1 monocytes.  Sublytic MAC 
deposition on the cell surface induces primary and secondary Calcium flux events across chemiosmotic gradient and from 
IP3R gated channels respectively. Chelation of calcium using BAPTA-AM and inhibition of IP3R channels using Xestospongin 
C statistically significantly inhibited MAC mediated IL-1β secretion. The influx of Calcium may directly activate signalling 
pathways or NLRP3 itself or may mediate the activation of secondary messengers such as ROS/RNS production, which when 
neutralised through antioxidant pre-treatment of the cells statistically significantly inhibited IL-1β secretion. Both Calcium 
influx and ROS/RNS production can mediate MAPK activation, with ERK1/2 and JNK inhibition being the most potent 
combination for inhibiting IL-1β secretion and Caspase-1 activation. 
 
Because  MAC deposition results in  NLRP3 inflammasome activation and NLRP3 has been 
implicated in driving pyroptotic cell death, the links between MAC, inflammasomes and cell 
survival and death pathways were investigated (Fink and Cookson 2005; Triantafilou et al 
2013). SW 982 synovial cells were subjected to CRISPR/CAS9 mediated deletion of NLRP3, 
verified by western blot and RT-PCR (Figure 5.1). These cells were then subjected to 
complement deposition and viability assays in a similar manner to THP-1 cells. Surprisingly, 
the NLRP3 -/- SW 982 cells demonstrated robust resistance to MAC mediated cell death in 
response to COS-1 antiserum + NHS in both LDH and PI cell death assays (Figures 5.2 and 5.3). 
To investigate the cause of this, complement regulator expression and complement activation 
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fragment deposition was compared between the knockout and WT control cells, 
demonstrating comparable C3b staining (Figure 5.8). I then demonstrated a marked increase 
in CD59 expression in the NLRP3 -/- cells relative to WT and antibody blockade of CD59 on 
NLRP3 -/- cells rendered them equally sensitive to MAC mediated cell death as WT cells 
(Figures 5.9 and 5.13). To investigate the cause of differential CD59 expression, WT SW 982 
cells were treated with the NLRP3 inhibitor MCC950; this caused a marked increase in CD59 
cell surface staining within 1 hour and partial protection from MAC mediated cell death 
(Figures 5.11 and 5.5). The rapid nature of this upregulation suggested that the changes 
observed were due to shuttling of CD59 from intracellular stores rather than changes in gene 
expression and de novo protein synthesis. This was supported through permeabilization and 
staining for CD59 of the WT and NLRP3 -/- SW 982 cells; WT and KO cells stained equally for 
CD59 upon permeabilization, suggesting the differences observed with MCC950 treatment 
and under normal conditions is due to differences in the cellular distribution of CD59 rather 
than overall expression (Figure 5.11). Immunofluorescence imaging supported this finding 
with the bulk of CD59 in WT cells present in intracellular stores, generating CD59 positive 
staining upon cell permeabilization (Figure 5.12). 
The modulation of sensitivity to complement and MAC mediated cell death in synovial cells 
may have consequences in pathologies, including RA. Both pyroptotic and necroptotic forms 
of cell death have been implicated in RA pathogenesis; published studies and the data 
presented here suggest that these could be mediated by excessive complement activation 
(Van de Walle et al 2014;  Wu et al 2018; Chen et al 2018). Furthermore, NLRP3 activation 
and Gasdermin D oligomerisation drive NET formation, heavily implicated in RA pathogenesis; 
this may also be partly attributable to MAC activation of NLRP3 in Neutrophils (Sollberger et 
al 2018; Kenny et al 2018). MAC deposition has also been shown to drive production of 
hypercitrullination patterns on neutrophils (Romero et al 2013). If the observed effects of 
MCC950 in this thesis in upregulating CD59 cell surface expression on SW 982 cells is 
reciprocated in vivo, this may prevent the Calcium influx responsible for activation of the 
citrullinating enzyme PAD4, which in turn induces citrullination, thus linking MAC, NLRP3 and 
CD59 in the disease. MCC950 has already been used in mouse CAIA models, with statistically 
significant decreases in inflammatory cytokine levels, joint histopathology and clinical score 
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(Guo et al 2018); whether these effects may in part be through regulation of the above 
described MAC mediated processes remains to be explored.  
 
Therefore, the main conclusions of the work presented in this thesis are: 
1) Sublytic MAC, generated through reactive lysis or classical activation, is capable of 
inducing NLRP3 activation in primed THP-1 monocytes and primary macrophages. 
2) The induction of NLRP3 activation by sublytic MAC is Ca2+ dependent, K+ independent 
and may involve ROS. 
3) Pharmacological manipulation of sublytic MAC induced NLRP3 activation is possible 
with inflammasome specific inhibitors, modulators of Calcium signalling or agents 
targeting MAPK associated pathways. 
4) In SW982 synovial cells, NLRP3 activity determined CD59 surface expression. 
Consequently, NLRP3 -/- cells are highly resistant to MAC mediated cell death in 
comparison to WT counterparts. This can be partially reciprocated using MCC950 
treatment of WT SW 982 cells and abrogated through the blocking of CD59 function 
using the CD59 functional blocking antibody MEM43. 
 
6.4 – Future Directions 
 
 This work has identified and/or confirmed some of the signalling pathways associated with 
sublytic MAC mediated NLRP3 activation; however, a deeper investigation is still required in 
multiple cell types to establish any conserved roles and pathways by which MAC activates. 
The proliferative pathways initially investigated, such as PI3K, AKT and mTORC1, failed to elicit 
specific significant changes upon pharmacological inhibition, suggesting that the damage and 
cell death pathways implicated in response to sublytic MAC, such as MAPK and JNK activation, 
may be more relevant for MAC mediated NLRP3 activation. The recent observation that MAC 
induced cell death in K562 cells was necroptosis mediated (Lusthaus et al 2018), together with 
a significant literature linking necroptosis and NLRP3 activation, aligns MAC, necroptosis and 
NLRP3 in a cell damage / stress axis. However, in preliminary experiments, Necrostatin-1, a 
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RIPK1 inhibitor used to inhibit necroptosis in the literature, failed to elicit the same protective 
effects in terms of MAC mediated cell death in THP-1 cells.   
The next steps to build on the current work might involve an investigation of the effects of 
MAC in primary macrophages using MAPK, JNK and Necroptosis inhibitors in the contexts of 
both cell death and NLRP3 activation; such a study would increase the relevance of the work 
by demonstrating that the mechanisms displayed are not unique to the immortalised cell line. 
Furthermore, the highlighted MAPK associated inhibitors, alongside canonical NLRP3 
inhibitors such as MCC950, could be tested in vivo in models of complement-driven diseases, 
for example, RA, Alzheimer’s or atherosclerosis. The value of inhibition of NLRP3 using 
MCC950 has already been demonstrated in models of various inflammatory diseases 
including Ischaemia reperfusion injury, atherosclerosis and Alzheimer’s disease; a role for 
complement is also established in each of these model diseases. Whether the administration 
of MAPK inhibitors alongside or instead of MCC950 may be suppressive of inflammation in 
such conditions is unclear; however, the evidence presented here implicating these pathways 
and the potential for ERK and JNK to drive other inflammatory outputs such as IL-6 and IL-8 
secretion, may which may allow further amelioration of complement associated inflammation 
(Wang et al 2012).  
The association of NLRP3 expression and synovial cell susceptibility to MAC mediated cell 
death was a surprising outcome of this study, with the mechanism shown to be CD59 
dependent and through translocation of the protein from intracellular stores to the cell 
surface as shown by flow cytometry and confocal microscopy. Taking this observation forward 
would require replication in primary synovial cells and further work to address the mechanism 
underpinning this NLRP3-dependent translocation of CD59. The working hypothesis 
proposed, involving ER stress and cholesterol translocation, would require further validation; 
nevertheless, the work would provide exciting and novel links between complement and 
NLRP3 activation in the context of inflammatory disease.  
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